Apostolia M. Tsimberidou, MD, PhD, FASCO, FAAAS

Peer-Reviewed Articles

1. Tsimberidou AM, Sireci A, Dumanois R, Pritchard D. Strategies to Address the Clinical Practice Gaps Affecting the Implementation of Personalized Medicine in Cancer Care. JCO Oncol Pract 20(6):761-766, 2024. e-Pub 2024. PMID: 38442324.
2. Piha-Paul SA, Xu B, Dumbrava EE, Fu S, Karp DD, Meric-Bernstam F, Hong DS, Rodon JA, Tsimberidou AM, Raghav K, Ajani JA, Conley AP, Mott F, Fan Y, Fan J, Peng P, Wang H, Ni S, Sun C, Qiang X, Levin WJ, Ngo B, Ru QC, Wu F, Javle MM. First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients with Advanced Solid Tumors. Oncologist 29(4):e514-e525, 2024. PMID: 38297981.
3. Knisely A, Ahmed J, Stephen B, Piha-Paul SA, Karp D, Zarifa A, Fu S, Hong DS, Rodon Ahnert J, Yap TA, Tsimberidou AM, Alshawa A, Dumbrava EE, Yang Y, Song J, Meric-Bernstam F, Jazaeri AA, Naing A. Phase 1/2 trial of avelumab combined with utomilumab (4-1BB agonist), PF-04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignancies. Cancer 130(3):400-409, 2024. e-Pub 2023. PMID: 37864520.
4. Nelson BE, Tsimberidou AM, Fu X, Fu S, Subbiah V, Sood AK, Rodon J, Karp DD, Blumenschein G, Kopetz S, Pant S, Piha-Paul SA. A phase I trial of bevacizumab and temsirolimus in combination with valproic acid in advanced solid tumors. Oncologist 28(12):1100-e1292, 2023. e-Pub 2023. PMID: 37311055.
5. Lockwood CM, Borsu L, Cankovic M, Earle JSL, Gocke CD, Hameed M, Jordan D, Lopategui JR, Pullambhatla M, Reuther J, Rumilla KM, Tafe LJ, Temple-Smolkin RL, Terraf P, Tsimberidou AM. Recommendations for cell-free DNA assay validations: a joint consensus recommendation of the Association for Molecular Pathology and College of American Pathologists. J Mol Diagn 25(12):876-897, 2023. e-Pub 2023. PMID: 37806433.
6. Bulliard Y, Andersson BS, Baysal MA, Damiano J, Tsimberidou AM. Reprogramming T cell differentiation and exhaustion in CAR-T cell therapy. J Hematol Oncol 16(1):108, 2023.
7. Fountzillas E, Vo HH, Mueller P, Kurzrock R, Tsimberidou AM. Dataset of phase I and II immunotherapy clinical trials used for a meta-analysis to assess the role of biomarkers in treatment outcomes in diverse cancers. Data in Brief 51:109698. e-Pub 2023. PMID: 38020439.
8. Tsimberidou AM, Verschraegen CF, Wesolowski R, Shia CS, Hsu P, Pearce TE. Phase 1 dose-escalation study evaluating the safety, pharmacokinetics, and clinical activity of OBI-3424 in patients with advanced or metastatic solid tumors. Br J Cancer 129(2):266-274, 2023. e-Pub 2023. PMID: 37173365.
9. Piha-Paul SA, Tseng C, Tran HT, Gao M, Karp DD, Subbiah V, Tsimberidou AM, Kawedia JD, Fu S, Pant S, Yap TA, Morris VK, Kee BK, Blum Murphy M, Lim J, Meric-Bernstam F. A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation. Cancer Chemother Pharmacol 92(2):107-118, 2023. e-Pub 2023. PMID: 37314501.
10. Fountzilas E, Vo HH, Mueller P, Kurzrock R, Tsimberidou AM. Correlation between biomarkers and treatment outcomes in diverse cancers: a systematic review and meta-analysis of phase I and II immunotherapy clinical trials. Eur J of Cancer 189:112927, 2023. e-Pub 2023. PMID: 37364526.
11. Chelariu-Raicu A, Piha-Paul SA, Chavez-MacGregor M, Johnson J, Sawaya R, McAleer MF, Nguyen A, Hartnett A, Tsimberidou AM, Meric-Bernstam F, Dumbrava EE. Multidisciplinary care of a large brain metastasis in a patient with hormone-receptor-positive breast cancer with ataxia-telangiectasia mutation. J Immunother Precis Oncol 6(3):158-161, 2023. e-Pub 2023. PMID: 37637237.
12. Nelson BE, Saleem S, Damodaran S, Somaiah N, Piha-Paul S, Moore JA, Yilmaz B, Ogbonna D, Karp DD, Dumbrava E, Tsimberidou AM, Hong DS, Rodon Ahnert J, Milton DR, Zheng X, Booser DJ, Ibrahim NK, Conley AP, Bhosale P, Rojas Hernandez CM, Tripathy D, Naing A, Meric-Bernstam F. Phase 1b study of combined selinexor and eribulin for the treatment of advanced solid tumors and triple-negative breast cancer. Cancer 129(14):2201-2213, 2023. e-Pub 2023. PMID: 37016732.
13. Tsimberidou AM, Guenther K, Andersson BS, Mendrzyk R, Alpert A, Wagner C, Nowak A, Aslan K, Satelli A, Richter F, Kuttruff-Coqui S, Schoor O, Fritsche J, Coughlin Z, Mohamed AS, Sieger K, Norris B, Ort R, Beck J, Vo HH, Hoffgaard F, Ruh M, Backert L, Wistuba II, Fuhrmann D, Ibrahim NK, Morris VK, Kee BK, Halperin DM, Nogueras-González GM, Kebriaei P, Shpall EJ, Vining D, Hwu P, Singh-Jasuja H, Reinhardt C, Britten CM, Hilf N, Weinschenk T, Maurer D, Walter S. Feasibility and safety of personalized, multi-target, adoptive cell therapy (IMA101): first-in-human clinical trial in patients with advanced metastatic cancer. Cancer Immunol Res 11(7):925-945, 2023. e-Pub 2023. PMID: 37172100.
14. Carmagnani Pestana R, Moyers JT, Roszik J, Sen S, Hong DS, Naing A, Herzog CE, Fu S, Piha-Paul SA, Rodon J, Yap TA, Karp DD, Tsimberidou AM, Pant S, Zarzour MA, Ratan R, Ravi V, Benjamin RS, Lazar AJ, Wang WL, Daw N, Gill JB, Harrison DJ, Lewis VO, Roland CL, Patel SR, Livingston JA, Somaiah N, Ludwig JA, Conley AP, Hamerschlak N, Gorlick R, Meric-Bernstam F, Subbiah V. Impact of biomarker-matched therapies on outcomes in patients with sarcoma enrolled in early-phase clinical trials (SAMBA 101). Clin Cancer Res 29(9):1708-1718, 2023. e-Pub 2023. PMID: 37058010.
15. Ahn ER, Rothe M, Mangat PK, Garrett-Mayer E, Ali-Ahmad HM, Chan J, Maitland ML, Patel SR, Reese Z, Balmanoukian AS, Drescher CW, Li R, Tsimberidou AM, Leath III CA, O'Lone R, Grantham GN, Halabi S, Schilsky RL. Pertuzumab plus trastuzumab in patients with endometrial cancer with ERBB2/3 amplification, overexpression or mutation: Results from the TAPUR study. JCO Precis Onc 7:e2200609, 2023. PMID: 37027810.
16. Alhalabi O, Groisberg R, Zinner R, Hahn AW, Naing A, Zhang S, Tsimberidou AM, Rodon J, Fu S, Yap TA, Hong DS, Sun M, Jiang Y, Pant S, Shah AY, Zurita A, Tannir NM, Vikram R, Roszik J, Meric-Bernstam F, Subbiah V. Phase I study of sapanisertib with carboplatin and paclitaxel in mTOR pathway altered solid malignancies. NPJ Precis Oncol 7(1):37, 2023. e-Pub 2023. PMID: 37072571.
17. Fu S, Yao S, Yuan Y, Previs RA, Elias AD, Carvajal RD, George TJ, Yuan Y, Yu L, Westin SN, Xing Y, Dumbrava EE, Karp DD, Piha-Paul SA, Tsimberidou AM, Ahnert JR, Takebe N, Lu K, Keyomarsi K, Meric-Bernstam F. Multicenter phase II Trial of the WEE1 inhibitor adavosertib in refractory solid tumors harboring CCNE1 amplification. J Clin Oncol 41(9):1725-1734, 2023. e-Pub 2022. PMID: 36469840.
18. Song I-W, Vo HH, Chen Y-S, Baysal MA, Kahle M, Johnson A, Tsimberidou AM. Precision oncology: evolving clinical trials across tumor types. Cancers 15(7):1967. e-Pub 2023. PMID: 37046628.
19. Son J, Lin HY, Fu S, Biter AB, Dumbrava EE, Karp DD, Naing A, Pant S, Piha-Paul SA, Rodon J, Subbiah V, Tsimberidou AM, Yap TA, Frumovitz MM, Jazaeri AA, Ramirez PT, Westin SN, Yuan Y, Meric-Bernstam F, Hong DS. Predictors of oncologic outcome in patients receiving phase I investigational therapy for recurrent or metastatic cervical cancer. J Immunother Precis Oncol 6(1):10-18, 2023. e-Pub 2023. PMID: 36751659.
20. Nelson BE, Roszik J, Janku F, Hong DS, Kato S, Naing A, Piha-Paul S, Fu S, Tsimberidou A, Cabanillas M, Busaidy NL, Javle M, Byers LA, Heymach JV, Meric-Bernstam F, Subbiah V. BRAF v600E-mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study. NPJ Precis Oncol 7(1):19, 2023. e-Pub 2023. PMID: 36801912.
21. Subbiah V, Coleman N, Piha-Paul SA, Tsimberidou AM, Janku F, Rodon J, Pant S, Dumbrava EE, Fu S, Hong DS, Zhang S, Sun M, Jiang Y, Roszik J, Song J, Yuan Y, Meric-Bernstam F, Naing A. Phase I study of mTORC1/2 inhibitor sapanisertib in combination with metformin in patients with mTOR/AKT/PI3K pathway alterations and advanced solid malignancies. Cancer Res Commun 4(2):378-387, 2023. e-Pub 2023. PMID: 38126764.
22. Yap TA, Daver N, Mahendra M, Zhang J, Kamiya-Matsuoka C, Meric-Bernstam F, Kantarjian HM, Ravandi F, Collins ME, Francesco MED, Dumbrava EE, Fu S, Gao S, Gay JP, Gera S, Han J, Hong DS, Jabbour EJ, Ju Z, Karp DD, Lodi A, Molina JR, Baran N, Naing A, Ohanian M, Pant S, Pemmaraju N, Bose P, Piha-Paul SA, Rodon J, Salguero C, Sasaki K, Singh AK, Subbiah V, Tsimberidou AM, Xu QA, Yilmaz M, Zhang Q, Li Y, Bristow CA, Bhattacharjee MB, Tiziani S, Heffernan TP, Vellano CP, Jones P, Heijnen CJ, Kavelaars A, Marszalek JR, Konopleva M. Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials. Nat Med 29(1):115-126, 2023. e-Pub 2023. PMID: 36658425.
23. Tsimberidou AM, Vo HH, Beck J, Shia C-S, Hsu P, Pearce TE. First-in-human study of OBI-999, a globo H-targeting antibody-drug conjugate, in patients with advanced solid tumors. JCO Precis Oncol 7:e2200496, 2023. PMID: 36701651.
24. Westin SN, Fu S, Tsimberidou A, Piha-Paul S, Akhmedzhanov F, Yilmaz B, McQuinn L, Brink AL, Gong J, Leung CH, Lin H, Hong DS, Pant S, Carter B, Jazaeri A, Gershenson D, Sood AK, Coleman RL, Shah J, Meric-Bernstam F, Naing A. Selinexor in combination with weekly paclitaxel in patients with metastatic solid tumors: results of an open label, single-center, multi-arm phase 1b study with expansion phase in ovarian cancer. Gynecol Oncol 168:76-82. e-Pub 2022. PMID: 36423446.
25. Vo HH, Fu S, Hong DS, Karp DD, Piha-Paul S, Subbiah V, Janku F, Naing A, Yap TA, Rodon J, Ajani JA, Cartwright C, Johnson A, Song I-W, Beck J, Kahle M, Nogueras-Gonzalez GM, Miller V, Chao C, Vining DJ, Berry DA, Meric-Bernstam F, Tsimberidou AM. Challenges and opportunities associated with the MD Anderson IMPACT2 randomized study in precision oncology. NPJ Precis Oncol 6(1):78, 2022. PMID: 36302890.
26. Mendoza TR, Hong DS, Peterson CB, Stephen B, Dumbrava E, Pant S, Tsimberidou AM, Yap TA, Sheshadri A, Altan M, George G, Castillo L, Rodriguez E, Gong J, Subbiah V, Janku F, Fu S, Piha-Paul SA, Ahnert JR, Karp DD, Cleeland C, Meric-Bernstam F, Naing A. Patient-reported symptom burden in patients with rare cancers receiving pembrolizumab in a phase II clinical trial. Sci Rep 12(1):14367, 2022. e-Pub 2022. PMID: 35999229.
27. Fountzilas E*, Tsimberidou AM*, Vo HH, Kurzrock R. Clinical trial design in the era of precision medicine. Genome Med 14(1):101, 2022. e-Pub 2022. PMID: 36045401.
28. Gouda MA, Huang HJ, Piha-Paul SA, Call SG, Karp DD, Fu S, Naing A, Subbiah V, Pant S, Dustin DJ, Tsimberidou AM, Hong DS, Rodon J, Meric-Bernstam F, Janku F. Longitudinal monitoring of circulating tumor DNA to predict treatment outcomes in advanced cancers. JCO Precis Oncol 6:e2100512, 2022. PMID: 35834760.
29. Tsimberidou AM, Skliris A, Valentine A, Shaw J, Hering U, Vo HH, Chan TO, Armen RS, Cottrell JR, Pan JQ, Tsichlis PN. AKT inhibition in the central nervous system induces signaling defects resulting in psychiatric symptomatology. Cell Biosci 12(1):56, 2022. e-Pub 2022. PMID: 35525984.
30. Yao S, Meric-Bernstam F, Hong D, Janku F, Naing A, Piha-Paul SA, Tsimberidou AM, Karp D, Subbiah V, Yap TA, Ahnert JR, Pant S, Dumbrava EEI, Wathoo C, Campbell E, Yu L, Yamamura Y, Fu S. Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiences. Sci Rep 12(1):8701, 2022. e-Pub 2022. PMID: 35610322.
31. Thein KZ, Karp DD, Tsimberidou A, Gong J, Sulovic S, Shah J, Milton DR, Hong DS, Janku F, McQuinn L, Stephen BA, Colen R, Carter BW, Yap TA, Piha-Paul SA, Fu S, Meric-Bernstam F, Naing A. Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: results of a single-center, multi-arm phase Ib study. Invest New Drugs 40(2):290-299, 2022. e-Pub 2021. PMID: 34562230.
32. Thein KZ, Piha-Paul SA, Tsimberidou A, Karp DD, Janku F, Zarifa A, Shah J, Milton DR, Bean S, McQuinn L, Gong J, Colen R, Carter BW, Subbiah V, Ogbonna DC, Pant S, Meric-Bernstam F, Naing A. Correction to: Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: results of an open-label, single-center, multi-arm phase Ib study. Invest New Drugs 40(2):461, 2022. e-Pub 2021. PMID: 34705134.
33. Thein KZ, Karp DD, Tsimberidou A, Gong J, Sulovic S, Shah J, Milton DR, Hong DS, Janku F, McQuinn L, Stephen BA, Colen R, Carter BW, Yap TA, Piha-Paul SA, Fu S, Meric-Bernstam F, Naing A. Correction to: Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: results of a single-center, multi-arm phase Ib study. Invest New Drugs 40(2):463, 2022. e-Pub 2021. PMID: 34731355.
34. Vo HH, Cartwright C, Song IW, Karp DD, Nogueras Gonzalez GM, Xie Y, Karol M, Hitron M, Vining D, Tsimberidou AM. Ipilimumab, pembrolizumab, or nivolumab in combination with BBI608 in patients with advanced cancers treated at MD Anderson Cancer Center. Cancers (Basel) 14(5), 2022. e-Pub 2022. PMID: 35267638.
35. Dev R, Zhong LL, Zarifa A, Albittar AA, Rubin L, Liu S, Yap TA, Dalal S, Hui D, Karp DD, Tsimberidou AM, Piha-Paul SA, Ahnert JR, Fu S, Meric-Bernstam F, Naing A. Supportive care for the prevention of nausea, vomiting and anorexia in a phase 1B study of selinexor in advanced cancer patients: an exploratory study. Invest New Drugs 40(1):124-133, 2022. e-Pub 2021. PMID: 34559346.
36. Yao S, Janku F, Koenig K, Tsimberidou A, Piha-Paul SA, Shi N, Stewart J, Johnston A, Bomalaski J, Meric-Bernstam F, Fu S. Phase 1 trial of ADI-PEG 20 and liposomal doxorubicin in patients with metastatic solid tumors. Cancer Med 11(2):340-347, 2022. e-Pub 2021. PMID: 34841717.
37. Thein KZ, Fu S, Janku F, Tsimberidou A, Piha-Paul SA, Karp DD, Shah J, Milton DR, Gong J, Sulovic S, McQuinn S, Stephen BA, Colen R, Carter BW, Meric-Bernstam F, Naing A. Selinexor in combination with carboplatin and pemetrexed in patients with advanced or metastatic solid tumors: results of an open-label, single-center, multi-arm phase 1b study. J Immunother Precis Oncol 5(1):1-3. e-Pub 2022.
38. Fountzilas E, Kurzrock R, Hiep Vo H, Tsimberidou AM. Wedding of molecular alterations and immune checkpoint blockade: genomics as a matchmaker. J Natl Cancer Inst 113(12):1634-1647, 2021. e-Pub 2021. PMID: 33823006.
39. Thein KZ, Piha-Paul SA, Tsimberidou A, Karp DD, Janku F, Fu S, Subbiah V, Hong DS, Yap TA, Shah J, Milton DR, McQuinn L, Gong J, Tran Y, Carter BW, Colen R, Meric-Bernstam F, Naing A. Selinexor in combination with standard chemotherapy in patients with advanced or metastatic solid tumors. Exp Hematol Oncol 10(1):59, 2021. e-Pub 2021. PMID: 34965890.
40. Thein KZ, Piha-Paul SA, Tsimberidou A, Karp DD, Janku F, Zarifa A, Shah J, Milton DR, Bean S, McQuinn L, Gong J, Colen R, Carter BW, Subbiah V, Ogbonna DC, Pant S, Meric-Bernstam F, Naing A. Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study. Invest New Drugs 39(5):1357-1365, 2021. e-Pub 2021. PMID: 33909232.
41. Ferrarotto R, Sousa LG, Qing Y, Kaya D, Stephen B, Jain D, Bell D, Pant S, Tsimberidou AM, Janku F, Blumenschein G, Glisson BS, Ahnert JR, Piha-Paul SA, Lee JJ, Wong MK, Lu C, Meric-Bernstam F, Naing A. Pembrolizumab in patients with refractory cutaneous squamous cell carcinoma: a phase II trial. Adv Ther 38(8):4581-4591, 2021. e-Pub 2021. PMID: 34241781.
42. Tsimberidou AM, Shaw JV, Juric D, Verschraegen C, Weise AM, Sarantopoulos J, Lopes G, Nemunaitis J, Mita M, Park H, Ellers-Lenz B, Tian H, Xiong W, Kaleta R, Kurzrock R. Phase 1 study of M2698, a p70S6K/AKT dual inhibitor, in patients with advanced cancer. J Hematol Oncol 14(1):127, 2021. e-Pub 2021. PMID: 34407844.
43. Dumbrava EI, Call SG, Huang HJ, Stuckett AL, Madwani K, Adat A, Hong DS, Piha-Paul SA, Subbiah V, Karp DD, Fu S, Naing A, Tsimberidou AM, Moulder SL, Koenig KH, Barcenas CH, Kee BK, Fogelman DR, Kopetz ES, Meric-Bernstam F, Janku F. PIK3CA mutations in plasma circulating tumor DNA predict survival and treatment outcomes in patients with advanced cancers. ESMO Open 6(5):100230. e-Pub 2021. PMID: 34479035.
44. Tsimberidou AM, Vo HH, Subbiah V, Janku F, Piha-Paul SA, Yilmaz B, Gong J, Naqvi MF, Tu S-M, Campbell M, Meric-Bernstam F, Naing A. Pembrolizumab in patients with advanced metastatic germ cell tumors. Oncologist 26(7):558-e1098, 2021. e-Pub 2021. PMID: 33491277.
45. Al-Zubidi N, Gombos DS, Hong DS, Subbiah V, Fu S, Ahnert JR, Piha-Paul SA, Tsimberidou AM, Karp DD, Bernstam FM, Naing A. Overview of ocular side effects of selinexor. Oncologist 26(7):619-623, 2021. e-Pub 2021. PMID: 33728727.
46. Huey RW, George GC, Phillips P, White R, Fu S, Janku F, Karp DD, Naing A, Piha-Paul S, Subbiah V, Tsimberidou AM, Pant S, Yap TA, Rodon J, Meric-Bernstam F, Shih YT, Hong DS. Patient-reported out-of-pocket costs and financial toxicity during early-phase oncology clinical trials. Oncologist 26(7):588-596, 2021. e-Pub 2021. PMID: 33783054.
47. Tsimberidou AM, Beer PA, Cartwright CA, Haymaker C, Vo HH, Kiany S, Cecil AR, Dow J, Haque K, Silva FA, Coe L, Berryman H, Bone EA, Nogueras González GM, Vining D, McElwaine-Johnn H, Wistuba II. Preclinical development and first in human study of KA2507, a selective and potent inhibitor of histone deacetylase 6, for patients with refractory solid tumors. Clin Cancer Res 27(13):3584-3594, 2021. e-Pub 2021. PMID: 33947698.
48. Tsimberidou AM, Morris VK, Vo HH, Eck S, Lin Y-F, Rivas JM, Andersson BS. T-cell receptor-based therapy: an innovative therapeutic approach for solid tumors. J Hematol Oncol 14(1):102, 2021. PMID: 34193217.
49. Lazar V, Magidi S, Girard N, Savignoni A, Martini J-F, Massimini G, Bresson C, Berger R, Onn A, Raynaud J, Wunder F, Berindan-Neagoe I, Sekacheva M, Brana I, Tabernero J, Felip E, Porgador A, Kleinman C, Batist G, Solomon B, Tsimberidou AM, Soria J-C, Rubin E, Kurzrock R, Schilsky RL. Digital display precision predictor: the prototype of a global novel biomarker model to guide treatments with targeted therapy and predict progression-free survival. NPJ Precis Oncol 5(1):33, 2021. PMID: 33911192.
50. Yao S, Janku F, Subbiah V, Stewart J, Patel SP, Kaseb A, Westin SN, Naing A, Tsimberidou AM, Hong D, Piha-Paul SA, Shi N, Johnston A, Bomalaski J, Fu S. Phase 1 trial of ADI-PEG20 plus cisplatin in patients with pretreated metastatic melanoma or other advanced solid malignancies. Br J Cancer 124(9):1533-1539, 2021. e-Pub 2021. PMID: 33674736.
51. Ballhausen A, Wheler JJ, Karp DD, Piha-Paul SA, Fu S, Pant S, Tsimberidou AM, Hong DS, Subbiah V, Holley VR, Huang H, Brewster AM, Koenig KB, Ibrahim NK, Meric-Bernstam F, Janku F. Phase I study of everolimus, letrozole, and trastuzumab in patients with hormone receptor-positive metastatic breast cancer or other solid tumors. Clin Cancer Res 27(5):1247-1255, 2021. e-Pub 2020. PMID: 33115815.
52. Tsimberidou AM, Hong DS, Fu S, Karp DD, Piha-Paul S, Kies MS, Ravi V, Subbiah V, Patel SM, Tu S-M, Janku F, Heymach J, Johnson A, Cartwright C, Zhao L, Zhang J, Berry DA, Vining DJ, Futreal A, Miller VA, Meric-Bernstam F. Precision medicine: preliminary results from the initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT2) study. NPJ Precis Oncol 5(1):21, 2021. PMID: 33742104.
53. Naqvi MF, Vo HH, Vining D, Tsimberidou AM. Prolonged response to treatment based on cell-free DNA analysis and molecular profiling in three patients with metastatic cancer: a case series. Ther Adv Med Oncol 13:17588359211001538, 2021. e-Pub 2021. PMID: 33995588.
54. Janku F, Sakamuri D, Kato S, Huang HJ, Call G, Naing A, Holley VR, Patel SP, Amaria RN, Falchook GS, Piha-Paul SA, Zinnner RG, Tsimberidou AM, Hong DS, Meric-Bernstam F. Dose escalation study of vemurafenib with sorafenib or crizotinib in patients with BRAF-mutated advanced cancers. Cancer 127(3):391-402, 2021. e-Pub 2020. PMID: 33119140.
55. Tsimberidou AM, Elkin S, Dumanois R, Pritchard D. Clinical and economic value of genetic sequencing for personalized therapy in non-small-cell lung cancer. Clin Lung Cancer 21(6):477-481, 2020. e-Pub 2020. PMID: 32718774.
56. Mendoza T, Sheshadri A, Altan M, Hess K, George G, Stephen B, Castillo L, Rodriguez E, Gong J, Peterson C, Rodon Ahnert J, Fu S, Piha-Paul SA, Pant S, Dumbrava E, Yap TA, Janku F, Tsimberidou AM, Subbiah V, Karp DD, Zarifa A, McQuinn LM, Cleeland C, Hong DS, Naing A. Evaluating the psychometric properties of the Immunotherapy module of the MD Anderson Symptom Inventory. J Immunother Cancer 8(2), 2020. PMID: 33097611.
57. George GC, Mendoza TR, Iwuanyanwu EC, Manandhar M, Afshar SF, Piha-Paul SA, Tsimberidou A, Naing A, Cleeland CS, Hong DS. Factors affecting symptom presentation in an early-phase clinical trials clinic patient population. Invest New Drugs 38(4):1166-1174, 2020. e-Pub 2019. PMID: 31761957.
58. Jimenez C, Subbiah V, Stephen B, Ma J, Milton D, Xu M, Zarifa A, Akhmedzhanov FO, Tsimberidou A, Habra MA, Rodon Anhert J, Fu S, Naing A. Phase II clinical trial of pembrolizumab in patients with progressive metastatic pheochromocytomas and paragangliomas. Cancers (Basel) 12(8), 2020. e-Pub 2020. PMID: 32824391.
59. Tsimberidou AM, Fountzilas E, Nikanjam M, Kurzrock R. Review of precision cancer medicine: Evolution of the treatment paradigm. Cancer Treat Rev 86:102019, 2020. e-Pub 2020. PMID: 32251926.
60. Naing A, Meric-Bernstam F, Stephen B, Karp DD, Hajjar J, Rodon Ahnert J, Piha-Paul SA, Colen RR, Jimenez C, Raghav KP, Ferrarotto R, Tu SM, Campbell M, Wang L, Sabir SH, Tapia C, Bernatchez C, Frumovitz M, Tannir N, Ravi V, Khan S, Painter JM, Abonofal A, Gong J, Alshawa A, McQuinn LM, Xu M, Ahmed S, Subbiah V, Hong DS, Pant S, Yap TA, Tsimberidou AM, Dumbrava EEI, Janku F, Fu S, Simon RM, Hess KR, Varadhachary GR, Amir Habra M. Phase 2 study of pembrolizumab in patients with advanced rare cancers. J Immunother Cancer 8(1), 2020. PMID: 32188704.
61. Mahalingam D, Patel MR, Sachdev JC, Hart LL, Halama N, Ramanathan RK, Sarantopoulos J, Völkel D, Youssef A, de Jong FA, Tsimberidou AM. Phase I study of imalumab (BAX69), a fully human recombinant antioxidized macrophage migration inhibitory factor antibody in advanced solid tumours. Br J Clin Pharmacol 86(9):1836-1848, 2020. e-Pub 2020. PMID: 32207164.
62. Wang Y, Janku F, Piha-Paul S, Hess K, Broaddus R, Liu L, Shi N, Overman M, Kopetz S, Subbiah V, Naing A, Hong D, Tsimberidou AM, Karp D, Yao J, Fu S. Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies. Sci Rep 10(1):3080, 2020. PMID: 32080210.
63. Fountzilas E, Kotoula V, Koliou GA, Giannoulatou E, Gogas H, Papadimitriou C, Tikas I, Zhang J, Papadopoulou K, Zagouri F, Christos Christodoulou C, Koutras A, Makatsoris T, Chrisafi S, Linardou H, Varthalitis I, G Papatsibas G, Razis E, Papakostas P, Samantas E, Aravantinos G, Psyrri A, Pentheroudakis G, Pectasides D, Futreal A, Fountzilas G, Tsimberidou AM. Pathogenic mutations and overall survival in 3,084 patients with cancer: The Hellenic Cooperative Oncology Group precision medicine initiative. Oncotarget 11(1):1-14, 2020. e-Pub 2020. PMID: 32002119.
64. Said R, Guibert N, Oxnard GR, Tsimberidou AM. Circulating tumor DNA analysis in the era of precision oncology. Oncotarget 11(2):188-211, 2020. PMID: 32010431.
65. Subbiah V, Dumbrava EI, Jiang Y, Thein KZ, Naing A, Hong DS, Fu S, Piha-Paul SA, Tsimberidou AM, Janku F, Meric-Bernstam F, Kurzrock R, Falchook G. Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial. Exp Hematol Oncol 9:7, 2020. e-Pub 2020. PMID: 32337094.
66. Tsimberidou AM, Hong DS, Wheler JJ, Falchook GS, Janku F, Naing A, Fu S, Piha-Paul SA, Cartwright C, Broaddus RR, Nogueras Gonzalez GM, Hwu P, Kurzrock R. Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine. J Hematol Oncol 12(1):145, 2019. e-Pub 2019. PMID: 31888672.
67. Schneeweiss A, Hess D, Joerger M,Varga A, Moulder S, Tsimberidou AM, Ma C, Hurvitz SA, Rentzsch C, Rudolph M, Thiele S, Boix O, Wilkinson G, Lagkadinou E, Ocker M. Phase 1 dose escalation study of the allosteric AKT inhibitor BAY 1125976 in advanced solid cancer-lack of association between activating AKT mutation and AKT inhibition-derived efficacy. Cancers 11(12):e1987, 2019. e-Pub 2019. PMID: 31835495.
68. Maymani H, Hess K, Groisberg R, Hong DS, Naing A, Piha-Paul S, Janku F, Fu S, Tsimberidou AM, Pant S, Karp D, Liu S, Sun M, Heymach J, Simon G, Meric-Bernstam F, Subbiah V. Corrigendum to "Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials" [Lung Cancer 120 (June) (2018) 137-141]. Lung Cancer 136:158, 2019. e-Pub 2019. PMID: 31445783.
69. Xu, Y, Muller P, Tsimberidou AM, Berry D. A nonparametric bayesian basket trial design. Biom J 61(5):1160-1174, 2019. PMID: 29808479.
70. Rodon J, Soria J-C, Berger R, Miller WH, Rubin E, Kugel A, Tsimberidou AM, Saintigny P, Ackerstein A, Brana I, Loriot y, Afshar M, Miller v, Wunder F, Bresson C, Martini J-F, Raynaud J, Mendelsohn J, Gerald B, Onn A, Tabernero J, Schilsky RL, Lazar V, Lee JJ, Kurzrock R. Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial. Nature Medicine 25(5):751-758, 2019. e-Pub 2019. PMID: 31011205.
71. Ou Y, Xu Y, Gore L, Harvey RD, Mita A, Papadopoulos KP, Wang Z, Cutler RE, Pinchasik DE, Tsimberidou AM. Physiologically-based pharmacokinetic modelling to predict oprozomib CYP3A drug-drug interaction potential in patients with advanced malignancies. Br J Clin Pharmacol 85(3):530-539, 2019. e-Pub 2018. PMID: 30428505.
72. Bhatty M, Kato S, Piha-Paul SA, Naing A, Subbiah V, Huang HJ, Karp DD, Tsimberidou AM, Zinner RG, Hwu WJ, Javle M, Patel SP, Hu MI, Varadhachary GR, Conley AP, Ramzanali NM, Holley VR, Kurzrock R, Meric-Bernstam F, Kwang Chae Y, Kim KB, Falchook GS, Janku F. Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients With BRAF-mutated melanoma and other advanced malignancies. Cancer 125(3):463-472, 2019. e-Pub 2018. PMID: 30383888.
73. Tsimberidou AM, Levit LA, Schilsky RL, Averbuch SD, Chen D, Kirkwood JM, McShane LM, Sharon E, Mileham KF, Postow MA. Trial reporting in immuno-oncology (TRIO): An American Society of Clinical Oncology-Society for Immunotherapy of Cancer statement. J Clin Oncol 37(1):72-80, 2019. e-Pub 2018. PMID: 30339040.
74. Dumbrava EEI, Balaji K, Raghav K, Hess K, Javle M, Blum-Murphy M, Ajani J, Kopetz S, Broaddus R, Routbort M, Demirhan M, Zheng X, Pant S, Tsimberidou AM, Subbiah V, Hong DS, Rodon J, Shaw KM, Piha-Paul SA, Meric-Bernstam F. Targeting ERBB2 (HER2) amplification identified by next-generation sequencing in patients with advanced or metastatic solid tumors beyond conventional indications. JCO Precis Oncol 3, 2019. e-Pub 2019. PMID: 32923865.
75. Fountzilas E, Palmer G, Vining D, Tsimberidou AM. Prolonged partial response to bevacizumab and valproic acid in a patient with glioblastoma. JCO Precis Oncol 2, 2018. e-Pub 2018. PMID: 31544169.
76. Fountzilas E, Krishnan E, Janku F, Fu S, Karp DD, Naing A, Subbiah V, Hong DS, Piha-Paul SA, Vining DJ, Tsimberidou AM. A phase I clinical trial of hepatic arterial infusion of oxaliplatin and oral capecitabine, with or without intravenous bevacizumab, in patients with advanced cancer and predominant liver involvement. Cancer Chemother Pharmacol 82(5):877-885, 2018. e-Pub 2018. PMID: 30182147.
77. Merker JD, Oxnard GR, Compton C, Diehn M, Hurley P, Lazar AJ, Lindeman N, Lockwood CM, Rai A, Schilsky RL, Tsimberidou AM, Vasalos P, Billman B, Oliver T, Bruinooge SS, Hayes DF, Turner NC. Circulating tumor DNA analysis in patients with cancer: American Society of Clinical Oncology and College of American Pathologists joint review. Arch Pathol Lab Med 142(10):1242-1253, 2018. e-Pub 2018. PMID: 29504834.
78. Tsimberidou AM, Levit LA, Schilsky RL, Averbuch SD, Chen D, Kirkwood JM, McShane L, Sharon E, Mileham KF, Postow MA. Trial reporting in immuno-oncology (TRIO): an American Society of Clinical Oncology - Society for Immunotherapy of Cancer statement. J Immunother Cancer 6(1):108, 2018. PMID: 30340549.
79. Ileana Dumbrava E, Smith V, Alfattal R, El-Naggar AK, Penas-Prado M, Tsimberidou AM. Autoimmune granulomatous inflammation of lacrimal glands and axonal neuritis following treatment with ipilimumab and radiation therapy. J Immunother 41(7):336-339, 2018. e-Pub 2018. PMID: 29787423.
80. Dembla V, Somaiah N, Barata P, Hess K, Fu S, Janku F, Karp DD, Naing A, Piha-Paul SA, Subbiah V, Tsimberidou AM, Shaw K, Meric-Bernstam F, Hong DS. Prevalence of MDM2 amplification and coalterations in 523 advanced cancer patients in the MD Anderson phase 1 clinic. Oncotarget 9(69):33232-33243, 2018. e-Pub 2018. PMID: 30237864.
81. Wang Y, Wang Z, Piha-Paul S, Janku F, Subbiah V, Shi N, Hess K, Broaddus R, Shan B, Naing A, Hong D, Tsimberidou AM, Karp D, Lu C, Papadimitrakopoulou V, Heymach J, Meric-Bernstam F, Fu S.. Outcome analysis of phase I trial patients with metastatic KRAS and/or TP53 mutant non-small cell lung cancer. Oncotarget 9(70):33258-33270, 2018. PMID: 30279957.
82. Fujii T, Colen RR, Bilen MA, Hess KR, Hajjar J, Suarez-Almazor ME, Alshawa A, Hong DS, Tsimberidou AM, Janku F, Gong J, Stephen B, Subbiah V, Piha-Paul SA, Fu S, Sharma P, Mendoza T, Patel A, Thirumurthi S, Sheshadri A, Meric-Bernstam F, Naing A. Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience. Invest New Drugs 36(4):638-646, 2018. e-Pub 2017. PMID: 29159766.
83. Fountzilas E*, Tsimberidou AM*. Overview of precision oncology trials: Challenges and opportunities. Expert Rev Clin Pharmacol 11(8):797-804, 2018. e-Pub 2018. PMID: 30044653.
84. Dumbrava EI, Alfattal R, Miller VA, Tsimberidou AM. Complete response to a fibroblast growth factor receptor inhibitor in a patient with head and neck squamous cell carcinoma harboring FGF amplifications. JCO Precis Oncol 2:PO.18.00100, 2018. e-Pub 2018. PMID: 31123723.
85. Groisberg R, Hong DS, Roszik J, Janku F, Tsimberidou AM, Javle M, Meric-Bernstam F, Subbiah V. Clinical next-generation sequencing for precision oncology in rare cancers. Mol Cancer Ther 17(7):1595-1601, 2018. e-Pub 2018. PMID: 29654067.
86. Merker JD, Oxnard GR, Compton C, Diehn M, Hurley P, Lazar AJ, Lindeman N, Lockwood CM, Rai A, Schilsky RL, Tsimberidou AM, Vasalos P, Billman B, Oliver T, Bruinooge SS, Hayes DF, Turner NC. Circulating tumor DNA analysis in patients with cancer: American Society of Clinical Oncology and College of American Pathologists joint review. J Clin Oncol 36(16):1631-1641, 2018. e-Pub 2018. PMID: 29504847.
87. Kato S, Jardim DL, Johnson FM, Subbiah V, Piha-Paul S, Tsimberidou AM, Falchook GS, Karp D, Zinner R, Wheler J, Janku F, Fu S, Lim J, Bean S, Nguyen L, Urban S, Browne E, Meric-Bernstam F, Hong DS. Phase I study of the combination of crizotinib (as a MET inhibitor) and dasatinib (as a c-SRC inhibitor) in patients with advanced cancer. Invest New Drugs 36(3):416-423, 2018. e-Pub 2017. PMID: 29047029.
88. Liu L, Toung JM, Jassowicz AF, Vijayaraghavan R, Kang H, Zhang R, Kruglyak KM, Huang HJ, Hinoue T, Shen H, Salathia N, Hong DS, Naing A, Subbiah V, Piha-Paul SA, Bibikova M, Granger G, Barnes B, Shen R, Gutekunst K, Fu S, Tsimberidou AM, Lu C, Eng C, Moulder SL, Kopetz ES, Amaria RN, Meric-Bernstam F, Laird PW, Fan JB, Janku F. Targeted methylation sequencing of plasma cell-free DNA for cancer detection and classification. Ann Oncol 29(6):1445-1453, 2018. e-Pub 2018. PMID: 29635542.
89. Maymani H, Hess K, Groisberg R, Hong DS, Naing A, Piha-Paul S, Janku F, Fu S, Tsimberidou AM, Pant S, Karp D, Liu S, Sun M, Heymach J, Simon G, Meric-Bernstam F, Subbiah V. Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials. Lung Cancer 120:137-141, 2018. e-Pub 2018. PMID: 29748008.
90. Subbiah IM, Tang C, Rao A, Falchook GS, Subbiah V, Tsimberidou AM, Karp D, Kurzrock R, Hong DS. Older adults in phase I clinical trials: a comparative analysis of participation and clinical benefit rate among older adults versus middle age and AYA patients on phase I clinical trials with VEGF/VEGFR inhibitors. Oncotarget 9(48):28842-28848, 2018. e-Pub 2018. PMID: 29989021.
91. Sen S, Kato S, Agarwal R, Piha-Paul S, Hess K, Karp D, Janku F, Fu S, Naing A, Pant S, Falchook G, Tang C, Wu X, Ye Y, Tsimberidou A, Subbiah V, Kurzrock R, Byers L, Westin S, Lim J, Bean S, Bass A, Nguyen L, Meric-Bernstam F, Hong D. Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers. Br J Cancer 118(11):1419-1424, 2018. e-Pub 2018. PMID: 29695765.
92. Sakamuri D, Glitza IC, Betancourt Cuellar SL, Subbiah V, Fu S, Tsimberidou AM, Wheler JJ, Hong DS, Naing A, Falchook GS, Fanale MA, Cabanillas M, and Janku F. Phase I dose-escalation study of anti-CTLA-4 antibody ipilimumab and lenalidomide in patients with advanced cancers. Mol Cancer Ther 17(3):671-676, 2018. e-Pub 2017. PMID: 29237802.
93. Sen S, Hess KR, Hong DS, Naing A, Piha-Paul SA, Janku F, Subbiah I, Liu H, Khanji R, Huang L, Moorty S, Karp, DD, Tsimberidou AM, Meric-Bernstam, Subbiah V F. Development of a prognostic scoring system for patients with advanced cancer enrolled in immune checkpoint inhibitor phase 1 clinical trials. Br J Cancer 118(6):763-769, 2018. e-Pub 2018. PMID: 29462132.
94. Fountzilas E, Said R, Tsimberidou AM. Expanded access to investigational drugs: balancing patient safety with potential therapeutic benefits. Expert Opinion on Investigational Drugs 27(2):155-162, 2018. PMID: 29353505.
95. Möhrmann L, Huang H, Hong DS, Tsimberidou AM, Fu S, Piha-Paul S, Subbiah V, Karp DD, Naing A, Krug AK, Enderle D, Priewasser T, Noerholm M, Eitan E, Coticchia C, Stoll G, Jordan LM, Eng C, Kopetz S, Skog J, Meric-Bernstam F, Janku F. Liquid biopsies using plasma exosomal nucleic acids and plasma cell-free DNA compared with clinical outcomes of patients with advanced cancers. Clin Cancer Res 24(1):181-188, 2018. e-Pub 2017. PMID: 29051321.
96. Li MM, Datto M, Duncavage EJ, Kulkarni S, Lindeman NI, Roy S, Tsimberidou AM, Vnencak-Jones CL, Wolff DJ, Younes A, Nikiforova MN. Authors' Reply. J Mol Diagnostics 20(1):125-126, 2018. PMID: 29249244.
97. Goldstein JB, Tang C, Hess KR, Hong D, Subbiah V, Janku F, Fu S, Karp DD, Naing A, Tsimberidou AM, Wheler J, Zinner R, Javle M, Varadhachary GR, Wolff RA, Fogelman DR, Meric-Bernstam F, Piha-Paul SA. Outcomes of phase I clinical trials for patients with advanced pancreatic cancer: update of the MD Anderson Cancer Center experience. Oncotarget 8(50):87163-87173, 2017. e-Pub 2017. PMID: 29152071.
98. Tsimberidou AM, Hong DS, Ye Y, Cartwright C, Wheler JJ, Falchook GS, Naing A, Fu S, Piha-Paul S, Janku J, Meric-Bernstam F, Hwu P, Kee B, Kies MS, Broaddus R, Mendelsohn J, Hess KR, Kurzrock R. Initiative for molecular profiling and advanced cancer therapy (IMPACT): an MD Anderson precision medicine study. JCO Precis Oncol 1:PO.17.00002, 2017. e-Pub 2017. PMID: 29082359.
99. Fujii T, Barzi A, Sartore-Bianchi A, Cassingena A, Siravegna G, Karp DD, Piha-Paul SA, Subbiah V, Tsimberidou AM, Huang HJ, Veronese S, Di Nicolantonio F, Pingle S, Vibat CRT, Hancock S, Berz D, Melnikova VO, Erlander MG, Luthra R, Kopetz ES, Meric-Bernstam F, Siena S, Lenz HJ, Bardelli A, Janku F. Mutation-enrichment next-generation sequencing for quantitative detection of KRAS mutations in urine cell-free DNA from patients with advanced cancers. Clin Cancer Res 23(14):3657-3666, 2017. e-Pub 2017. PMID: 28096270.
100. Kehl KL, Fullmer CP, Fu S, George GC, Hess KR, Janku F, Karp DD, Kato S, Kizer CK, Kurzrock R, Naing A, Pant S, Piha-Paul SA, Subbiah V, Tsimberidou AM, Hong DS. Insurance clearance for early-phase oncology clinical trials following the affordable care act. Clin Cancer Res 23(15):1-8. e-Pub 2017. PMID: 28729355.
101. Subbiah IM, Tsimberidou A, Subbiah V, Janku F, Roy-Chowdhuri S, Hong DS. Next generation sequencing of carcinoma of unknown primary reveals novel combinatorial strategies in a heterogeneous mutational landscape. Oncoscience 4(5-6):47-56, 2017. e-Pub 2017. PMID: 28781987.
102. Tsimberidou AM. Initiative for molecular profiling and advanced cancer therapy and challenges in the implementation of precision medicine. Curr Probl Cancer 41(3):176-181, 2017. e-Pub 2017. PMID: 28410846.
103. Wang Z, Piha-Paul S, Janku F, Subbiah V, Shi N, Gong J, Wathoo C, Shaw K, Hess K, Broaddus R, Naing A, Hong D, Tsimberidou AM, Karp D, Yao J, Meric-Bernstam F, Fu S. Antiangiogenesis and gene aberration-related therapy may improve overall survival in patients with concurrent KRAS and TP53 hotspot mutant cancer. Oncotarget 8(20):33796-33806, 2017. PMID: 28430579.
104. Subbiah V, Khawaja MR, Hong DS, Amini B, Yungfang J, Liu H, Johnson A, Schrock AB, Ali SM, Sun JX, Fabrizio D, Piha-Paul S, Fu S, Tsimberidou AM, Naing A, Janku F, Karp DD, Overman M, Eng C, Kopetz S, Meric-Bernstam F, Falchook GS. First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients. JCI Insight 2(8):e90380, 2017. e-Pub 2017. PMID: 28422758.
105. Tang C, Welsh JW, de Groot P, Massarelli E, Chang JY, Hess KR, Basu S, Curran MA, Cabanillas ME, Subbiah V, Fu S, Tsimberidou AM, Karp D, Gomez DR, Diab A, Komaki R, Heymach JV, Sharma P, Naing A, Hong DS. Ipilimumab with stereotactic ablative radiation therapy: phase I results and immunologic correlates from peripheral T cells. Clin Cancer Res 23(6):1388-1396, 2017. e-Pub 2016. PMID: 27649551.
106. Janku F, Huang HJ, Fujii T, Shelton DN, Madwani K, Fu S, Tsimberidou AM, Piha-Paul SA, Wheler JJ, Zinner RG, Naing A, Hong DS, Karp DD, Cabrilo G, Kopetz ES, Subbiah V, Luthra R, Kee BK, Eng C, Morris VK, Karlin-Neumann GA, Meric-Bernstam F. Multiplex KRASG12/G13 mutation testing of unamplified cell-free DNA from the plasma of patients with advanced cancers using droplet digital polymerase chain reaction. Ann Oncol 28(3):642-650, 2017. PMID: 27993791.
107. Li MM*, Datto M*, Duncavage EJ*, Kulkarni S*, Lindeman NI*, Roy S*, Tsimberidou AM*, Vnencak-Jones CL*, Wolff DJ*, Younes A*, Nikiforova MN*. Standards and guidelines for the interpretation and reporting of sequence variants in cancer: A joint consensus recommendation of the association for molecular pathology, American Society of Clinical Oncology, and College of American Pathologists. J Mol Diagn 19(1):4-23, 2017. PMID: 27993330.
108. Reilley MJ, Bailey A, Subbiah V, Janku F, Naing A, Falchook G, Karp D, Piha-Paul S, Tsimberidou AM, Fu S, Lim J, Bean S, Bass A, Montez S, Vence L, Sharma P, Allison J, Meric-Bernstam F, Hong DS. Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies. J Immunother Cancer 5:35, 2017. e-Pub 2017. PMID: 28428884.
109. Kinahan H, Maiti A, Hess K, Dempsey J, Beatty L, Baldwin S, Hong DS, Naing A, Fu S, Tsimberidou AM, Piha-Paul S, Janku F, Karp D, Reddy S, Yennu S, Epner D, Bruera E, Meric-Bernstam F, Falchook G, Subbiah V. Post-discharge survival outcomes of patients with advanced cancer from the University of Texas MD Anderson Cancer Center Investigational Cancer Therapeutics (Phase I Trials) Inpatient Unit. Oncology 92(1):14-20, 2017. e-Pub 2016. PMID: 27802448.
110. Subbiah IM, Wheler JJ, Hess KR, Hong DS, Naing A, Fu S, Kurzrock R, Tsimberidou AM. Outcomes of patients ≥65 years old with advanced cancer treated on phase I trials at MD Anderson Cancer Center. Int J Cancer 140(1):208-215, 2017. e-Pub 2016. PMID: 27599876.
111. Hong DS, Morris VK, El Osta B, Sorokin AV, Janku F, Fu S, Overman MJ, Piha-Paul S, Subbiah V, Kee B, Tsimberidou AM, Fogelman D, Bellido J, Shureiqi I, Huang H, Atkins J, Tarcic G, Sommer N, Lanman R, Meric-Bernstam F, Kopetz S. Phase IB study of vemurafenib in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with BRAFV600E mutation. Cancer Discov 6(12):1352-1365, 2016. e-Pub 2016. PMID: 27729313.
112. Wang Z, Shi N, Naing A, Janku F, Subbiah V, Araujo DM, Patel SR, Ludwig JA, Ramondetta LM, Levenback CF, Ramirez PT, Piha-Paul SA, Hong D, Karp DD, Tsimberidou AM, Meric-Bernstam F, Fu S. Survival of patients with metastatic leiomyosarcoma: the MD Anderson Clinical Center for Targeted Therapy experience. Cancer Med 5(12):3437-3444, 2016. e-Pub 2016. PMID: 27882721.
113. George GC, Iwuanyanwu EC, Anderson KO, Yusuf A, Zinner RG, Piha-Paul SA, Tsimberidou AM, Naing A, Fu S, Janku F, Subbiah V, Cleeland CS, Mendoza TR, Hong DS. Sleep quality and its association with fatigue, symptom burden, and mood in patients with advanced cancer in a clinic for early-phase oncology clinical trials. Cancer 122(21):3401-3409, 2016. PMID: 27412379.
114. Wheler JJ, Janku F, Naing A, Li Y, Stephen B, Zinner R, Subbiah V, Fu S, Karp D, Falchook GS, Tsimberidou AM, Piha-Paul S, Anderson R, Ke D, Miller V, Yelensky R, Lee JJ, Hong D, Kurzrock R. TP53 alterations correlate with response to VEGF/VEGFR inhibitors: implications for targeted therapeutics. Mol Cancer Ther 15(10):2475-2485, 2016. e-Pub 2016. PMID: 27466356.
115. Subbiah V, Hess KR, Khawaja MR, Wagner MJ, Tang C, Naing A, Fu S, Janku F, Piha-Paul S, Tsimberidou AM, Herzog CE, Ludwig JA, Patel S, Ravi V, Benjamin RS, Meric-Bernstam F, Hong DS. Evaluation of novel targeted therapies in aggressive biology sarcoma patients after progression from US FDA approved therapies. Sci Rep 6:35448, 2016. PMID: 27748430.
116. Park H, Garrido-Laguna I, Naing A, Fu S, Falchook GS, Piha-Paul SA, Wheler JJ, Hong DS, Tsimberidou AM, Subbiah V, Zinner RG, Kaseb AO, Patel S, Fanale MA, Velez-Bravo VM, Meric-Bernstam F, Kurzrock R, Janku F. Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. Oncotarget 7(41):67521-67531, 2016. e-Pub 2016. PMID: 27589687.
117. Wheler JJ, Janku F, Naing A, Li Y, Stephen B, Zinner R, Subbiah V, Fu S, Karp D, Falchook GS, Tsimberidou AM, Piha-Paul S, Anderson R, Ke D, Miller V, Yelensky R, Lee JJ, Hong DS, Kurzrock R. Cancer therapy directed by comprehensive genomic profiling: A single center study. Cancer Res 76(13):3690-701, 2016. e-Pub 2016. PMID: 27197177.
118. Hou MM, Wang Z, Janku F, Piha-Paul S, Naing A, Hong D, Westin S, Coleman RL, Sood AK, Tsimberidou AM, Subbiah V, Wheler J, Zinner R, Lu K, Meric-Bernstam F, Fu S. Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: Phase I trial experience. Oncotarget 7(23):35132-43, 2016. e-Pub 2016. PMID: 27147567.
119. Janku F, Huang HJ, Claes B, Falchook GS, Fu S, Hong D, Ramzanali NM, Nitti G, Cabrilo G, Tsimberidou AM, Naing A, Piha-Paul SA, Wheler JJ, Karp DD, Holley VR, Zinner RG, Subbiah V, Luthra R, Kopetz S, Overman MJ, Kee BK, Patel S, Devogelaere B, Sablon E, Maertens G, Mills GB, Kurzrock R, Meric-Bernstam F. BRAF mutation testing in cell-free DNA from the plasma of patients with advanced cancers using a rapid, automated molecular diagnostics system. Mol Cancer Ther 15(6):1397-1404, 2016. e-Pub 2016. PMID: 27207774.
120. Khawaja MR, Nick AM, Madhusudanannair V, Fu S, Hong D, McQuinn LM, Ng CS, Piha-Paul SA, Janku F, Subbiah V, Tsimberidou AM, Karp D, Meric-Bernstam F, Lu KH, Naing A. Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancers. Cancer Chemother Pharmacol 77(5):973-7, 2016. e-Pub 2016. PMID: 27014780.
121. Said R, Kakadiaris E, Piha-Paul S, Fu S, Falchook G, Janku F, Wheler JJ, Zinner R, Hong DS, Kurzrock R, Tsimberidou AM. Phase I clinical trial of lenalidomide in combination with bevacizumab in patients with advanced cancer. Cancer Chemother Pharmacol 77(5):1097-102, 2016. e-Pub 2016. PMID: 27085994.
122. Le Tourneau C, Kamal M, Tsimberidou AM, Bedard P, Pierron G, Callens C, Rouleau E, Vincent-Salomon A, Servant N, Alt M, Rouzier R, Paoletti X, Delattre O, Bièche I. Treatment algorithms based on tumor molecular profiling: the essence of precision medicine trials. J Natl Cancer Inst 108(4):1-10, 2016. e-Pub 2015. PMID: 26598514.
123. Maiti A, Brown RE, Corn PG, Murthy R, Ganeshan DM, Tsimberidou AM, Subbiah V. Antitumor response to combined antiangiogenic and cytotoxic chemotherapy in recurrent metastatic chromophobe renal cell carcinoma: response signatures and proteomic correlates. Clin Genitourin Cancer 14(2):e187-93, 2016. e-Pub 2015. PMID: 26684814.
124. Liu X, Kambrick S, Fu S, Naing A, Subbiah V, Blumenschein GR, Glisson BS, Kies MS, Tsimberidou AM, Wheler JJ, Zinner RG, Hong DS, Kurzrock R, Piha-Paul SA. Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus. Oncotarget 7(17):23227-38, 2016. e-Pub 2016. PMID: 26933802.
125. Said R, Ye Y, Hong DS, Naing A, Falchook G, Fu S, Wheler JJ, Piha-Paul S, Tsimberidou AM. Phase I clinical trial of lenalidomide in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol 77(3):575-81, 2016. e-Pub 2016. PMID: 26825327.
126. Tsimberidou AM. Targeted therapy in cancer. Cancer Chemother Pharmacol 76(6):1113-32, 2015. e-Pub 2015. PMID: 26391154.
127. Tsimberidou AM, Kurzrock R. What defines precision medicine? Lessons learned from the SHIVA trial. Lancet Oncol 16(16):e579-80, 2015. PMID: 26678197.
128. Subbiah IM, Falchook GS, Kaseb AO, Hess KR, Tsimberidou AM, Fu S, Subbiah V, Hong DS, Naing A, Piha-Paul SA, Akmal O, Janku F, Kurzrock R. Exploring response signals and targets in aggressive unresectable hepatocellular carcinoma: an analysis of targeted therapy phase 1 trials. Oncotarget 6(29):28453-62, 2015. e-Pub 2015. PMID: 26164085.
129. Janku F, Claes B, Huang HJ, Falchook GS, Devogelaere B, Kockx M, Bempt IV, Reijans M, Naing A, Fu S, Piha-Paul SA, Hong DS, Holley VR, Tsimberidou AM, Stepanek VM, Patel SP, Kopetz ES, Subbiah V, Wheler JJ, Zinner RG, Karp DD, Luthra R, Roy-Chowdhuri S, Sablon E, Meric-Bernstam F, Maertens G, Kurzrock R. BRAF mutation testing with a rapid, fully integrated molecular diagnostics system. Oncotarget 6(29):26886-94, 2015. e-Pub 2015. PMID: 26330075.
130. Janku F, Angenendt P, Tsimberidou AM, Fu S, Naing A, Falchook GS, Hong DS, Holley VR, Cabrilo G, Wheler JJ, Piha-Paul SA, Zinner RG, Bedikian AY, Overman MJ, Kee BK, Kim KB, Kopetz ES, Luthra R, Diehl F, Meric-Bernstam F, Kurzrock R. Erratum: Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies. Oncotarget 6(27):24581, 2015. PMID: 26405159.
131. Rodon J, Soria JC, Berger R, Batist G, Tsimberidou A, Bresson C, Lee JJ, Rubin E, Onn A, Schilsky RL, Miller WH, Eggermont AM, Mendelsohn J, Lazar V, Kurzrock R. Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a worldwide innovative network (WIN) consortium trial. Ann Oncol 26(8):1791-8, 2015. e-Pub 2015. PMID: 25908602.
132. Said R, Kurzrock R, Naing A, Hong DS, Fu S, Piha-Paul SA, Wheler JJ, Janku F, Kee BK, Bidyasar S, Lim J, Wallace M, Tsimberidou AM. Dose-finding study of hepatic arterial infusion of irinotecan-based treatment in patients with advanced cancers metastatic to the liver. Invest New Drugs 33(4):911-20, 2015. e-Pub 2015. PMID: 25990659.
133. Meric-Bernstam F, Johnson A, Holla V, Bailey AM, Brusco L, Chen K, Routbort M, Patel KP, Zeng J, Kopetz S, Davies MA, Piha-Paul SA, Hong DS, Eterovic AK, Tsimberidou AM, Broaddus R, Bernstam EV, Shaw KR, Mendelsohn J, Mills GB. A decision support framework for genomically informed investigational cancer therapy. J Natl Cancer Inst 107(7), 2015. e-Pub 2015. PMID: 25863335.
134. Hong DS, Janku F, Naing A, Falchook GS, Piha-Paul S, Wheler JJ, Fu S, Tsimberidou AM, Stecher M, Mohanty P, Simard J, Kurzrock R. Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancer. Invest New Drugs 33(3):621-31, 2015. e-Pub 2015. PMID: 25822109.
135. Rodrigues HV, Ke D, Lim J, Stephen B, Bellido J, Janku F, Zinner R, Tsimberidou A, Hong D, Piha-Paul S, Fu S, Naing A, Subbiah V, Karp D, Falchook G, Kurzrock R, Wheler J. Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy. Invest New Drugs 33(3):700-9, 2015. e-Pub 2015. PMID: 25902899.
136. Fu S, Hou MM, Naing A, Janku F, Hess K, Zinner R, Subbiah V, Hong D, Wheler J, Piha-Paul S, Tsimberidou A, Karp D, Araujo D, Kee B, Hwu P, Wolff R, Kurzrock R, Meric-Bernstam F. Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation. Ann Oncol 26(5):1012-8, 2015. e-Pub 2015. PMID: 25669829.
137. Janku F, Angenendt P, Tsimberidou AM, Fu S, Naing A, Falchook GS, Hong DS, Holley VR, Cabrilo G, Wheler JJ, Piha-Paul SA, Zinner RG, Bedikian AY, Overman MJ, Kee BK, Kim KB, Kopetz ES, Luthra R, Diehl F, Meric-Bernstam F, Kurzrock R. Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies. Oncotarget 6(14):12809-21, 2015. PMID: 25980577.
138. Singh HM, Ungerechts G, Tsimberidou AM. Gene and cell therapy for pancreatic cancer. Expert Opin Biol Ther 15(4):1-12, 2015. e-Pub 2015. PMID: 25582170.
139. Bilen MA, Fu S, Falchook GS, Ng CS, Wheler JJ, Abdelrahim M, Erguvan-Dogan B, Hong DS, Tsimberidou AM, Kurzrock R, Naing A. Phase I trial of valproic acid and lenalidomide in patients with advanced cancer. Cancer Chemother Pharmacol 75(4):869-74, 2015. e-Pub 2015. PMID: 25666183.
140. Falchook GS, Moulder S, Naing A, Wheler JJ, Hong DS, Piha-Paul SA, Tsimberidou AM, Fu S, Zinner R, Janku F, Jiang Y, Huang M, Parkhurst KL, Kurzrock R. A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancer. Invest New Drugs 33(1):177-86, 2015. e-Pub 2014. PMID: 25323060.
141. Falchook GS, Wheler JJ, Naing A, Piha-Paul SA, Fu S, Tsimberidou AM, Hong DS, Janku F, Zinner R, Jiang Y, Huang M, Lin Q, Parkhurst K, Kurzrock R. Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors. Invest New Drugs 33(1):215-24, 2015. e-Pub 2014. PMID: 25363205.
142. Wheler J, Yelensky R, Falchook G, Kim KB, Hwu P, Tsimberidou AM, Stephens PJ, Hong D, Cronin MT, Kurzrock R. Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistance. BMC Cancer 15(1):61, 2015. e-Pub 2015. PMID: 25886620.
143. Tsimberidou AM, Said R, Culotta K, Wistuba I, Jelinek J, Fu S, Falchook G, Naing A, Piha-Paul S, Zinner R, Siddik ZH, He G, Hess K, Stewart DJ, Kurzrock R, Issa JP. Phase I study of azacitidine and oxaliplatin in patients with advanced cancers that have relapsed or are refractory to any platinum therapy. Clin Epigenetics 7(1):29, 2015. e-Pub 2015. PMID: 25806091.
144. Liu X, George GC, Tsimberidou AM, Naing A, Wheler JJ, Kopetz S, Fu S, Piha-Paul SA, Eng C, Falchook GS, Janku F, Garrett C, Karp D, Kurzrock R, Zinner R, Raghav K, Subbiah V, Hess K, Meric-Bernstam F, Hong DS, Overman MJ. Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response. BMC Cancer 15(1):713, 2015. e-Pub 2015. PMID: 26474549.
145. Fu S, Shi N, Wheler J, Naing A, Janku F, Piha-Paul S, Gong J, Hong D, Tsimberidou AM, Zinner R, Subbiah V, Hou MM, Ramirez P, Ramondetta L, Lu K, Meric-Bernstam F. Characteristics and outcomes for patients with advanced vaginal or vulvar cancer referred to a phase I clinical trials program: the MD Anderson cancer center experience. Gynecol Oncol Res Pract 2:10, 2015. e-Pub 2015. PMID: 27231570.
146. Hong DS, Henary H, Falchook GS, Naing A, Fu S, Moulder S, Wheler JJ, Tsimberidou AM, Durand JB, Khan R, Yang P, Johansen M, Newman RA, Kurzrock R. First-in-human study of pbi-05204, an oleander-derived inhibitor of Akt, FGF-2, NF-kβ and p70S6K, in patients with advanced solid tumors. Invest New Drugs 32(6):1204-12, 2014. e-Pub 2014. PMID: 24919855.
147. Ganesan P, Moulder S, Lee JJ, Janku F, Valero V, Zinner RG, Naing A, Fu S, Tsimberidou AM, Hong D, Stephen B, Stephens P, Yelensky R, Meric-Bernstam F, Kurzrock R, Wheler JJ. Triple-negative breast cancer patients treated at MD Anderson Cancer Center in phase I trials: improved outcomes with combination chemotherapy and targeted agents. Mol Cancer Ther 13(12):3175-84, 2014. e-Pub 2014. PMID: 25253784.
148. Jardim DL, Tang C, Gagliato Dde M, Falchook GS, Hess K, Janku F, Fu S, Wheler JJ, Zinner RG, Naing A, Tsimberidou AM, Holla V, Li MM, Roy-Chowdhuri S, Luthra R, Salgia R, Kurzrock R, Meric-Bernstam F, Hong DS. Analysis of 1,115 patients tested for MET amplification and therapy response in the MD Anderson Phase I Clinic. Clin Cancer Res 20(24):6336-45, 2014. e-Pub 2014. PMID: 25326232.
149. Tang C, Hess K, Jardim DL, Gagliato Dde M, Tsimberidou AM, Falchook G, Fu S, Janku F, Naing A, Piha-Paul S, Subbiah V, Wheler J, Zinner RG, Kurzrock R, Ellis LM, Meric-Berstam F, Hong DS. Synergy between VEGF/VEGFR inhibitors and chemotherapy agents in the phase I clinic. Clin Cancer Res 20(23):5956-63, 2014. e-Pub 2014. PMID: 25316815.
150. Hou MM, Liu X, Wheler J, Naing A, Hong D, Coleman RL, Tsimberidou A, Janku F, Zinner R, Lu K, Kurzrock R, Fu S. Targeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: A phase I clinical experience. Oncotarget 5(22):11168-79, 2014. PMID: 25426553.
151. Said R, Ye Y, Falchook GS, Janku F, Naing A, Zinner R, Blumenschein GR, Fu S, Hong DS, Piha-Paul SA, Wheler JJ, Kurzrock R, Palmer GA, Aldape K, Hess KR, Tsimberidou AM. Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trials. Oncotarget 5(19):8937-46, 2014. e-Pub 2014. PMID: 25313136.
152. Tsimberidou AM, Keating MJ, Jabbour EJ, Ravandi-Kashani F, O'Brien S, Estey E, Bekele N, Plunkett WK, Kantarjian H, Borthakur G. A phase I study of fludarabine, cytarabine, and oxaliplatin therapy in patients with relapsed or refractory acute myeloid leukemia. Clin Lymphoma Myeloma Leuk 14(5):395-400.e1, 2014. e-Pub 2014. PMID: 24637132.
153. Hong DS, Garrido-Laguna I, Ekmekcioglu S, Falchook GS, Naing A, Wheler JJ, Fu S, Moulder SL, Piha-Paul S, Tsimberidou AM, Wen Y, Culotta KS, Anderes K, Davis DW, Liu W, George GC, Camacho LH, Percy Ivy S, Kurzrock R. Dual inhibition of the vascular endothelial growth factor pathway: A phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors. Cancer 120(14):2164-73, 2014. e-Pub 2014. PMID: 24752867.
154. Tsimberidou AM, Wen S, Hong DS, Wheler JJ, Falchook GS, Fu S, Piha-Paul SA, Naing A, Janku F, Aldape KD, Ye Y, Kurzrock R, Berry DA. Personalized medicine for patients with advanced cancer in the phase I program at MD Anderson: validation and landmark analyses. Clin Cancer Res 20(18):4827-36, 2014. e-Pub 2014. PMID: 24987059.
155. Corrales-Medina FF, Herzog C, Hess K, Egas-Bejar D, Hong DS, Falchook G, Anderson P, Nunez C, Huh WW, Naing A, Tsimberidou AM, Wheler J, Paul SP, Janku F, Kleinerman ES, Kurzrock R, Subbiah V. Clinical characteristics and outcomes of pediatric oncology patients with aggressive biology enrolled in phase I clinical trials designed for adults: The University of Texas MD Anderson Cancer Center experience. Oncoscience 1(7):522-30, 2014. PMID: 25587555.
156. Fu S, Hou MM, Wheler J, Hong D, Naing A, Tsimberidou AM, Janku F, Zinner R, Piha-Paul S, Falchook G, Kuo MT, Kurzrock R. Exploratory study of carboplatin plus the copper-lowering agent trientine in patients with advanced malignancies. Invest New Drugs 32(3):465-72, 2014. e-Pub 2013. PMID: 24306314.
157. Said R, Ye Y, Hong DS, Janku F, Fu S, Naing A, Wheler JJ, Kurzrock R, Thomas C, Palmer GA, Hess KR, Aldape K, Tsimberidou AM. Characteristics and survival of patients with advanced cancer and p53 mutations. Oncotarget 5(11):3871-9, 2014. PMID: 25003695.
158. Janku F, Kaseb AO, Tsimberidou AM, Wolff RA, Kurzrock R. Identification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular Carcinoma using targeted next generation sequencing. Oncotarget 5(10):3012-22, 2014. PMID: 24931142.
159. Hong DS, Hui D, Bruera E, Janku F, Naing A, Falchook GS, Piha-Paul S, Wheler JJ, Fu S, Tsimberidou AM, Stecher M, Mohanty P, Simard J, Kurzrock R. MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion study. Lancet Oncol 15(6):656-66, 2014. e-Pub 2014. PMID: 24746841.
160. Hou MM, Liu X, Wheler J, Naing A, Hong D, Bodurka D, Schmeler K, Tsimberidou AM, Janku F, Zinner R, Piha-Paul S, Hu CY, Lu K, Kurzrock R, Fu S. Outcomes of patients with metastatic cervical cancer in a phase I clinical trials program. Anticancer Res 34(5):2349-55, 2014. PMID: 24778042.
161. Wheler JJ, Parker BA, Lee JJ, Atkins JT, Janku F, Tsimberidou AM, Zinner R, Subbiah V, Fu S, Schwab R, Moulder S, Valero V, Schwaederle M, Yelensky R, Miller VA, Stephens MP, Meric-Bernstam F, Kurzrock R. Unique molecular signatures as a hallmark of patients with metastatic breast cancer: Implications for current treatment paradigms. Oncotarget 5(9):2349-54, 2014. e-Pub 2014. PMID: 24811890.
162. Wheler JJ, Moulder SL, Naing A, Janku F, Piha-Paul SA, Falchook GS, Zinner R, Tsimberidou AM, Fu S, Hong DS, Atkins JT, Yelensky R, Stephens PJ, Kurzrock R. Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway. Oncotarget 5(10):3029-38, 2014. PMID: 24912489.
163. Ganesan P, Piha-Paul S, Naing A, Falchook G, Wheler J, Fu S, Hong DS, Kurzrock R, Janku F, Laday S, Bedikian AY, Kies M, Wolff RA, Tsimberidou AM. Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced cancer. Invest New Drugs 32(2):279-86, 2014. e-Pub 2013. PMID: 23756764.
164. Piha-Paul SA, Wheler JJ, Fu S, Levenback C, Lu K, Falchook GS, Naing A, Hong DS, Tsimberidou AM, Kurzrock R. Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the MTOR inhibitor temsirolimus. Oncotarget 5(7):1846-55, 2014. PMID: 24742900.
165. Wheler JJ, Janku F, Falchook GS, Jackson TL, Fu S, Naing A, Tsimberidou AM, Moulder SL, Hong DS, Yang H, Piha-Paul SA, Atkins JT, Garcia-Manero G, Kurzrock R. Phase I study of Anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers. Cancer Chemother Pharmacol 73(3):495-501, 2014. e-Pub 2014. PMID: 24435060.
166. Tsimberidou AM, Adamopoulos AM, Ye Y, Piha-Paul S, Janku F, Fu S, Hong D, Falchook GS, Naing A, Wheler J, Fortier A, Kurzrock R, Hess KR. Phase I clinical trial of bendamustine and bevacizumab for patients with advanced cancer. J Natl Compr Canc Netw 12(2):194-203, 2014. PMID: 24586081.
167. Said R, Banchs J, Wheler J, Hess KR, Falchook G, Fu S, Naing A, Hong D, Piha-Paul S, Ye Y, Yeh E, Wolff RA, Tsimberidou AM. The prognostic significance of left ventricular ejection fraction in patients with advanced cancer treated in phase I clinical trials. Ann Oncol 25(1):276-82, 2014. PMID: 24356639.
168. Janku F, Hong DS, Fu S, Piha-Paul SA, Naing A, Falchook GS, Tsimberidou AM, Stepanek VM, Moulder SL, Lee JJ, Luthra R, Zinner RG, Broaddus RR, Wheler JJ, Kurzrock R. Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors. Cell Rep 6(2):377-87, 2014. e-Pub 2014. PMID: 24440717.
169. Tang C, Jardim DL, Falchook GS, Hess K, Fu S, Wheler JJ, Zinner RG, Naing A, Tsimberidou AM, De Melo Galgiato D, Westin SN, Meric-Bernstam F, Kurzrock R, Hong DS. MET nucleotide variations and amplification in advanced ovarian cancer: characteristics and outcomes with c-Met inhibitors. Oncoscience 1(1):5-13, 2014. e-Pub 2013. PMID: 25593979.
170. Jardim DL, Wheler JJ, Hess K, Tsimberidou AM, Zinner R, Janku F, Subbiah V, Naing A, Piha-Paul SA, Westin SN, Roy-Chowdhuri S, Meric-Bernstam F, Hong DS. FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors. PLoS One 9(2):e89388, 2014. e-Pub 2014. PMID: 24586741.
171. Rolfo C, Fanale D, Hong DS, Tsimberidou AM, Piha-Paul SA, Pauwels P, Van Meerbeeck JP, Caruso S, Bazan V, Cicero G, Russo A, Giovannetti E. Impact of microRNAs in resistance to chemotherapy and novel targeted agents in non-small cell lung cancer. Curr Pharm Biotechnol 15(5):475-85, 2014. e-Pub 2014. PMID: 24846062.
172. Falchook GS, Naing A, Wheler JJ, Tsimberidou AM, Zinner R, Hong DS, Fu S, Piha-Paul SA, Janku F, Hess KR, Bastida C, Kurzrock R. Dual EGFR inhibition in combination with anti-VEGF treatment in colorectal cancer. Oncoscience 1(8):540-9, 2014. e-Pub 2014. PMID: 25594061.
173. Wheler JJ, Naing A, Stepanek V, Falchook GS, F S, Garrido-Laguna I, Tsimberidou AM, Piha-Paul SA, Moulder S, Lee JJ, Luthra R, Hong D, Kurzrock R. PIK3CA mutations in advanced cancers: characteristics and outcomes. Oncotarget 3(12):1566-75, 2013.
174. Veasey-Rodrigues H, Parsons HA, Janku F, Naing A, Wheler JJ, Tsimberidou AM, Kurzrock R. A pilot study of temsirolimus and body composition. J Cachexia Sarcopenia Muscle 4(4):259-65, 2013. e-Pub 2013. PMID: 23893509.
175. Ganesan P, Janku F, Naing A, Hong DS, Tsimberidou AM, Falchook GS, Wheler JJ, Piha-Paul SA, Fu S, Stepanek VM, Lee JJ, Luthra R, Overman MJ, Kopetz ES, Wolff RA, Kurzrock R. Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations. Mol Cancer Ther 12(12):2857-63, 2013. e-Pub 2013. PMID: 24092809.
176. Ganesan P, Piha-Paul S, Naing A, Falchook G, Wheler J, Janku F, Zinner R, Laday S, Kies M, Tsimberidou AM. Phase I clinical trial of lenalidomide in combination with temsirolimus in patients with advanced cancer. Invest New Drugs 31(6):1505-13, 2013. e-Pub 2013. PMID: 23982248.
177. Garcia SS, Atkins JT, Falchook GS, Tsimberidou AM, Hong DS, Trivedi MV, Kurzrock R. Transient severe hyperbilirubinemia after hepatic arterial infusion of oxaliplatin in patients with liver metastases. Cancer Chemother Pharmacol 72(6):1265-71, 2013. e-Pub 2013. PMID: 24101145.
178. Tsimberidou AM, Vaklavas C, Fu S, Wen S, Lim JA, Hong D, Wheler J, Naing A, Uehara C, Wallace M, Kurzrock R. Hepatic arterial infusion therapy in advanced cancer and liver-predominant disease: the MD Anderson Experience. Hepatogastroenterology 60(127):1611-23, 2013. PMID: 24634931.
179. Veasey Rodrigues H, Baracos VE, Wheler JJ, Parsons HA, Hong DS, Naing A, Fu S, Falchoock G, Tsimberidou AM, Piha-Paul S, Chisholm G, Kurzrock R. Body composition and survival in the early clinical trials setting. Eur J Cancer 49(15):3068-75, 2013. e-Pub 2013. PMID: 23867127.
180. Tsimberidou AM, Wierda WG, Wen S, Plunkett W, O'Brien S, Kipps TJ, Jones JA, Badoux X, Kantarjian H, Keating MJ, Chronic Lymphocytic Leukemia Research Consortium. Phase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab therapy in aggressive relapsed/refractory chronic lymphocytic leukemia or richter syndrome. Clin Lymphoma Myeloma Leuk 13(5):568-74, 2013. e-Pub 2013. PMID: 23810245.
181. Wheler JJ, Tsimberidou AM, Falchook GS, Zinner RG, Hong DS, Fok JY, Fu S, Piha-Paul SA, Naing A, Kurzrock R. Combining erlotinib and cetuximab is associated with activity in patients with non-small cell lung cancer (including squamous cell carcinomas) and wild-type EGFR or resistant mutations. Mol Cancer Ther 12(10):2167-75, 2013. e-Pub 2013. PMID: 23963360.
182. Hong D, Said R, Falchook G, Naing A, Moulder S, Tsimberidou AM, Galluppi G, Dakappagari N, Storgard C, Kurzrock R, Rosen LS. Phase I study of BIIB028, a selective heat shock protein 90 inhibitor, in patients with refractory metastatic or locally advanced solid tumors. Clin Cancer Res 19(17):4824-31, 2013. e-Pub 2013. PMID: 23873691.
183. Henary H, Hong DS, Falchook GS, Tsimberidou AM, George GC, Wen S, Wheler J, Fu S, Naing A, Piha-Paul S, Janku F, Kim KB, Hwu P, Kurzrock R. Melanoma patients in a phase I clinic: molecular aberrations, targeted therapy and outcomes. Ann Oncol 24(8):2158-65, 2013. e-Pub 2013. PMID: 23576709.
184. Féliz LR, Tsimberidou AM. Anti-vascular endothelial growth factor therapy in the era of personalized medicine. Cancer Chemother Pharmacol 72(1):1-12, 2013. e-Pub 2013. PMID: 23463481.
185. Wheler J, Hong D, Swisher SG, Falchook G, Tsimberidou AM, Helgason T, Naing A, Stephen B, Janku F, Stephens PJ, Yelensky R, Kurzrock R. Thymoma patients treated in a phase I clinic at MD Anderson Cancer Center: responses to mTOR inhibitors and molecular analyses. Oncotarget 4(6):890-8, 2013. PMID: 23765114.
186. Said R, Hong DS, Warneke CL, Lee JJ, Wheler JJ, Janku F, Naing A, Falchook GS, Fu S, Piha-Paul S, Tsimberidou AM, Kurzrock R. P53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapy. Oncotarget 4(5):705-14, 2013. e-Pub 2013. PMID: 23670029.
187. Wheler J, Falchook G, Tsimberidou AM, Hong D, Naing A, Piha-Paul S, Chen SS, Heymach J, Fu S, Stephen B, Fok JY, Janku F, Kurzrock R. Revisiting clinical trials using EGFR inhibitor-based regimens in patients with advanced non-small cell lung cancer: a retrospective analysis of an MD Anderson Cancer Center phase I population. Oncotarget 4(5):772-84, 2013. PMID: 23800712.
188. Tsimberidou AM, Ye Y, Wheler J, Naing A, Hong D, Nwosu U, Hess KR, Wolff RA. A phase I study of hepatic arterial infusion of nab-paclitaxel in combination with intravenous gemcitabine and bevacizumab for patients with advanced cancers and predominant liver metastases. Cancer Chemother Pharmacol 71(4):955-63, 2013. e-Pub 2013. PMID: 23377373.
189. Wheler JJ, Falchook GS, Tsimberidou AM, Hong DS, Naing A, Piha-Paul SA, Chen SS, Fu S, Stephen B, Fok JY, Janku F, Kurzrock R. Aberrations in the epidermal growth factor receptor gene in 958 patients with diverse advanced tumors: Implications for therapy. Ann Oncol 24(3):838-42, 2013. e-Pub 2012. PMID: 23139256.
190. Holsinger FC, Piha-Paul SA, Janku F, Hong DS, Atkins JT, Tsimberidou AM, Kurzrock R. Biomarker-directed therapy of squamous carcinomas of the head and neck: Targeting PI3K/PTEN/mTOR pathway. J Clin Oncol 31(9):e137-40, 2013. e-Pub 2013. PMID: 23358976.
191. Tsimberidou AM, Leick MB, Lim J, Fu S, Wheler J, Piha-Paul SA, Hong D, Falchook GS, Naing A, Subbiah IM, Fortier A, Avritscher R, Kurzrock R. Dose-finding study of hepatic arterial infusion of oxaliplatin-based treatment in patients with advanced solid tumors metastatic to the liver. Cancer Chemother Pharmacol 71(2):389-97, 2013. e-Pub 2012. PMID: 23143207.
192. Falchook GS, Naing A, Hong DS, Zinner R, Fu S, Piha-Paul SA, Tsimberidou AM, Morgan-Linnell SK, Jiang Y, Bastida C, Wheler JJ, Kurzrock R. Dual EGFR inhibition in combination with anti-VEGF treatment: a phase I clinical trial in non-small cell lung cancer. Oncotarget 4(1):118-27, 2013. PMID: 23435217.
193. Janku F, Wheler JJ, Naing A, Falchook GS, Hong DS, Stepanek VM, Fu S, Piha-Paul SA, Lee JJ, Luthra R, Tsimberidou AM, Kurzrock R. PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early phase clinical trials. Cancer Res 73(1):276-84, 2013. e-Pub 2012. PMID: 23066039.
194. Shim S, Stemke-Hale K, Tsimberidou AM, Noshari J, Anderson TE, Gascoyne PR. Antibody-independent isolation of circulating tumor cells by continuous-flow dielectrophoresis. Biomicrofluidics 7(1):12, 2013. e-Pub 2013. PMID: 24403989.
195. Vinas LR, Tsimberidou AM. Safety of bevacizumab. Journal of Symptoms and Signs 2(3):127-136, 2013.
196. Fu S, McQuinn L, Naing A, Wheler JJ, Janku F, Falchook GS, Piha-Paul SA, Tu D, Howard A, Tsimberidou AM, Zinner R, Hong DS, Kurzrock R. Barriers to study enrollment in patients with advanced cancer referred to a phase I clinical trials unit. Oncologist 18(12):1315-20, 2013. e-Pub 2013. PMID: 24153239.
197. Gupta V, Richards S, Rowe J, Acute Leukemia Stem Cell Transplantation Trialists' Collaborative Group [Tsimberidou A]. Allogeneic, but not autologous, hematopoietic cell transplantation improves survival only among younger adults with acute lymphoblastic leukemia in first remission: an individual patient data meta-analysis. Blood 121(2):339-50, 2013. e-Pub 2012. PMID: 23165481.
198. Subbiah IM, Subbiah V, Tsimberidou AM, Naing A, Kaseb AO, Javle M, Fu S, Hong DS, Piha-Paul S, Wheler JJ, Hess KR, Janku F, Falchook GS, Wolff RA, Kurzrock R. Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trials. Oncotarget 4(1):156-65, 2013. PMID: 23391555.
199. Hong DS, Patel JC, Wheler J, Naing A, Garrido-Laguna I, Falchook G, Fu S, Tsimberidou AM, Kopetz S, Win S, Kurzrock R. Outcomes in 144 patients with colorectal cancer treated in a phase I clinic: the MD Anderson Cancer Center experience. Clin Colorectal Cancer 11(4):297-303, 2012. e-Pub 2012. PMID: 22537607.
200. Tsimberidou AM, Iskander NG, Hong DS, Wheler JJ, Falchook GS, Fu S, Piha-Paul S, Naing A, Janku F, Luthra R, Ye Y, Wen S, Berry D, Kurzrock R. Personalized medicine in a phase I clinical trials program: The MD Anderson Cancer Center Initiative. Clin Cancer Res 18(22):6373-83, 2012. e-Pub 2012. PMID: 22966018.
201. Naing A, Veasey-Rodrigues H, Hong DS, Fu S, Falchook GS, Wheler JJ, Tsimberidou AM, Wen S, Fessahaye SN, Golden EC, Aaron J, Ewer MS, Kurzrock R. Electrocardiograms (ECGs) in phase I anticancer drug development: the MD Anderson Cancer Center experience with 8518 ECGs. Ann Oncol 23(11):2960-3, 2012. e-Pub 2012. PMID: 22745218.
202. Wheler JJ, Tsimberidou AM, Hong DS, Naing A, Falchook GS, Fu S, Moulder S, Stephen B, Wen S, Kurzrock R. Risk of serious toxicity in 1,181 patients treated in phase I clinical trials of predominantly targeted anticancer drugs: The MD Anderson Cancer Center Experience. Ann Oncol 23(8):1963-7, 2012. e-Pub 2012. PMID: 22377564.
203. Fu S, Barber FD, Naing A, Wheler J, Hong D, Falchook G, Piha-Paul S, Tsimberidou A, Howard A, Kurzrock R. Advance care planning in patients with cancer referred to a phase I clinical trials program: The MD Anderson Cancer Center experience. J Clin Oncol 30(23):2891-6, 2012. e-Pub 2012. PMID: 22778314.
204. Segler A, Tsimberidou AM. Lenalidomide in solid tumors. Cancer Chemother Pharmacol 69(6):1393-406, 2012. e-Pub 2012. PMID: 22584909.
205. Tsimberidou AM, Fu S, Subbiah IM, Naing A, Hong DS, Wen S, Fortier AH, Lim J, Kurzrock R. Intraperitoneal and intravenous chemotherapy in peritoneal carcinomatosis. Hepatogastroenterology 59(116):960-4, 2012. PMID: 22580643.
206. Wheler J, Tsimberidou AM, Hong D, Naing A, Falchook G, Piha-Paul S, Fu S, Moulder S, Stephen B, Wen S, Kurzrock R. Survival of 1,181 patients in a phase I clinic: The MD Anderson Clinical Center for Targeted Therapy Experience. Clin Cancer Res 18(10):2922-9, 2012. e-Pub 2012. PMID: 22452943.
207. Garrido-Laguna I, Janku F, Vaklavas C, Falchook GS, Fu S, Hong DS, Naing A, Tsimberidou AM, Wen S, Kurzrock R. Validation of the Royal Marsden Hospital prognostic score in patients treated in the phase I clinical trials program at the MD Anderson Cancer Center. Cancer 118(5):1422-8, 2012. e-Pub 2011. PMID: 21823111.
208. Janku F, Wheler JJ, Westin SN, Moulder SL, Naing A, Tsimberidou AM, Fu S, Falchook GS, Hong DS, Garrido-Laguna I, Luthra R, Lee JJ, Lu KH, Kurzrock R. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol 30(8):777-82, 2012. e-Pub 2012. PMID: 22271473.
209. Parsons HA, Tsimberidou AM*, Pontikos M, Fu S, Hong D, Wen S, Baracos VE, Kurzrock R. Evaluation of the clinical relevance of body composition parameters in patients with cancer metastatic to the liver treated with hepatic arterial infusion chemotherapy. Nutr Cancer 64(2):206-17, 2012. e-Pub 2012. PMID: 22229660.
210. Tsimberidou AM, Lewis N, Reid T, Burris H, Urban P, Tan EY, Anand S, Uehara C, Kurzrock R. Pharmacokinetics and antitumor activity of patupilone combined with midazolam or omeprazole in patients with advanced cancer. Cancer Chemother Pharmacol 68(6):1507-16, 2011. e-Pub 2011. PMID: 21499896.
211. Nabhan C, Tsimberidou AM. Therapy-related myeloid neoplasia after fludarabine and cyclophosphamide for chronic lymphocytic leukemia. Blood 118(13):3525-7, 2011. e-Pub 2011. PMID: 21803850.
212. Tsimberidou AM, Letourneau K, Fu S, Hong D, Naing A, Wheler J, Uehara C, McRae SE, Wen S, Kurzrock R. Phase I clinical trial of hepatic arterial infusion of paclitaxel in patients with advanced cancer and dominant liver involvement. Cancer Chemother Pharmacol 68(1):247-53, 2011. e-Pub 2010. PMID: 20941597.
213. Tsimberidou AM, Letourneau K, Wen S, Wheler J, Hong D, Naing A, Iskander NG, Uehara C, Kurzrock R. Phase I clinical trial outcomes in 93 patients with brain metastases: The MD Anderson Cancer Center experience. Clin Cancer Res 17(12):4110-8, 2011. e-Pub 2011. PMID: 21415223.
214. Vaklavas C, Chatzizisis YS, Tsimberidou AM. Common cardiovascular medications in cancer therapeutics. Pharmacol Ther 130(2):177-90, 2011. e-Pub 2011. PMID: 21277894.
215. Hong DS, Cabanillas ME, Wheler J, Naing A, Tsimberidou AM, Ye L, Waguespack SG, Hernandez M, El Naggar AK, Bidyasar S, Wright J, Sherman SI, Kurzrock R. Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies. J Clin Endocrinol Metab 96(4):997-1005, 2011. e-Pub 2011. PMID: 21289252.
216. Janku F, Tsimberidou AM, Garrido-Laguna I, Wang X, Luthra R, Hong DS, Naing A, Falchook GS, Moroney JW, Piha-Paul SA, Wheler JJ, Moulder SL, Fu S, Kurzrock R. PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Mol Cancer Ther 10(3):558-65, 2011. e-Pub 2011. PMID: 21216929.
217. Tsimberidou AM, Takimoto CH, Moulder S, Uehara C, Mita M, Mita A, Urban P, Tan E, Wang Y, Vining D, Kurzrock R. Effects of patupilone on the pharmacokinetics and pharmacodynamics of warfarin in patients with advanced malignancies: a phase I clinical trial. Mol Cancer Ther 10(1):209-17, 2011. PMID: 21220503.
218. Vaklavas C, Tsimberidou AM*, Wen S, Hong D, Wheler J, Ng CS, Naing A, Uehara C, Wolff RA, Kurzrock R. Phase 1 clinical trials in 83 patients with pancreatic cancer: the M. D. Anderson Cancer Center experience. Cancer 117(1):77-85, 2011. e-Pub 2010. PMID: 20737567.
219. El-Osta H, Hong D, Wheler J, Fu S, Naing A, Falchook G, Hicks M, Wen S, Tsimberidou AM, Kurzrock R. Outcomes of research biopsies in phase I clinical trials: the MD Anderson Cancer Center Experience. Oncologist 16(9):1292-8, 2011. e-Pub 2011. PMID: 21859821.
220. Subbiah IM, Lenihan DJ, Tsimberidou AM. Cardiovascular toxicity profiles of vascular-disrupting agents. Oncologist 16(8):1120-30, 2011. e-Pub 2011. PMID: 21742963.
221. Janku F, Tsimberidou AM, Wang X, Hong DS, Naing A, Gong J, Garrido-Laguna I, Parsons HA, Zinner RG, Kurzrock R. Outcomes of patients with advanced non-small cell lung cancer treated in a phase I clinic. Oncologist 16(3):327-35, 2011. e-Pub 2011. PMID: 21339262.
222. El-Osta H, Falchook G, Tsimberidou A, Hong D, Naing A, Kim K, Wen S, Janku F, Kurzrock R. BRAF mutations in advanced cancers: clinical characteristics and outcomes. PLoS One 6(10):e25806, 2011. e-Pub 2011. PMID: 22039425.
223. Tsimberidou AM, Akerley W, Schabel MC, Hong DS, Uehara C, Chhabra A, Warren T, Mather GG, Evans BA, Woodland DP, Swabb EA, Kurzrock R. Phase I clinical trial of MPC-6827 (Azixa), a microtubule destabilizing agent, in patients with advanced cancer. Mol Cancer Ther 9(12):3410-9, 2010. PMID: 21159616.
224. Tsimberidou AM, Moulder S, Fu S, Wen S, Naing A, Bedikian AY, Daring S, Uehara C, Ng C, Wallace M, Camacho L, Kurzrock R. Phase I clinical trial of hepatic arterial infusion of cisplatin in combination with intravenous liposomal doxorubicin in patients with advanced cancer and dominant liver involvement. Cancer Chemother Pharmacol 66(6):1087-93, 2010. e-Pub 2010. PMID: 20204368.
225. Tsimberidou AM, Fu S, Ng C, Lim JA, Wen S, Hong D, Wheler J, Bedikian AY, Eng C, Wallace M, Camacho LH, Kurzrock R. A phase 1 study of hepatic arterial infusion of oxaliplatin in combination with systemic 5-fluorouracil, leucovorin, and bevacizumab in patients with advanced solid tumors metastatic to the liver. Cancer 116(17):4086, 2010. e-Pub 2010. PMID: 20564148.
226. Vaklavas C, Sotelo-Rafiq EP, Lovy J, Escobar MA, Tsimberidou AM. Progressive multifocal leukoencephalopathy in a patient without apparent immunosuppression. Virol J 7:256, 2010. PMID: 20920200.
227. Tsimberidou AM, Keating MJ. Treatment of patients with fludarabine-refractory chronic lymphocytic leukemia: need for new treatment options. Leuk Lymph 51(7):1188-1199, 2010. PMID: 20545582.
228. Wheler J, Tsimberidou AM, Moulder S, Cristofanilli M, Hong D, Naing A, Pathak R, Liu S, Feng L, Kurzrock R. Clinical outcomes of patients with breast cancer in a phase I clinic: The M. D. Anderson Cancer Center Experience. Clin Breast Cancer 10(1):46-51, 2010. PMID: 20133258.
229. Tarrand JJ, Keating MJ, Tsimberidou AM, O'Brien S, LaSala RP, Han XY, Bueso-Ramos CE. Epstein-Barr virus latent membrane Protein 1 mRNA is expressed in a significant proportion of patients with chronic lymphocytic leukemia. Cancer 116(4):880-7, 2010. e-Pub 2010. PMID: 20052729.
230. Tsimberidou AM, Rudek MA, Hong D, Ng CS, Blair J, Goldsweig H, Kurzrock R. Phase 1 first-in-human, clinical study of S-trans, trans-farnesylthiosalicylic acid (salirasib) in patients with solid tumors. Cancer Chemother Pharmacol (Cover Sidebar) 65(2):235-41, 2010. e-Pub 2009. PMID: 19484470.
231. Vaklavas C, Lenihan D, Kurzrock R, Tsimberidou AM. Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: What are the important clinical markers to target?. Oncologist 15(2):130-41, 2010. e-Pub 2010. PMID: 20139170.
232. Tsimberidou AM, Braiteh F, Stewart DJ, Kurzrock R. Ultimate fate of oncology drugs approved by the Food and Drug Administration without a randomized trial. J Clin Oncol (Cover Sidebar) 27(36):6243-50, 2009. e-Pub 2009. PMID: 19826112.
233. Aguilera DG, Vaklavas C, Tsimberidou AM*, Wen S, Medeiros LJ, Corey SJ. Pediatric therapy-related myelodysplastic syndrome/acute myeloid leukemia: The M. D. Anderson Cancer Center Experience. J Pediatr Hematol Oncol 31(11):803-11, 2009. PMID: 19801947.
234. Tsimberidou AM, Vaklavas C, Wen S, Hong D, Wheler J, Ng C, Naing A, Tse S, Busaidy N, Markman M, Sherman SI, Kurzrock R. Phase I clinical trials in 56 patients with thyroid cancer: The M. D. Anderson Cancer Center Experience. J Clin Endocrinol Metab 94(11):4423-32, 2009. e-Pub 2009. PMID: 19820016.
235. Vemulapalli S, Chintala L, Tsimberidou AM*, Dhillon N, Lei X, Hong D, Kurzrock R. Clinical outcomes and factors predicting development of venous thromboembolic complications in patients with advanced refractory cancer in a phase I clinic: The M. D. Anderson Cancer Center Experience. Am J Hematol 84(7):408-13, 2009. e-Pub 2009. PMID: 19437507.
236. Aguilera DG, Tsimberidou AM. Dasatinib in chronic myeloid leukemia: a review. Ther Clin Risk Manag 5(2):281-9, 2009. e-Pub 2009. PMID: 19536317.
237. Wheler J, Tsimberidou AM, Hong D, Naing A, Jackson T, Liu S, Feng L, Kurzrock R. Survival of patients in a phase 1 clinic: the M. D. Anderson Cancer Center experience. Cancer 115(5):1091-9, 2009. PMID: 19165805.
238. Tsimberidou AM, Wen S, McLaughlin P, O'Brien S, Wierda WG, Lerner S, Strom S, Freireich EJ, Medeiros LJ, Kantarjian HM, Keating MJ. Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma. J Clin Oncol 27(6):904-10, 2009. e-Pub 2008. PMID: 19114699.
239. Tsimberidou AM, Tam C, Abruzzo LV, O'Brien S, Wierda WG, Lerner S, Kantarjian K, Keating MJ. Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia. Cancer 115(2):373-80, 2009. PMID: 19117034.
240. Tsimberidou AM, Keating MJ. Treatment of fludarabine-refractory chronic lymphocytic leukemia. Cancer 115(13):2824-36, 2009. PMID: 19402170.
241. Tsimberidou AM, Keating MJ. Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma: analysis of 2028 patients. Am J Hematol (Cover Sidebar) 8(9):430-32, 2009.
242. Tsimberidou AM, Camacho LH, Verstovsek S, Ng C, Hong DS, Uehara CK, Gutierrez C, Daring S, Stevens J, Komarnitsky PB, Schwartz B, Kurzrock R. A phase I clinical trial of darinaparsin in patients with refractory solid tumors. Clin Cancer Res (Cover Sidebar) 15(14):4769-76, 2009. e-Pub 2009. PMID: 19584162.
243. Tsimberidou AM, Estey E, Wen S, Pierce S, Kantarjian H, Albitar M, Kurzrock R. The prognostic significance of cytokine levels in newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndromes. Cancer 113(7):1605-13, 2008. PMID: 18683214.
244. Tsimberidou AM, Estey E. Relevance of clinical trials in acute myeloid leukaemia. Hematol Oncol 26(3):182-3, 2008. PMID: 18381703.
245. Tsimberidou AM, Kantarjian HM, Wen S, O'Brien S, Cortes J, Wierda WG, Koller C, Pierce S, Brandt M, Freireich EJ, Keating MJ, Estey E. The prognostic significance of serum β2 microglobulin levels in acute myeloid leukemia and prognostic scores predicting survival: analysis of 1,180 patients. Clin Cancer Res 14(3):721-30, 2008. PMID: 18245532.
246. Tsimberidou AM, Wierda WG, Plunkett W, Kurzrock RA, O'Brien S, Wen S, Ferrajoli A, Ravandi F, Garcia-Manero G, Estrov Z, Kipps TJ, Brown JR, Fiorentino A, Lerner S, Kantarjian HM, Keating MJ.. Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 26(2):196-203, 2008. PMID: 18182662.
247. Tsimberidou AM, Kantarjian HM, Wen S, Keating MJ, O'Brien S, Brandt M, Pierce S, Freireich EJ, Medeiros LJ, Estey E. Myeloid sarcoma is associated with superior event-free survival and overall survival compared with acute myeloid leukemia. Cancer 113(6):1370-8, 2008. PMID: 18623376.
248. Tsimberidou AM, Wen S, O'Brien S, McLaughlin P, Wierda WG, Ferrajoli A, Faderl S, Manning J, Lerner S, Mai CV, Rodriguez AM, Hess M, Do KA, Freireich EJ, Kantarjian HM, Medeiros LJ, Keating MJ. Assessment of chronic lymphocytic leukemia and small lymphocytic lymphoma by absolute lymphocyte counts in 2,126 patients: 20 years of experience at the University of Texas M. D. Anderson Cancer Center. J Clin Oncol 25(29):4648-56, 2007. PMID: 17925562.
249. Tam CS, O'Brien S, Lerner S, Khouri I, Ferrajoli A, Faderl S, Browning M, Tsimberidou AM, Kantarjian H, Wierda WG.. The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy. Leuk Lymphoma 48(10):1931-9, 2007.
250. Tsimberidou AM, Estey E, Kantarjian H, Keating MJ, Pierce S, Garcia-Manero G. Granulocyte colony stimulating factor administration associated with cerebral hemorrhage in acute promyelocytic leukemia. Leukemia 20(8):1452-3, 2006. e-Pub 2006. PMID: 16728980.
251. Tsimberidou AM, Estey E. Induction mortality risk in adult acute myeloid leukemia. Leuk Lymphoma 47(7):1199-200, 2006. PMID: 16923545.
252. Tsimberidou AM, Catovsky D, Schlette E, O'Brien S, Wierda WG, Kantarjian H, Garcia-Manero G, Wen S, Do KA, Lerner S, Keating MJ. Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone. Cancer 107(1):125-35, 2006. PMID: 16700034.
253. Tsimberidou AM, Giles FJ, Estey E, O'Brien S, Keating MJ, Kantarjian HM. The role of gemtuzumab ozogamicin in acute leukaemia therapy. Br J Haematol 132(4):398-409, 2006. PMID: 16412015.
254. Tsimberidou AM, Tirado-Gomez M, Andreef M, O'Brien S, Kantarjian H, Keating MJ, Lopez-Berestein G, Estey E.. Single-agent liposomal all-trans retinoic acid can cure some patients with untreated acute promyelocytic leukemia: An update of the University of Texas M. D. Anderson Cancer Center series. Leuk Lymphoma 47(6):1062-8, 2006. PMID: 16840198.
255. Garcia GM, Deavers MT, Knoblock R, Chen W, Tsimberidou AM, Manning JT, Medeiros LJ.. Myeloid sarcoma involving the gynecologic tract: a report of 11 cases and review of the literature. Am J Clin Pathol 125(5):783-90, 2006.
256. Tsimberidou AM, Keating MJ, Bueso-Ramos CE, Kurzrock R. Epstein-Barr virus in patients with chronic lymphocytic leukemia: a pilot study. Leuk Lymphoma 47(5):827-36, 2006. PMID: 16753866.
257. Liu Q, Fayad L, Cabanillas F, Hagemeister FB, Ayers GD, Hess M, Romaguera J, Rodriguez MA, Tsimberidou AM, Verstovsek S, Younes A, Pro B, Lee MS, Ayala A, McLaughlin P.. Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at the University of Texas M. D. Anderson Cancer Center. J Clin Oncol (Cover Sidebar) 24(10):1582-9, 2006. PMID: 16575009.
258. Tsimberidou AM, O'Brien S, Khouri I, Giles FJ, Kantarjian HM, Champlin R, Wen S, Do K-A, Smith SC, Lerner S, Freireich EJ, Keating MJ.. Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem cell transplantation. J Clin Oncol 24(15):2343-51, 2006. PMID: 16710033.
259. Bruzzi JF, Macapinlac HA, Tsimberidou AM, Truong MT, Keating MJ, Marom EM, Munden RF.. Detection of Richter's transformation of chronic lymphocytic leukemia by PET/CT. J Nucl Med 47(8):1267-73, 2006. PMID: 16883004.
260. Tsimberidou AM, O'Brien S, Kantarjian HM, Koller C, Hagemeister FB, Fayad L, Lerner S, Bueso-Ramos CE, Keating MJ.. Hodgkin transformation of chronic lymphocytic leukemia: the M. D. Anderson Cancer Center experience. Cancer 107(6):1294-302, 2006. PMID: 16902984.
261. Ahmed B, Estey E, Manning J, David C, Keating MJ, Kantarjian H, Tsimberidou AM. Anaplastic large cell lymphoma with involvement of the pancreas presenting as panniculitis in a patient with a history of acute myeloid leukemia - case report and review of the literature. Haematologica 91(12 Suppl):ECR55, 2006. PMID: 17194661.
262. Giles FJ, Kantarjian HM, Cortes JE, Faderl S, Verstovsek S, Thomas D, Garcia-Manero G, Wierda W, Ferrajoli A, Kornblau S, Mattiuzzi GN, Tsimberidou AM, Albitar M, O'Brien SM, Estey E. Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes. Leukemia Res 29(6):649-52, 2005. e-Pub 2005. PMID: 15863204.
263. Estey E, Koller C, Tsimberidou AM, O'Brien S, Beran M, Cortes J, Tirado-Gomez M, Lopez-Berestein G, Kantarjian H. Potential curability of newly diagnosed acute promyelocytic leukemia without use of chemotherapy: the example of liposomal all-trans retinoic acid. Blood 105(3):1366-7, 2005. PMID: 15659618.
264. Tsimberidou AM Giles FJ, Khouri I, Bueso-Ramos C, Pilat S, Thomas DA, Cortes J, Kurzrock R. Low-dose interleukin-11 in patients with bone marrow failure: update of the M. D. Anderson Cancer Center experience. Ann Oncol 16(1):139-45, 2005. PMID: 15598951.
265. Tsimberidou AM, Younes A, Romaguera J, Hagemeister FB, Rodriguez MA, Feng L, Ayala A, Smith TL, Cabanillas F, McLaughlin P. Immunosuppression and infectious complications in patients with stage IV indolent lymphoma treated with a fludarabine, mitoxantrone, and dexamethasone regimen. Cancer 104(2):345-53, 2005. PMID: 15948158.
266. Tsimberidou AM, Estey E, Whitman GJ, Dryden MJ, Ratnam S, Pierce S, Faderl S, Giles F, Kantarjian HM, Garcia-Manero G. Extramedullary relapse in a patient with acute promyelocytic leukemia: treatment with arsenic trioxide, all-trans retinoic acid and gemtuzumab ozogamicin therapies. Leukemia Res 28(9):991-4, 2004. PMID: 15234578.
267. Tsimberidou AM, Giles FJ, Duvic M, Kurzrock R. Pilot study of etanercept in patients with relapsed cutaneous T-cell lymphomas. J Am Acad Dermatol 51(2):200-4, 2004. PMID: 15280837.
268. Tsimberidou AM, Medina J, Cortes J, Rios A, Bonnie G, Faderl S, Kantarjian H, Garcia-Manero G. Chronic myeloid leukemia in a patient with acquired immune deficiency syndrome: complete cytogenetic response with imatinib mesylate: report of a case and review of the literature. Leukemia Res 28(6):657-60, 2004. PMID: 15120945.
269. Tsimberidou AM, Murray JL, O'Brien S, Wierda WG, Keating MJ. Yttrium-90 ibritumomab tiuxetan radioimmunotherapy in Richter's syndrome. Cancer 100(10):2195-200, 2004. PMID: 15139064.
270. Tsimberidou AM, Giles F, Romaguera J, Duvic M, Kurzrock R. Activity of interferon-alpha and isotretinoin in patients with advanced, refractory lymphoid malignancies. Cancer 100(3):574-80, 2004. PMID: 14745875.
271. Tsimberidou AM, Giles F, Duvic M, Fayad L, Kurzrock R. Phase II study of pentostatin in advanced T-cell lymphoid malignancies: update of an M.D. Anderson Cancer Center series. Cancer 100(2):342-9, 2004. PMID: 14716770.
272. Tsimberidou AM, Keating MJ, Giles FJ, Wierda WG, Ferrajoli A, Lerner S, Beran M, Andreeff M, Kantarjian HM, O'Brien S. Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia. Cancer 100(12):2583-91, 2004. PMID: 15197800.
273. Tsimberidou AM, Colburn DE, Welch MA, Cortes JE, Verstovsek S, O'Brien SM, Albitar M, Kantarjian HM, Giles FJ. Anagrelide and imatinib mesylate combination therapy in patients with chronic myeloproliferative disorders. Cancer Chemother Pharmacol 52(3):229-34, 2003. e-Pub 2003. PMID: 12783207.
274. Tsimberidou AM, Estey E, Cortes JE, Garcia-Manero G, Faderl S, Verstovsek S, Thomas DA, Ferrajoli A, Keating MJ, O'Brien S, Kantarjian HM, Giles FJ. Mylotarg, fludarabine, cytarabine, and cyclosporine regimen as post-remission therapy in acute myelogenous leukemia. Cancer Chemother Pharmacol 52(6):449-52, 2003. e-Pub 2003. PMID: 13680159.
275. Apostolidou E, Cortes J, Tsimberidou A, Estey E, Kantarjian H, Giles FJ. Pilot study of gemtuzumab ozogamicin, liposomal daunorubicin, cytarabine and cyclosporine regimen in patients with refractory acute myelogenous leukemia. Leukemia Res 27(10):887-91, 2003. PMID: 12860007.
276. Tsimberidou A, Cortes J, Thomas D, Garcia-Manero G, Verstovsek S, Faderl S, Albitar M, Kantarjian H, Estey E, Giles FJ. Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia. Leukemia Res 27(10):893-97, 2003. PMID: 12860008.
277. Tsimberidou AM, Kantarjian HM, Estey E, Cortes JE, Verstovsek S, Faderl S, Thomas DA, Garcia-Manero G, Ferrajoli A, Manning JT, Keating MJ, Albitar M, O'Brien S, Giles FJ. Outcome in patients with nonleukemic granulocytic sarcoma treated with chemotherapy with or without radiotherapy. Leukemia 17(6):1100-3, 2003. PMID: 12764375.
278. Tsimberidou AM, Waddelow T, Kantarjian HM, Albitar M, Giles FJ. Pilot study of recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein (TNFR:Fc; Enbrel) in patients with refractory multiple myeloma: increase in plasma TNF alpha levels during treatment. Leukemia Res 27(5):375-80, 2003. PMID: 12620287.
279. Apostolidou E, Estey E, Cortes J, Garcia-Manero G, Faderl S, Thomas D, Tsimberidou A, Kantarjian H, Giles FJ. Mitoxantrone and prolonged infusion gemcitabine as salvage therapy in patients with acute myelogenous leukemia. Leukemia Res 27(4):301-4, 2003. PMID: 12531220.
280. Tsimberidou AM, Kantarjian HM, Cortes J, Thomas DA, Faderl S, Garcia-Manero G, Verstovsek S, Ferrajoli A, Wierda W, Alvarado Y, O'Brien SM, Albitar M, Keating MJ, Giles FJ. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia. Cancer 97(7):1711-20, 2003. PMID: 12655528.
281. Tsimberidou AM, Medina J, Earl M, Sierra M, Shriki JE, Bueso-Ramos C, Giralt S, Beran M, Giles FJ, Garcia-Manero G. Metastatic gastric adenocarcinoma following allogeneic stem cell transplantation in a patient with acute myelogenous leukemia. Bone Marrow Transplant 31(5):413-14, 2003. PMID: 12634736.
282. Tsimberidou AM, Estey E, Cortes J, Thomas D, Faderl S, Verstovsek S, Garcia-Manero G, Keating M, Albitar M, O'Brien S, Kantarjian H, Giles F. Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes. Cancer 97(6):1481-7, 2003. PMID: 12627513.
283. Alvarado Y, Tsimberidou A, Kantarjian H, Cortes J, Garcia-Manero G, Faderl S, Thomas D, Estey E, Giles FJ. Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia. Cancer Chemother Pharmacol 51(1):87-90, 2003. e-Pub 2002. PMID: 12497211.
284. Tsimberidou AM, Giles FJ, Kantarjian HM, Keating MJ, O'Brien SM. Anti-B4 blocked ricin post chemotherapy in patients with chronic lymphocytic leukemia-long-term follow-up of a monoclonal antibody-based approach to residual disease. Leuk Lymphoma 44(10):1719-25, 2003. PMID: 14692524.
285. Tsimberidou AM, Stavroyianni N, Viniou N, Papaioannou M, Tiniakou M, Marinakis T, Skandali A, Sakellari I, Yataganas X. Comparison of allogeneic stem cell transplantation, high-dose cytarabine, and autologous peripheral stem cell transplantation as postremission treatment in patients with de novo acute myelogenous leukemia. Cancer 97(7):1721-31, 2003. PMID: 12655529.
286. Yazji S, Giles FJ, Tsimberidou AM, Estey EH, Kantarjian HM, O'Brien SA, Kurzrock R. Antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndromes. Leukemia 17(11):2101-06, 2003. PMID: 12931212.
287. Cortes J, Tsimberidou AM, Alvarez R, Thomas D, Beran M, Kantarjian H, Estey E, Giles FJ. Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia. Cancer Chemother Pharmacol 50(6):497-500, 2002. e-Pub 2002. PMID: 12451477.
288. Tsimberidou AM, Jiang Y, Ford RJ, Lichtiger B, Lee MS, Medeiros LJ, McLaughlin P, Cabanillas F, Sarris AS.. Quantitative real-time polymerase chain reaction for detection of circulating cells with t(14;18) in volunteer blood donors and patients with follicular lymphoma. Leuk Lymphoma 43(8):1589-98, 2002. PMID: 11842389.
289. Tsimberidou AM, Alvarado Y, Giles FJ. Evolving role of ribonucleoside reductase inhibitors in hematologic malignancies. Expert Rev Anticancer Ther 2(4):437-48, 2002. PMID: 12647987.
290. Tsimberidou AM, Giles FJ. TNF-alpha targeted therapeutic approaches in patients with hematologic malignancies. Expert Rev Anticancer Ther 2(3):277-86, 2002. PMID: 12113051.
291. Tsimberidou AM, Giles FJ. Essential thrombocythemia: moving from palliation to cure. Hematology 7(6):315-23, 2002. PMID: 12475736.
292. Tsimberidou AM, McLaughlin P, Younes A, Rodriguez MA, Hagemeister FB, Sarris A, Romaguera J, Hess M, Smith TL, Yang Y, Ayala A, Preti A, Lee MS, Cabanillas F. Fludarabine, mitoxantrone, dexamethasone compared with an alternating triple therapy regimen in patients with stage IV indolent lymphoma. Blood 100(13):4351-4357, 2002. PMID: 12393618.
293. Tsimberidou AM, O'Brien SM, Cortes JE, Faderl S, Andreeff M, Kantarjian HM, Keating MJ, Giles FJ. Phase II study of fludarabine, cytarabine, cyclophosphamide, cisplatin and GM-CSF in patients with Richter's syndrome or refractory lymphoproliferative disorders. Leuk Lymphoma 43(4):767-72, 2002. PMID: 12153163.
294. Tsimberidou AM, Paterakis G, Androutsos G, Anagnostopoulos N, Galanopoulos A, Kalmantis T, Meletis J, Rombos Y, Sagriotis A, Symeonidis A, Tiniakou M, Zoumbos N, Yataganas X. Evaluation of the clinical relevance of the expression and function of P-glycoprotein, multidrug resistance protein and lung resistance protein in patients with primary acute myelogenous leukemia. Leukemia Res 26(2):143-54, 2002. PMID: 11755464.
295. Tsimberidou AM, Thomas D, O'Brien S, Andreeff M, Kurzrock R, Keating M, Albitar M, Kantarjian H, Giles F. Recombinant human soluble tumor necrosis factor receptor fusion protein Enbrel in patients with refractory hematologic malignancies. Cancer Chemother Pharmacol 50(3):237-42, 2002. PMID: 12203106.
296. Tsimberidou AM, Sarris AH, Medeiros LJ, Mesina O, Rodriguez MA, Hagemeister FB, Romaguera J, Pro B, McLaughlin P, Dang N, Cabanillas F. Hodgkin's disease in patients infected with human immunodeficiency virus: frequency, presentation and clinical outcome. Leuk Lymphoma 41(5-6):535-44, 2001. PMID: 11378571.
297. Sarris AH, Hagemeister F, Romaguera J, Rodriguez MA, McLaughlin P, Tsimberidou AM, Medeiros LJ, Samuels B, Pate O, Oholendt M, Kantarjian H, Burge C, Cabanillas F. Liposomal vincristine in relapsed non-Hodgkin's lymphomas: early results of an ongoing phase II trial. Ann Oncol 11(1):69-72, 2000. PMID: 10690390.
298. Tsimberidou AM, Yataganas X. Mechanisms of multiple drug resistance (MDR) in hematologic malignancies and solid tumors. Iatriki 78:413-24, 2000.
299. Meletis J, Samarkos M, Mesogitis S, Meletis C, Mougiou A, Terpos E, Tsimberidou A, Andreopoulos A, Konstantopoulos K, Loukopoulos D. Severe aplastic anaemia relapsing during a pregnancy; spontaneous remission following termination. Haematologia (Budapest) 29(2):147-51, 1998. PMID: 9728807.
300. Meletis J, Tsimberidou A, Tsironi M, Stratigaki M, Meletis C, Samarkos M, Terpos E, Poziopoulos C, Konstantopoulos K, Loukopoulos D. Acute de novo basophilic leukemia presenting with skin involvement and upper gastrointestinal tract ulcerations. Haema 1:100-4, 1998.
301. Meletis J, Terpos E, Tsimberidou A. Congenital dyserythropoietic anemia type II (HEMPAS). Archives of Hellenic Medicine 15:215, 1998.
302. Meletis J, Terpos E, Tsimberidou A. Flashes in clinical haematology: Case 2. Haema 1:107, 1998.
303. Michali E, Terpos E, Samarkos M, Meletis C, Tsimberidou A, Nodaros K, Vavourakis E, Konstantopoulos K, Kanellopoulou G, Variami E, Loukopoulos D, Meletis J. Detection of PNH red cell populations in hematologic disorders. Hippocrates 6:21-7, 1998.
304. Meletis J, Michali E, Samarkos M, Konstantopoulos K, Meletis C, Terpos E, Tsimberidou A, Chandrinou E, Viniou N, Rombos Y, Pangalis GA, Yataganas X, Loukopoulos D. Detection of PNH red cell populations in hematological disorders using the Sephacryl Gel Test micro typing system. Leuk Lymphoma 28(1-2):177-82, 1997. PMID: 9498717.
305. Meletis J, Terpos E, Tsimberidou A. Disseminated candida albicans infection in a patient with hereditary myeloperoxidase deficiency. Archives of Hellenic Medicine 14:338, 1997. e-Pub 1997.

Invited Articles

1. Tsimberidou AM, Baysal MA, Chakraborty A, Andersson BS. Autologous Engineered T Cell Receptor Therapy in Advanced Cancer. Hum Vaccin Immunother 19(3):2290356. e-Pub 2023. PMID: 38114231.
2. Tsimberidou AM, Kahle M, Vo HH, Baysal MA, Johnson A, Meric-Bernstam F. Molecular tumour boards - current and future considerations for precision oncology. Nat Rev Clin Oncol 20(12):843-863, 2023. e-Pub 2023. PMID: 37845306.
3. Tsimberidou AM, Müller P, Ji Y. Innovative trial design in precision oncology. Semin Cancer Biol S1044-579X(20):30195-4. e-Pub 2020. PMID: 33022355.
4. Tsimberidou AM, Fountzilas E, Bleris L, Kurzrock R. Transcriptomics and solid tumors: the next frontier in precision cancer medicine. Semin Cancer Biol S1044-579X(20):30196-6. e-Pub 2020. PMID: 32950605.
5. Said R, Tsimberidou AM. Basket trials and the MD Anderson precision medicine clinical trials platform. Cancer J 25(4):282–286, 2019. PMID: 31335392.
6. Tsimberidou AM, Said R, Conley BA, Takebe N. Defining, identifying, and understanding 'exceptional responders' in oncology using the tools of precision medicine. Cancer J 25(4):296–299, 2019. PMID: 31335394.
7. Said R, Tsimberidou AM. Obinutuzumab for the treatment of chronic lymphocytic leukemia and other B-cell lymphoproliferative disorders. Expert Opin Biol Ther 17(11):1463-1470, 2017. e-Pub 2017. PMID: 28893099.
8. Tsimberidou AM. Health policy: Strategies to optimize expedited investigational new drug safety reports. Nat Rev Clin Oncol 13(4):207-8, 2016. PMID: 26997460.
9. Tsimberidou AM, Eggermont AM, Schilsky RL. Precision cancer medicine: The future is now, only better. Am Soc Clin Oncol Educ Book:61-9, 2014. e-Pub 2014. PMID: 24857061.
10. Said R, Tsimberidou AM. Pharmacokinetic evaluation of vincristine for the treatment of lymphoid malignancies. Expert Opin Drug Metab Toxicol 10(3):483-94, 2014. e-Pub 2014. PMID: 24512004.
11. Tsimberidou AM, Ringborg U, Schilsky RL. Strategies to overcome clinical, regulatory, and financial challenges in the implementation of personalized medicine. Am Soc Clin Oncol Educ Book:118-25, 2013. PMID: 23714475.
12. Tsimberidou AM, Chandhasin C, Kurzrock R. Farnesyltransferase Inhibitors: Where are we now?. Expert Opin Investig Drugs 19(12):1569-80, 2010. e-Pub 2010. PMID: 21083522.
13. Tsimberidou AM. Ofatumumab in the treatment of chronic lymphocytic leukemia. Drugs of Today - Prous Thomson Reuters 46(7):451-61, 2010. PMID: 20683500.
14. Bustinza E, Kurzrock R, Tsimberidou AM. Salirasib in the treatment of pancreatic cancer. Future Oncology, (Cover Sidebar) 6(6):885-91, 2010.
15. Tsimberidou AM, Keating MJ. Other malignancies in chronic lymphocytic leukemia/small lymhocytic lymphoma: Analysis of 2028 patients. Am J Hematol Oncol 8(9):430-2, 2009.
16. Aguilera D, Tsimberidou AM. A review of dasatinib in the treatment of chronic myelogenous leukemia. Ther Clin Risk Manag 5:281-9, 2009.
17. Tsimberidou AM, Keating MJ, Wierda WG.. Richter transformation in chronic lymphocytic leukemia. Curr Hematol Malig Rep 2(4):265-71, 2007. PMID: 20425379.
18. Tsimberidou AM, Estey E.. Treatment of older patients with acute myeloid leukemia. Aging Health 3(5):663-73, 2007.
19. Tsimberidou AM, Keating MJ. Richter's transformation in chronic lymphocytic leukemia. Semin Oncol 33(2):250-6, 2006. PMID: 16616072.
20. Tsimberidou AM, Khouri I, Keating MJ.. Response, survival, failure-free survival, and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem cell transplantation. Am J Clin Oncol 5(1):662-5, 2006.
21. Tsimberidou AM, Keating MJ. Richter syndrome: biology, incidence, and therapeutic strategies. Cancer 103(2):216-28, 2005. PMID: 15578683.
22. Tsimberidou AM, Keating MJ. Richter's syndrome: Biology, incidence, and therapeutic strategies. Am J Clin Oncol Review 4:392-7, 2005.
23. Sarris AH, Jiang Y, Tsimberidou AM, Thomaides A, Rassidakis GZ, Ford RJ, Medeiros LJ, Cabanillas F, McLaughlin P.. Quantitative real-time polymerase chain reaction for monitoring minimal residual disease in patients with advanced indolent lymphomas treated with rituximab, fludarabine, mitoxantrone, and dexamethasone. Semin Oncol 29(Suppl 2):48-55, 2002.
24. Tsimberidou AM. TNF-α targeted therapeutic approaches in patients with hematologic malignancies. Expert Rev Anticancer Ther 2(3):277-86, 2002.
25. Tsimberidou AM, Alvarado Y, Giles FJ.. The evolving role of ribonucleotide reductase inhibitors in hematologic malignancies. Expert Rev Anticancer Ther 2(4):437-48, 2002.

Manuals, Teaching Aids, Other Teaching Publications

1. Tsimberidou AM. Rituximab. The Encyclopedia of Cancer: Berlin, Heidelberg, 2009.
2. Tsimberidou AM, Giles FJ. Chronic myelogenous leukemia. American College of Physicians, 2003.

Editorials

1. Said R, Tsimberidou AM. Left ventricular ejection fraction in advanced cancer patients: a valuable prognostic tool?. Future Oncol 11(14):1999-2002, 2015. PMID: 26198825.
2. Tsimberidou AM, Minotti G, Cardinale D. Managing cardiac risk factors in oncology clinical trials. Tex Heart Inst J 38(3):266-7, 2011. PMID: 21720468.
3. Tsimberidou AM, Estey EH. The significance of anemia in elderly patients with cancer. Oncology (Cover Sidebar) 21(1):100,104, 2007.
4. Tsimberidou AM, Estey E. Induction mortality risk in adult acute myeloid leukemia. Leuk Lymphoma 47(7):1199-1200, 2006.

Abstracts

1. Bhamidipati D, Haro-Silerio J, Dumbrava E, Fu S, Hong D, Karp D, Naing A, Pant S, Piha-Paul S, Rodon Ahnert J, Tsimberidou A, Johnson A, Lee M, Raghav K, Morris V, Overman M, Kopetz S, Meric-Bernstam F, Yap T, Dasari A. Clinical characterization and therapeutic outcomes of patients (pts) with colorectal cancer (CRC) harboring somatic BRCA1/2 mutations. J Clin Oncol 42(Suppl 3), 2024.
2. Tsimberidou A, Vandross AL, Sommerhalder D, Joseph C, Chandhasin C, Perabo F, Clarke MF. A Phase 1 dose escalation study of TACH101, a first-in-class KDM4 inhibitor for advanced solid tumors. Mol Cancer Ther 22(12_Suppl), 2023.
3. George GC, Piha-Paul SA, Fu S, Dumbrava E, Subbiah V, Tsimberidou A, Blumenschein G, Pant S, Appleton G, Noor L, Rodon Ahnert J, Yap T, Meric-Bernstam F, Cleeland C, Mendoza T, Hong DS. Patient-reported baseline symptomatic adverse events in early-phase trials of combination treatments with immune checkpoint blockade, and their association with concurrent global health status, health utilities and clinical factors. Mol Cancer Ther 22(12_Suppl), 2023.
4. Wilky B, Trent J, Gordon M, El-Khoueiry A, Bullock A, Henick B, Schwartz G, Agulnik M, Mahadevan D, Patel J, Grossman J, Rosenthal K, O'Day S, Tsimberidou AM. Efficacy and safety of botensilimab (BOT) plus balstilimab (BAL) in patients (pts) with refractory metastatic sarcoma. Ann Oncol 34(Suppl 2):S1032-S1033, 2023.
5. Yap TA, Piha-Paul SA, Karp D, Dumbrava EE, Hong DS, Fu S, Subbiah V, Tsimberidou AM, Rodon J, Rhudy J, Valladolid C, Yuan Y, Jana B, Spiliopoulou P, Randall L, Poklepovic A, Sehgal K, Shapiro GI, Said R, Meric-Bernstam F. NCI10221: Phase II Multicenter Biomarker Driven Combination Trial of Copanlisib and Nivolumab in Patients with Molecularly-selected Advanced Solid Tumors (BaCoN) 34(Suppl 2):S487-S488, 2023.
6. Nardo M, Gouda M, Ahmed J, Noia Barreto CM, Nelson B, Araujo D, Blumenschein G, Tsimberidou A, Piha-Paul S, Dumbrava E, Hong D. Predictors of survival outcomes in patients (pts) with advanced solid tumors treated with cellular therapies in early clinical trials. J Clin Oncol 41(Suppl 16). e-Pub 2023.
7. George GC, Piha-Paul SA, Fu S, Rodon Ahnert J, Yap TA, Subbiah V, Dumbrava E, Tsimberidou A, Pant S, Appleton G, Noor L, Meric-Bernstam F, Cleeland CS, Mendoza TR, Hong DS. Baseline symptom, health status, and health utilities in patients in early-phase clinical trials combining immune checkpoint blockade with other anticancer therapies. J Clin Oncol 41(Suppl 16), 2023.
8. Davidson T, Le H, Campbell E, Ozenne C, Dumbrava E, Fu S, Hong D, Karp D, Naing A, Piha-Paul S, Rodon Ahnert J, Tsimberidou A, Yap T, Meric-Bernstam F, Subbiah V. Clinical trial deserts: US urban vs rural patient enrollment among patients with advanced cancer in phase 1 clinical trials at a major cancer center. J Clin Oncol 41(Suppl 16), 2023.
9. Johnson B, Willis J, Williams C, Wang X, Smith G, You YN, Dumbrava E, Fu S, Karp D, Naing A, Piha-Paul S, Rodon Ahnert J, Tsimberidou A, Yap T, Overman M, Pant S, Hong D, Kopetz S, Meric-Bernstam F, Subbiah V. Molecular landscape and survival outcomes on early phase clinical trials in sporadic young onset colorectal cancer. J Clin Oncol 41(Suppl 16), 2023.
10. Daud A, Albany C, Velcheti V, Hauke R, Rodon Ahnert J, Karp D, Tsimberidou A, Cohen J, Schmidt E, Wang J, Chan CH, Fu S. First-in-human, phase 1a dose finding of LVGN6051 CD137/4-1BB agonistic antibody with or without pembrolizumab in patients with advanced solid tumors. J Clin Oncol 41(Suppl 16), 2023.
11. Nardo M, Reilley M, Biter A, Lim JA, Bean S, Nguyen L, Bhosale P, Ager C, Couillault C, Piha-Paul S, Fu S, Tsimberidou A, Yap T, Naing A, Rodon Ahnert J, Subbiah V, Karp D, Curran M, Hong D. Lefitolimod (TLR agonist) and ipilimumab in patients with advanced solid tumors: A phase I trial. J Clin Oncol 41(Suppl 16), 2023.
12. Tsimberidou A, Vining D, Arora S, de Achaval S, Larson J, Cartwright C, Avritscher R, Alibhai I, Kaseb A. Phase 1 trial evaluating TTI-101, a first-in-class, orally bioavailable, small molecule, inhibitor of STAT3, in patients with advanced solid tumors. J Clin Oncol 41(Suppl 16), 2023.
13. Fountzilas E, Vo H, Müller P, Kurzrock R, Tsimberidou A. Correlation between biomarkers and treatment outcomes in diverse cancers: A meta-analysis of phase I and II immunotherapy clinical trials. J Clin Oncol 41(Suppl 16), 2023.
14. Bullock A, Fakih M, Gordon M, Tsimberidou AM, El-Khoueiry A, Wilky B, Pimentel A, Margolin K, Mahadevan D, Balmanoukian A, Sanborn R, Schwartz G, Abou-Alfa G, Bockorny B, Moser J, Sharma S, Grossman J, Rosenthal K, O'Day S, Lenz H, Schlechter B. Results from an expanded phase 1 trial of botensilimab (BOT), a multifunctional anti-CTLA-4, plus balstilimab (BAL; anti-PD-1) for metastatic heavily pretreated microsatellite stable colorectal cancer (MSS CRC). Ann Oncol 34(Supplement 1):S178-S179, 2023.
15. Nelson BE, Janku F, Fu S, Dumbrava EI, Hong DS, Karp D, Naing A, Rodon J, Tsimberidou A, Amaria RN, Conley A, Damodaran S, Raghav KPS, Kreider BL, Tung D, Varterasian M, Khazaie K, Piha-Paul S. Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of Clostridium novyi-NT in Patients with Advanced Solid Tumors. Cancer Res 83(8_Suppl), 2023.
16. Ngoi NY, Lin HY, Dumbrava E, Fu S, Karp DD, Naing A, Pant S, Piha-Paul SA, Rodon J, Subbiah V, Tsimberidou AM, Campbell E, Urrutia S, Hong DS, Meric-Bernstam F, Yuan Y, Yap TA. Dynamic changes in monocyte and reticulocyte counts predict mechanism-based anemia development and recovery during ATR inhibitor treatment in phase I/II trials. Cancer Res 83(7_Suppl), 2023.
17. Navarro C, Tsimberidou AM, Bougeret C, Borghi E, Bridon E, Sicard H. DIACC3010, optimized inhibitor of S6 kinase, combined with endocrine therapy, has potent antitumor activity in treatment-resistant ER-positive HER2-negative metastatic breast cancer. Cancer Res 83(7_Suppl), 2023.
18. El-Khoueiry AB, Fakih M, Gordon MS, Tsimberidou AM, Bullock AJ, Wilky BA, Trent JC, Margolin KA, Mahadevan D, Sarkis Balmanoukian A, Sanborn RE, Schwartz GK, Bockorny B, Moser JC, Grossman JE, Ortuzar Feliu WI, Rosenthal K, O'Day S, Lenz H-J, Schlechter B. Results from a phase 1a/1b study of botensilimab (BOT), a novel innate/adaptive immune activator, plus balstilimab (BAL; anti-PD-1 antibody) in metastatic heavily pretreated microsatellite stable colorectal cancer (MSS CRC). J Clin Oncol 41(Suppl 4), 2023.
19. Alayli FA, Okrah K, Tsimberidou AM, Drakaki A, Khalil DN, Khan S, Hodi S, Oh D, Amouzgar M, Guatam S, Kageyama R, Pfeiffer S, Meier S, Cabanski C, Da Silva D, Kumar D, Santulli-Marotto S, Tetzlaff M, Foo WC, Hollman T, Li Y, Adamow M, Wong P, Spasic M, Chen RO, Bucktrout S, Fairchild J, Butterfield LH, LaVallee T, Padrón LJ, Salvador LM, O'Donnell-Tormey J, Dugan U, Sharma P. AMADEUS Trial: Tumor agnostic pre- and on-treatment biomarkers of response to nivolumab plus ipilimumab correlate with on-treatment tumoral T cell infiltration. J Immunother Cancer 10(Suppl 2):A613, 2022.
20. Britten CM, Araujo DM, Backert L, Bokemeyer C, Carvajal RD, Chatterjee M, Dash A, Freudenmann LK, Fritsche J, Fuhrmann D, Goldfinger V, Holderried TAW, Hoffgaard F, Hukelmann J, Jazaeri AA, Kaseb AO, Köhler F, Kowalewski D, Luke JJ, Morris V, Mukhi S, Ott M, Reshef R, Römer M, Rostock L, Satam S, Satelli A, Schräder C, Thambi M, Tsimberidou AM, Wagner M, Wermke M, Schuster H, Schoor O, Weinschenk T. The PRAME opportunity - high peptide copy numbers, homogenous expression and high prevalence to address a broad patient population across different solid cancers with TCR-based therapeutics. J Immunother Cancer 10(Suppl 2):A745, 2022.
21. Willky BA, El-Khoueiry AB, Bullock AJ, Tsimberidou AM, Mahadevan D, Margolin KA, Trent JC, Bockorny B, Moster JC, Hosein PJ, Fakih MG, Schlecter BL, Thomas JS, Balmanoukian AS, Sanborn RE, Abou-Alfa GK, Schwartz GK, Hanna DL, Ortuzar Feliu W, Grossman JE, Rosenthal K, Godwin JL, Patel JM, Bullock BL, Stebbing J, Rawal B, Cole H, Delepine C, Chow J, Walker RC, MacDermaid C, Chand D, Gordon MS, Lenz H-J, O'Day SJ. Botensilimab, a novel innate/adaptive immune activator, plus or minus balstilimab (anti-PD-1) in 'cold' and I-O refractory metastatic solid tumors . J Immunother Cancer 10(Suppl 2):A809, 2022.
22. Yap TA, Ngoi N, Dumbrava EE, Karp DD, Rodon Ahnert J, Fu S, Hong DS, Naing A, Pant S, Piha-Paul SA, Subbiah V, Tsimberidou AM, Dufner D, Rhudy J, Gore S, Ivy SP, Yuan Y, Westin SN, Mills GB, Meric-Bernstam F. NCI10329: Phase Ib Sequential Trial of Agents against DNA Repair (STAR) Study to investigate the sequential combination of the Poly(ADP-Ribose) Polymerase inhibitor (PARPi) olaparib (ola) and WEE1 inhibitor (WEE1i) adavosertib (ada) in patients (pts) with DNA Damage Response (DDR)-aberrant advanced tumors, enriched for BRCA1/2 mutated and CCNE1 amplified cancers. Eur J Cancer: Abstracts, 34th EORTC-NCI-AACR 174(Suppl 1):S7, 2022.
23. Ngoi NY, Lin H, Ileana Dumbrava EE, Fu S, Karp D, Naing A, Pant S, Rodon J, Piha-Paul SA, Subbiah V, Tsimberidou AM, Campbell E, Urrutia S, Hong DS, Meric-Bernstam F, Yuan Y, Yap TA. Correlation of clinical, genomic and hematological parameters with ATR inhibitor (ATRi) outcomes in phase I/II clinical trials. Ann Oncol 33(Suppl 7):S761-S762, 2022.
24. Nelson BE, Roszik J, Janku F, Hong D, Kato S, Naing A, Piha-Paul SA, Fu S, Tsimberidou A, Cabanillas M, Busaidy N, Javle M, Byers L, Heymach J, Meric-Bernstam F. B-Raf V600E harboring non-melanoma cancers treated with Vemurafenib monotherapy and in combination with Everolimus/Sorafenib/Crizotinib/Paclitaxel+ Carboplatin: A pooled analysis of five phase 1/2 studies. Cancer Res: Proceedings of the 113th Annual Meeting of the American Association for Cancer Research 82(12_Suppl), 2022.
25. Bullock A, Grossman J, Fakih M, Lenz H, Gordon M, Margolin K, Wilky B, Mahadevan D, Trent J, Bockorny B, Moser J, Balmanoukian A, Schlechter B, Ortuzar Feliu W, Rosenthal K, Bullock B, Stebbing J, Godwin J, O'Day S, Tsimberidou A, El-Khoueiry A. Botensilimab, a novel innate/adaptive immune activator, plus balstilimab (anti-PD-1) for metastatic heavily pretreated microsatellite stable colorectal cancer. Ann Oncol 33(Suppl 4):S376, 2022.
26. Nelson BE, Andersen C, Yuan Y, Hong DS, Naing A, Karp DD, Yap TA, Rodon Ahnert J, Campbell E, Tsimberidou AM, Dumbrava EE, Fu S, Piha-Paul SA, Pant S, Blumenschein GR, Altan M, Tawbi HA, Tannir NM, Meric-Bernstam F, Subbiah V. Effect of immunotherapy and time-of-day infusion chronomodulation on survival in advanced cancers. J Clin Oncol 40(Suppl. 16), 2022.
27. Coleman N, DiPeri TP, Nguyen D, Naing A, Piha-Paul SA, Tsimberidou AM, Zheng X, Johnson A, Wang W, Shaw KR, Dumbrava EE, Fu S, Rodon J, Rodon Ahnert J, Hong DS, Subbiah V, Yap TA, Luthra R, Patel KP, Meric-Bernstam F. Repeat large panel genomic sequencing identifies actionable alterations and characterizes the genomic landscape in patients with metastatic solid tumors. J Clin Oncol 40(Suppl. 16), 2022.
28. Tsimberidou AM, Hsu P, Pearce TE. First-in-human study of OBI-999: A globo H-targeting antibody-drug conjugate in patients with advanced solid tumors. J Clin Oncol 40(Suppl. 16), 2022.
29. Tsimberidou AM, Verschraegen CF, Hsu P, Pearce TE. Safety, pharmacokinetics, and clinical activity of OBI-3424, an AKR1C3‑activated prodrug, in patients with advanced or metastatic solid tumors: A phase 1 dose-escalation study. J Clin Oncol 40(Suppl. 16), 2022.
30. Nelson BE, Saleem S, Damodaran S, Somaiah N, Piha-Paul SA, More JA, Yilmaz B, Karp DD, Dumbrava EE, Tsimberidou AM, Hong DS, Rodon Ahnert J, Booser DJ, Ibrahim NK, Conley AP, Bhosale P, Rojas Hernandez CM, Tripathy D, Naing A, Meric-Bernstam F. Phase Ib study of selinexor and eribulin combination in advanced solid tumors and triple-negative breast cancer. J Clin Oncol 40(Suppl. 16), 2022.
31. Ngoi N, Lin HY, Dumbrava EE, Fu S, Karp DD, Naing A, Pant S, Piha-Paul SA, Rodon Ahnert J, Subbiah V, Tsimberidou AM, Campbell E, Hong DS, Meric-Bernstam F, Yuan Y, Yap TA. Baseline predictors of hematological toxicity in patients with advanced cancer treated with ATR inhibitors in phase I/II clinical trials. J Clin Oncol 40(Suppl. 16), 2022.
32. Sigal DS, Tsimberidou AM, Chen I-J, Hsu P, Pearce T. Globo H: A Globo series glycosphingolipid target antigen in breast cancer. 2021 San Antonio Breast Cancer Symposium Program Book:210. e-Pub 2021.
33. El-Khoueiry A, Bullock A, Tsimberidou A, Mahadevan D, Wilky B, Twardowski P, Bockorny B, Moser J, Ortuzar Feliu W, Grossman J, Rosenthal K, O'Day S, Gordon M. AGEN1181, an FC-enhanced ANTI-CTLA-4 antibody, alone and in combination with balstilimab (anti-Pd-1) in patients with advanced solid tumors: initial phase I results. J Immunother Cancer 9(Suppl 3), 2021. e-Pub 2021.
34. Wermke M, Tsimberidou AM, Mohamed A, Mayer-Mokler A, Satelli A, Reinhardt C, Araujo D, Maurer D, Blumenschein G Jr, Singh H, Luke J, Guenther K, Kalra M, Chatterjee M, Hilf N, Mendrzyk R, Walter S, Eck S, Holderried TAW, Weinschenk T, Morris V, Alsdorf W, Britten CM. Safety and anti-tumor activity of TCR-engineered autologous, PRAME-directed T cells across multiple advanced solid cancers at low doses – clinical update on the ACTengine® IMA203 trial. J Immunother Cancer 9(Suppl 3), 2021. e-Pub 2021.
35. Moyers J, Nguyen D, Hong DS, Ileana Dumbrava E, Fu S, Karp D, Naing A, Pant S, Janku F, Piha-Paul S, Rodon J, Subbiah V, Tsimberidou AM, Meric-Bernstam F, Yap T. Adherence to the Food and Drug Administration (FDA) guidance for the co-development of two or more investigational new drugs in phase 1/2 cancer trials. Ann Oncol 32(Suppl_5), 2021.
36. Alhalabi O, Naing A, Groisberg R, Hahn A, Zhang S, Berkey SC, Tsimbmeridou AM, Rodon J, Yap TA, Pant S, Shah AY, Zurita-Saavedra A, Tannir N, Meric-Bernstam F, Subbiah V. Phase I study of mTORC1-2 inhibitor sapanisertib (TAK-228) in combination with carboplatin plus paclitaxelin patients with advanced solid malignancies and mTOR pathway alterations. Cancer Res 81(13 Suppl), 2021.
37. Fu S, Yao S, Yuan Y, Previs RA, Elias AD, Carvajal R, George TJ, Yuan Y, Yamamura Y, Westin S, Xing Y, Ileana Dumbrava EE, Karp DD, Piha-Paul SA, Tsimberidou AM, Rodon J, Takebe N, Kunos C, Lu K, Keyomarsi K, Meric-Bernstam F. Phase II trial of the Wee1 inhibitor adavosertib in advanced refractory solid tumors with CCNE1 amplification. Cancer Res 81(13 Suppl), 2021.
38. Tsimberidou AM, Drakaki A, Khalil D, Kummar S, Hodi FS, Oh DY, Cabanski CR, Tezlaff M, LaBallee T, Spasic M, Nissola L, Kitch LJ, Bayless NL, Selinsky C, Ayran JC, O'Donnell-Tormey J, Hubbard-Lucey VM, Dugan U, Allison JP, Sharma P. An exploratory study of nivolumab (nivo) with or without ipilimumab (ipi) according to the percentage of tumoral CD8 cells in advanced metastatic cancer. J Clin Oncol 39(Suppl 15), 2021.
39. Yap TA, Dumbrava EE, Rodon Ahnert J, Hong DS, Pant S, Karp DD, Piha-Paul SA, Subbiah V, Tsimberidou AM, Fu S, Janku F, Montez S, Ahmad-Taha MT, Guerrero D, Nazarenko NN, Moore Y, Soth M, Kovacs J, Heffernan TP, Jones P. First-in-human biomarker-driven phase I trial of the potent and selective glutaminase-1 (GLS1) inhibitor IACS-6274 (IPN60090) in patients (pts) with molecularly selected advanced solid tumors. J Clin Oncol 39(Suppl 15), 2021.
40. Tsimberidou AM, de Achaval S, Alibhai I, Kaseb AO. First-in-man phase I clinical trial evaluating TTI-101, an orally bioavailable, small molecule inhibitor of STAT3, in patients with advanced solid tumors. J Clin Oncol 39(Suppl 15), 2021.
41. Vo HH, Fu S, Hong DS, Karp DD, Piha-Paul SA, Subbiah V, Janku F, Naing A, Yap TA, Rodon Ahnert J, Ajani JA, Cartwright C, Naqvi MF, Nogueras-Gonzalez GM, Miler VA, Palmer GA, Vining DJ, Berry DA, Meric-Bernstam F, Tsimberidou AM. Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT2): Challenges and Opportunities in Conducting an MD Anderson Randomized Study in Precision Oncology. J Clin Oncol 39(Suppl 15), 2021.
42. Abo-Zahrah R, Karp DD, Adat A, Yap TA, Fu S, Rodon Ahnert J, Piha-Paul SA, Tsimberidou AM, Naing A, Subbiah V, Dumbrava EE, Overman MJ, Pradyuman Patel S, Amaria RN, Neville Westin S, Meric-Bernstam F, Janku F. Patients with advanced solid cancers treated with ERK inhibitors exhibit pseudo-progession in lymphatic nodes. J Clin Oncol 39(Suppl 15), 2021.
43. Ali-Ahmad HM, Roth M, Mangat PK, Garrett-Mayer L, Ahn E, Chan J, Maitland ML, Balmanoukian AS, Patel SR, Reese Z, Drescher CW, Leath CA, Li R, Tsimberidou AM, Schilsky RL. Pertuzumab plus trastuzumab (P+T) in patients (Pts) with uterine cancer (UC) with ERBB2 or ERBB3 amplification, overexpression or mutation: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. J Clin Oncol 39(Suppl 15), 2021.
44. Coleman N, Naing A, Zhang S, Piha-Paul SA, Tsimberidou AM, Janku F, Rodon J, Pant S, Dumbrava EE, Fu S, Hong DS, Meric-Bernstam F, Subbiah V. Phase I study of mTORC1/2 inhibitor sapanisertib (TAK-228) in combination with metformin in patients (pts) with mTOR/AKT/PI3K pathway alterations and advanced solid malignancies. J Clin Oncol 39(Suppl 15), 2021.
45. Piha-Paul SA, Xu B, Janku F, Dumbrava EE, Fu S, Karp DD, Meric-Bernstam F, Hong DS, Rodon Ahnert J, Tsimberidou AM, Javle MM, Fan Y, Peng P, Levin WJ, Ngo B, Wang H, Sun C, Ru QC, Wu F. Phase I study of TT-00420, a multiple kinase inhibitor, as a single agent in advanced solid tumors. J Clin Oncol 39(Suppl 15), 2021.
46. Karakuzu O, Tsimberidou AM, Holley VR, Adat A, Pradyuman Patel S, Sood AK, Conley AP, Urschel GE, Healty DI, O'Neill V, Janku F. Targeting innate immunity with BXCL701 in combination with pembrolizumab in patients with advanced solid cancers: Phase 2 basket study. J Clin Oncol 39(Suppl 15), 2021.
47. Westin SN, Fu S, Tsimberidou AM, Piha-Paul SA, Akhmedzhanov F, Yilmaz B, McQuinn L, Brink AL, Gong J, Hong Leung C, Lin HY, Hong DS, Pant S, Jazaeri AA, Gershenson DM, Sood AK, Coleman RL, Shah JJ, Meric-Bernstam F, Naing A. Selinexor in combination with weekly paclitaxel in patients with advanced or metastatic solid tumors: Results of an open label, single-center, multiarm phase 1b study. J Clin Oncol 39(Suppl 15), 2021.
48. Tsimberidou AM, Guenther K, Alpert A, Andersson B, Coughlin Z, Fritsch J, Hilf N, Hwu PM, Kalra M, Kuttruf-Coqui S, Maurer D, Mendrzyk R, Mohamed A, Norris B, Nowak A, Ort R, Reinhardt C, Richter F, Satelli A, Schoor O, Sieger KA, Singh H, Vining D, Wagner C, Weinschenk T, Yee C, Walter S. Results of the first-in-human clinical trial with personalized multi-target adoptive cell therapy (ACTolog IMA101). J Immunother Cancer 8(3), 2020.
49. Janku F, Fu S, Murthy R, Karp DD, Hong DS, Tsimberidou AM, Gilllison ML, Adat A, Raina A, Call G, Kreider BL, Tung D, Varterasian M, Khazaie K. First-in-man clinical trial of intratumoral injection of Clostridium novyi-NT spores in combination with pembrolizumab in patients with treatment-refractory advanced solid tumors. J Immunother Cancer 8(3), 2020.
50. Janku F, Tsimberidou AM, Holley VR, Adat A, Karakuzu O, Call G, Urschel G, Healey D, O'Neal V. Targeting Innate Immunity with BXCL701 in Combination with Pembrolizumab in Patients with Advanced Solid Cancers: Phase 2 Basket Study. J Immunother Cancer 8(3), 2020.
51. Thein KZ, Tsimberidou AM, Piha-Paul SA, Janku F, Karp DD, Fu S, Zarifa A, Gong J, Yap TA, Hong DS, Subbiah V, Pant S, Meric-Bernstam F, Naing A. Selinexor in combination with carboplatin and pemetrexed (CP) in patients with advanced or metastatic solid tumors: Results of an open label, single-center, multi-arm phase Ib study. Ann Oncol 31(Suppl_6), 2020.
52. Thein KZ, Tsimberidou AM, Piha-Paul SA, Janku F, Karp DD, Fu S, Zarifa A, Gong J, Hong DS, Yap TA, Subbiah V, Pant S, Meric-Bernstam F, Naing A. Selinexor in combination with standard chemotherapy in patients with advanced solid tumours: Results of an open label, single-center, multi-arm phase Ib study. Ann Oncol 31(Suppl_6):S1270-S1272, 2020.
53. Brana I, Loriot Y, Berger R, Rubin E, Rodon J, Miller WH, Tsimberidou AM, Saintigny P, Dienstmann R, Nuciforo P, Bescos C, Lorente J, Viaplana C, Wunder F, Bresson C, Tabernero J, Schilsky RL, Lazar V, Kurzrock R, Soria J-C. Genomic and transcriptomic profiling in head and neck tumours to identify treatment options: The WINTHER trial experience. Ann Oncol 31(Suppl 4):S697, 2020.
54. Thein KZ, Tsimberidou AM, Piha-Paul S, Janku F, Karp DD, Fu S, Zarifa A, Gong J, Hong DS, Yap TA, Subbiah V, Pant S, Meric-Bernstam F, Naing A. Selinexor in combination with topotecan in patients with advanced or metastatic solid tumours: Results of an open label, single-center, multi-arm phase Ib study. Ann Oncol 31(Suppl_4), 2020.
55. Thein KZ, Tsimberidou AM, Piha-Paul SA, Janku F, Karp DD, Fu S, Zarifa A, Gong J, Yap TA, Hong DS, Subbiah V, Pant S, Meric-Bernstam F, Naing A. Selinexor in combination with carboplatin and paclitaxel in patients with advanced or metastatic solid tumours: Results of an open label, single-center, multi-arm phase Ib study. Ann Oncol 31(Suppl_4), 2020.
56. Glitza IC, Patel S, Zarifa A, Leug CH, Lin H, McQuinn L, Gong J, Yilmaz B, Chambers J, Sulovic S, John I, Hennegan T, Fu S, Tsimberidou AM, Janku F, Karp DD, Meric-Bernstam F, Naing A. Phase Ib study to evaluate the safety of selinexor (SEL) in combination with pembrolizumab (PEM) in patients with advanced malignancies- the: The melanoma experience. Ann Oncol 31(Suppl_4), 2020.
57. Nusrat M, Tapia C, Call SG, Hong DS, Piha-Paul SA, Subbiah V, Rodon J, Tsimberidou AM, Adat A, Wang Y, Meric-Bernstam F, Overman MJ, Kopetz S, Janku F. Evaluation of cytotoxic T cell infiltration and clinical benefit from PD-L1 checkpoint inhibition among PIK3CA mutant microsatellite stable (MSS) metastatic adenocarcinoma patients. Cancer Res 80(16 Suppl), 2020.
58. Tsimberidou AM, Beer P, Bendall J, Dow J, King J, McElwaine-Johnn H, Wistuba II. Phase I study of KA2507, a selective HDAC6 inhibitor, in patients with relapsed or refractory solid tumors. Cancer Res 80(16 Suppl), 2020.
59. Alaa Gouda M, Huang HJ, Piha-Paul SA, Call G, Karp DD, Fu S, Naing A, Subbiah V, Pant S, Tsimberidou AM, Hong DS, Rodon Ahnert J, Meric-Bernstam F, Janku F. Genomically informed longitudinal monitoring of circulating tumor DNA (ctDNA) predicts outcomes of cancer therapy. J Clin Oncol 38(15_Suppl), 2020.
60. Subbiah IM, Buzdar A, Dumbrava EI, Fu S, Janku F, Karp DD, Naing A, Pant S, Rodon J, Tsimberidou AM, Yap TA, Subbiah V, Meric-Bernstam F, Hong DS. Investigating the disparate enrollment of older adults on phase I clinical trials: evolving participation patterns of patients 65 years and older w advanced cancer on phase I trials. J Clin Oncol 38(15_Suppl), 2020.
61. Huey R, George G, Phillips P, White R, Fu S, Janku F, Karp DD, Naing A, Piha-Paul SA, Subbiah V, Tsimberidou AM, Pant S, Yap TA, Rodon Ahnert J, Meric-Bernstam F, Shih Y-CT, Hong DS. Patient-reported out-of-pocket costs and financial toxicity during early-phase oncology clinical trials. J Clin Oncol 38(15_Suppl), 2020.
62. S. Greg Call, Helen J. Huang, Jordi Rodon, Daniel D. Karp, Apostolia Maria Tsimberidou, Aung Naing, Filip Janku. Targeted next-generation sequencing (NGS) of 105 cancer-related genes in circulating tumor DNA (ctDNA) from patients with advanced cancers treated with immune checkpoint inhibitors (iCPI). J Clin Oncol 38(15_Suppl), 2020.
63. Tsimberidou AM, Verschraegen CF, Hsu P, Pearce TE. A first-in-man phase I/II study of OBI-3424, an AKR1C3-selective bis-alkylating agent prodrug, in subjects with advanced cancer, including hepatocellular carcinoma (HCC) and castrate-resistant prostate cancer (CRPC). J Clin Oncol 38(15_Suppl), 2020.
64. Tsimberidou AM, Ajani JA, Hsu P, Chen I-J, Pearce TE. A phase I/II, open‑label, dose-escalation, and cohort-expansion study evaluating the safety, pharmacokinetics, and therapeutic activity of OBI‑999 in patients with advanced solid tumors. J Clin Oncol 38(15_Suppl), 2020.
65. Colen RR, Ahmed S, Elshafeey N, Karp DD, Pant S, Subbiah V, Piha-Paul SA, Hong DS, Yap TA, Fu S, Tsimberidou AM, Stephen B, Gong J, Rodon Ahnert J, Naing A. Radiomics to predict response to pembrolizumab in patients with advanced rare cancers. J Clin Oncol 38(suppl 5), 2020.
66. Tsimberidou AM, Hong DS, Fu S, Karp D, Piha-Paul SA, Kies M, Ravi V, Subbiah V, Patel S, Tu S, Janku F, Heymach J, Johson A, Zhao L, Zhang J, Berry DA, Vining D, Futreal A, Miller VA, Meric-Bernstam F. Precision medicine: Preliminary results from the initiative for molecular profiling and advanced cancer therapy 2 (IMPACT 2) study. Ann Oncol 30(Suppl 5), 2019. e-Pub 2019.
67. Naing A, Meric-Bernstam F, Karp D, Rodon JA, Piha-Paul SA, Subbiah V, Hong DS, Pant S, Fu S, Janku F, Yap TA, Tsimberidou AM, Ileana Dumbrava EE, Colen Rr, Hess KR, Campbell MT, Tu S, Jimenez C, Habra MA, Varadhachary GR. Pembrolizumab in advanced rare cancers. Ann Oncol 30(Suppl 5), 2019. e-Pub 2019.
68. Tsimberidou AM. Implementation of precision oncology: strategies to overcome challenges. Oncogene: Abstracts from the 2nd International NOrges Teknisk-Naturvitenskapelige Universitet (NTNU) Symposium: Day 2 - Biomarkers in precision diagnosis and treatment 38(Supplement):6-7, 2019.
69. Klepin HD, Garrett-Mayer E, Kaltenbaugh M, Bruinooge SS, Rubinstein WS, Meersman SC, Miller RS, Lyman GH, Gray SW, Nekhlyudov L, Osterman TJ, Thota R, Tsimberidou AM, Visvanathan K, Schilsky RL, Hershman DL. Hypertension and use of bevacizumab among patients treated in community settings. J Clin Oncol 37(15_Suppl), 2019.
70. Huey R, George G, Phillips P, White R, Fu S, Janku F, Karp DD, Naing A, Piha-Paul SA, Subbiah V, Tsimberiodu AM, Pant S, Yap TA, Rodon Ahnert J, Meric-Bernstam F, Shih Y-CT, Hong DS. Out of pocket costs and financial toxicity experienced by patients in early phase clinical trials. J Clin Oncol 37(15_Suppl), 2019.
71. Reilley M, Tsimberidou AM, Piha-Paul SA, Yap TA, Fu S, Naing A, Rodon J, Nguyen LM, Ager C, Meng M, Jayaprakash P, Schmidt M, Baumann M, Meric-Bernstam F, Curran MA, Hong DS. Phase 1 trial of TLR9 agonist lefitolimod in combination with CTLA-4 checkpoint inhibitor ipilimumab in advanced tumors. J Clin Oncol 37(15_Suppl), 2019.
72. Yap TA, Rodon Ahnert J, Piha-Paul SA, Fu S, Janku F, Karp DD, Naing A, Ileana Dumbrava EE, Pant S, Subbiah V, Tsimberidou AM, Hong DS, Rose KM, Xu Q, Vellano CP, Mahendra M, Jones P, Di Francesco ME, Marszalek JR, Meric-Bernstam F. Phase I trial of IACS-010759 (IACS), a potent, selective inhibitor of complex I of the mitochondrial electron transport chain, in patients (pts) with advanced solid tumors. J Clin Oncol 37(15_Suppl), 2019.
73. Nowak A, Ulges A, Demberg T, Gunther K, Tsimberidou AM, Hwu P, Yee C, Reinhardt C, Walter S, Wagner C, Hilf N, Mendrzyk R, Maurer D. Cellular Immunomonitoring for the personalized adoptive cellular therapy trial ACTolog® IMA101-101. Cancer Immunotherapy Annual Meeting (CIMT) 2019 Abstracts. e-Pub 2019.
74. Vining DJ, Pitici A, Popovici C, Prisacariu A, KontakM, Tsimberidou AM. Calculation of immune-related response criteria using structured report data. European Congress of Radilogy (ECR) 2019 Abstracts. e-Pub 2019.
75. Reilley M, Ager C, Meng M, Tsimberidou AM, Piha-Paul SA, Yap T, Fu S, Naing A, Rodon J, Nguyen L, Bhosale P, Schmidt M, Baumann M, Meric-Bernstam F, Curran M, Hong DS. Combination of subcutaneously administered TLR9. Journal for Immunotherapy of Cancer 6(Suppl 1), 2018. e-Pub 2018.
76. Pant S, Subbiah V, Rodon J, Janku F, Hong D, Karp D, Piha-Paul S, Tsimberidou AM, Naing A, Fu S, Savage RE, Chai F, Yu Y, Tith K, Alfattal R, Schwartz B, Meric-Bernstam F, Yap T. A phase I dose escalation study of ARQ 751 in adult patients with advanced solid tumors with AKT1, 2, 3 genetic alterations, activating PI3K mutations, PTEN-null, or other known actionable PTEN mutations. Eur J Cancer: 30th EORTC-NCI-AACR Symposium Abstract Book 103S1, 2018.
77. Ahmed S, Elshafeey N, Huang HJ, Madwani K, Fu S, Tsimberidou AM, Piha-Paul SA, Naing A, Hong D, Karp DD, Cabrilo G, Kopetz S, Subbiah V, Kee BK, Eng C, Morris VK, Meric-Bernstam F, Colen R, Janku F. Circulating tumor cell-free DNA correlates with the total tumor volume and survival in patients with advanced cancers. Eur J Cancer: 30th EORTC-NCI-AACR Symposium Abstract Book 103S1, 2018.
78. Ferrarotto R, Glisson B, Blumenschein G, Hong D, Piha-Paul S, Rodon Ahnert J, Pant S, Tsimberidou A, Janku F, Alshawa A, Jain D, Rejon M, Hess K, Colen R, Lu C, Stephen B, Tapia C, Mendoza T, Meric-Bernstam F, Naing A. Efficacy of pembrolizuab in patients with cutaneous squamous cell carcinoma. Eur J Cancer: 30th EORTC-NCI-AACR Symposium Abstract book 103S1, 2018.
79. Fountzilas E, Kotoula V, Koliou G-A, Giannoulatou E, Gogas H, Papadimitriou C, TikasIS, Papadopoulou K, Zagouri F, Christodoulou C, Koutras A, Razis E, Papakostas P, Samantas E, Aravantinos G, Psyrri A, Pectasides DG, Futreal A, Tsimberidou AM, Fountzilas G. Actionable mutations and overall survival in 3,211 patients with cancer: The Hellenic cooperative oncology group precision medicine initiative. Ann Oncol 29(Suppl 8), 2018.
80. Tsimberidou AM, Ma H, Stewart C, Schoor O, Maurer D, Mendrzyk R, Satelli A, Fritsche J, Stephenns G, Mohamed A, Hwu P, Yee C, Reinhardt C, Weinschenk T, Gharpure K, Stungis A, Vining DJ, Singh H, Walter S, Andersson BS. Phase I adoptive cellular therapy trial with ex-vivo stimulated autologous CD8+ T-cells against multiple targets (ACTolog IMA101) in patients with relapsed and/or refractory solid cancers. Ann Oncol 29(Suppl 8), 2018.
81. Pant S, Subbiah V, Rodon J, Janku F, Hong DS, Karp D, Piha-Paul SA, Tsimberidou AM, Naing A, Fu S, Savage RE, Chai F, Yu Y, Schwartz B, Meric-Bernstam F, Yap T. Results of a phase I dose escalation study of ARQ 751 in adult subjects with advanced solid tumors with AKT1, 2, 3 genetic alterations, activating PI3K mutations, PTEN-null, or other known actionable PTEN mutations. Cancer Res 78(13 Suppl), 2018.
82. Ma H, Kuttruff S, Stewart C, Bulliard Y, Stephens G, Schoor O, Satelli A, Hilf N, Sieger K, Fritsche J, Maurer D, Mohamed A, Weinschenk T, Reinhardt C, Walter S, Singh H, Hwu P, Yee C, Andersson B, Tsimberidou AM. Phase I adoptive cellular therapy trial with actively personalized, multi-targeted CD8+ T-cells in patients with relapsed and/or refractory solid cancers (ACTologIMA101-101). Cancer Res 78(13 Suppl), 2018.
83. Tsimberidou AM, Verschraegen CF, Weise AM, Sarantopoulos J, Lopes G, Nemunaitis JJ, Hicking C, Shaw J, Kaleta R, Kurzrock R. Precision oncology: Results of a phase I study of M2698, a p70S6K/AKT targeted agent in patients with advanced cancer and tumor PI3K/AKT/mTOR (PAM) pathway abnormalities. J Clin Oncol 36(15 Suppl), 2018.
84. Tsimberidou AM, Andersson B, Stewart C, Ma H, Schoor O, Mauer D, Wagner C, Satelli A, Fritsche J, Stephens GL, Mohamed A, Coughlin Z, Stungis AM, Gharpure KM, Hwu P, Yee C, Weinschenk T, Reinhardt C, Walter S, Singh H. Phase I adoptive cellular therapy trial with ex-vivo stimulated autologous CD8+ T-cells against multiple targets (ACTolog IMA101) in patients with relapsed and/or refractory solid cancers. J Clin Oncol 36(15 Suppl), 2018.
85. Fountzilas E, Krishnan E, Janku F, Fu S, Karp DD, Naing A, Subbiah V, Hong DS, Piha-Paul SA, Vining DJ, Tsimberidou AM. A phase I clinical trial of hepatic arterial infusion of oxaliplatin and oral capecitabine, with or without systemic bevacizumab, for patients with advanced cancer and liver involvement. J Clin Oncol 36(15 Suppl), 2018.
86. Piha-Paul SA, Fu S, Hong DS, Janku F, Karp DD, Naing A, Pant S, Rodon Ahnert J, Subbiah V, Tsimberidou AM, Yap TA, Meric-Bernstam F. Phase I study of the pan-HER inhibitor neratinib given in combination with everolimus, palbociclib or trametinib in advanced cancer subjects with EGFR mutation/amplification, HER2 mutation/amplification or HER3/4 mutation. J Clin Oncol 36(15 Suppl), 2018.
87. Tsimberidou AM, Hong DS, Wheler JJ, Falchook GS, Naing A, Fu S, Piha-Paul SA, Janku F, Cartwright C, Broaddus R, Nogueras-Gonzalez GM, Hwu P, Kurzrock R. Precision medicine: Clinical outcomes including long-term survival according to the pathway targeted and treatment period—The IMPACT study. J Clin Oncol 36(18 Suppl), 2018.
88. Rodon J, Soria J-C, Berger R, Miller WH, Lazar V, Rubin E, Tsimberidou AM, Saintigny P, Ackerstein A, Brana I, Loriot Y, Afshar M, Miller VA, Wunder F, Bresson C, Martini J-F, Mendelsohn J, Schilsky RL, Lee JJ, Kurzrock R. WINTHER: An international WIN Consortium precision medicine trial using genomic and transcriptomic analysis in patients with advanced malignancies. J Clin Oncol 36(15 Suppl), 2018.
89. Piha-Paul SA, Xiong WW, Moss T, Mostorino RM, Sedelmeier S, Hess K, Fu S, Hong DS, Janku F, Karp D, Naing A, Pant S, Rodon J, Subbiah V, Tsimberidou AM, Yap T, Javle M, Tapia C, Shaw KR, Eterovic K, Mills GB, Meric-Bernstam F. Phase II study of the PARP inhibitor talazoparib in advanced cancer patients with somatic alterations in BRCA1/2, mutations/deletions in PTEN or PTEN loss, aberrations in other BRCA pathway genes, and germline mutations in BRCA1/2 (not breast or ovarian cancer). Mol Cancer Ther 17(1 Suppl), 2018.
90. Ileana Dumbrava E, Balaji K, Raghav K, Javle M, Blum-Murphy M, Sajan B, Kopetz S, Boraddus R, Routbort M, Pant S, Tsimberidou A, Subbiah V, Hong DS, Rodon Ahnert J, Shaw K, Piha-Paul S, Meric-Bernstam F. Targeting HER2 (ERBB2) amplification identified by next-generation sequencing (NGS) in patients with advanced or metastatic solid tumors. Mol Cancer Ther 17(1 Suppl), 2018.
91. Tsimberidou AM, Stewart C, Reinhardt C, Ma H, Walter S, Weinschenk T, Jazaeri AA, Andersson B, Hwu P, Yee C, Singh H. Phase I adoptive cellular therapy trial with ex-vivo stimulated autologous CD8+ T-cells against multiple targets (ACTolog IMA101) in patients with relapsed and/or refractory solid cancers. J Clin Oncol; Proceedings of the ASCO-SITC Clinical Immuno-Oncology Symposium 36(Suppl 5S), 2018.
92. Alshawa A, Fujii T, Abu Sbeih H, Blechacz B, Bilen MA, Hess KR, Suarez-Almazor ME, Hong DS, Tsimberidou AM, Gong J, Stephen B, Subbiah V, Piha-Paul SA, Fu S, Mendoza TR, Thirumurthi S, Meric-Bernstam F, Naing A, Miller E. Hepatotoxicity in advanced cancer patients receiving immune-based cancer treatment. J Clin Oncology; Proceedings of the ASCO-SITC Clinical Immuno-Oncology Symposium 36(Suppl 5S), 2018.
93. Kheder E, Huang HJ, Wu A, Hong DS, Piha-Paul SA, Karp DD, Fu S, Subbiah V, Tsimberidou AM, Naing A, Diab A, Javle M, Kopetz S, Sood AK, Kurie JM, Meric-Bernstam F, Gleeson M, Janku F. Detection of circulating antibodies against KRAS in patients with advanced cancers. Cancer Res 77(19), 2017.
94. Sen S, Hess K, Hong D, Naing A, Piha-Paul S, Janku F, Fu S, Liu H, Jiang Y, Khanji R, Karp D, Tsimberidou A, Tannier N, Meric-Bernstam F, Subbiah V. Development of a novel prognostic scoring system for patient selection in immune checkpoint inhibitor phase I clinical trials. Cancer Res 77(19), 2017.
95. Tsimberidou AM, Verschraegen C, Weise A, Sarantopoulos J, Lopes G, Nemunaitis J, Victor A, Shaw J, Kaleta R, Kurzrock R. Phase I dose escalation study of M2698, a p70S6K/AKT inhibitor, in patients with advanced cancer. Ann Oncol, ESMO 2017 Congress 28(Suppl 5), 2017.
96. Sakamuri D, Kato S, Huang HJ, Naing A, Holley VR, Patel S, Piha-Paul SA, Tsimberidou AM, Hong DS, Meric-Bernstam F, Janku F. Dose escalation study of vemurafenib with crizotinib or sorfenib in patients with BRAF-mutated advance cancers. Ann Oncol 28(Suppl 5), 2017.
97. Jassowicz A, Liu L, Huang H, Hong DS, Naing A, Subbiah V, Piha-Paul SA, Toung J, Vijayaraghavan R, Zhang R, Kang H, Fu S, Tsimberidou AM, Lu C, Eng C, Moulder S, Kopetz S, Amaria R, Meric-Bernstam F, Janku F. Targeted methylation sequencing of plasma cell-free DNA identifies patients with advanced breast, colorectal, non-small cell lung cancer, melanoma with poor outcomes. Ann Oncol 28(Suppl 5), 2017.
98. Groisberg R, Hong DS, Janku F, Tsimberidou AM, Javle MM, Meric-Berstam F, Subbiah V. Clinical next generation sequencing for precision oncology in rare cancers. J Clin Oncol, 2017 ASCO Annual Meeting 35(15_Suppl), 2017.
99. Tsimberidou AM, Hong DS, Cartwright C, Wheler JJ, Falchook G, Naing A, Fu S, Piha-Paul SA, Janku F, Hwu P, Kee BK, Kies MS, Broaddus R, Mendelsohn J, Hess KR, Kurzrock R. Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): An MD Anderson precision medicine study. J Clin Oncol, 2017 ASCO Annual Meeting 35(15_Suppl), 2017.
100. Naing A, Lopez-Berestein G, Fu S, Tsimberidou AM, Pant S, Piha-Paul SA, Janku F, Hong DS, Sulovic S, Mang X, Jazaeri AA, Ng CS, Karp DD, Subbiah V, Meric-Bernstam F, Mitra R, Wu S, Sood A, Coleman RL. EphA2 gene targeting using neutral liposomal small interfering RNA (EPHARNA) delivery: A phase I clinical trial. J Clin Oncol, 2017 ASCO Annual Meeting 35(15_Suppl), 2017.
101. Naing A, Fu S, Tsimberidou AM, Pant S, Piha-Paul SA, Janku F, Hong DS, Colen RR, Carter BW, Evans E, Abdul-Hassan Tawbi H, Karp DD, Subbiah V, Dev R, Hess KR, Ueno NT, Simon GR, Overman MJ, Coleman RL, Meric-Bernstam F. Phase IB study to evaluate the safety of selinexor in combination with multiple standard chemotherapy agents in patients with advanced malignancies. J Clin Oncol, 2017 ASCO Annual Meeting 35(15_suppl), 2017.
102. Sen S, Piha-Paul SA, Kato S, Karp DD, Janku F, Fu S, Naing A, Pant S, Tsimberidou AM, Subbiah V, Kurzrock R, Meric-Bernstam F, Hong DS. Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in advanced cancers. J Clin Oncol, 2017 ASCO Annual Meeting 35(15_suppl), 2017.
103. Groisberg R, Hong DS, Janku F, Jiang Y, Wei CJ, Karp DD, Tsimberidou AM, Naing A, Bhalla KN, Meric-Bernstam F, Subbiah V. SWI/SNF complex subunit aberrations in diverse cancers: Next-generation sequencing of 539 patients. J Clin Oncol, 2017 ASCO Annual Meeting 35(15_Suppl), 2017.
104. Varadhachary GR, Singh Raghav KP, Pant S, Janku F, Fu S, Hong DS, Piha-Paul SA, Colen RR, Subbiah V, Painter J, Tsimberidou AM, Stephen B, Karp DD, McQuinn L, Mendoza TR, Hess KR, Meric-Bernstam F, Naing A. Phase II study for the evaluation of efficacy of pembrolizumab (MK-3475) in patients with cancer of unknown primary. J Clin Oncol, 2017 ASCO Annual Meeting 35(15_Suppl), 2017.
105. Moehrmann L, Huang HJ, Hong DS, Tsimberidou AM, Fu S, Piha-Paul SA, Subbiah V, Karp DD, Naing A, Krug A, Enderle D, Priewasser T, Noerholm M, Eng C, Kopetz S, Skog J, Meric-Bernstam F, Janku F. Liquid biopsies of plasma exosomal nucleic acids, plasma cell-free DNA, and survival of patients with advanced cancers. J Clin Oncol, 2017 ASCO Annual Meeting 35(15_Suppl), 2017.
106. Soria JC, Rodon Ahnert J, Berger R, Miller WH, Brana I, Loriot Y, Mughal TI, Lazar V, Wunder F, Bresson C, Koscielny S, Afshar M, Saintigny P, Tsimberidou AM, Richon C, Batist G, Onn A, Ackerstein A, Rubin E, Kurzrock R, Roussy G. WINTHER: An international study to select rational therapeutics based on the analysis of matched tumor and normal biopsies in subjects with advanced malignancies. J Clin Oncol, 2017 ASCO Annual Meeting 35(15_Suppl), 2017.
107. Pant S, Wheler JJ, Fu S, Hong DS, Karp KK, Subbiah V, Tsimberidou AM, Holley VR, Brewster AM, Koenig KH, Ibrahim NK, Murthy RK, Meric-Bernstam F, Janku F. Proof-of concept phase I study of everolimus, letrozole and trastuzumab in hormone receptor-positive, HER2-positive/amplified or mutant metastatic breast cancer or other solid tumors: Evaluating synergy and overcoming resistance. J Clin Oncol, 2017 ASCO Annual Meeting 35(15_Suppl), 2017.
108. Janku F, Barzi A, Sartore-Bianchi A, Fujii T, Cassingena A, Siravegna G, Karp DD, Piha-Paul SA, Subbiah V, Tsimberidou AM, Huang HJ, Veronese S, Di Nicolantonio F, Erlander MG, Luthra R, Kopetz S, Meric-Bernstam F, Siena S, Lenz H-J, Bardelli A. Mutation enrichment next-generation sequencing for quantitative detection of KRAS mutations in urine cell-free DNA from patients with advanced colorectal and other cancers. J Clin Oncol; 2017 Gastrointestinal Cancers Symposium 35(4S), 2017.
109. Fujii T, Colen R, Bilen M, Hess K, Jajjar J, Suarez-Almazor M, Alshawa A, Hong D, Stephen B, Janku F, Subbiah V, Kato S, Karp D, Piha-Paul S, Tsimberidou A, Fu S, Sharma P, Meric-Bernstam F, Naing A. Incidence of immune-related adverse events in patients who received immunotherapy and radiographic analysis to predict pneumonitis. Eur J Cancer; 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 68(Suppl 1), 2016.
110. Dembla V, Ray D, Lockett P, Fullmer C, Subramanian H, Subbiah V, Fu S, Janku F, Tsimberidou AM, Naing A, Piha-Paul SA, Hong DS, Pant S, Miller VA, Lim J, Le H, Karp DD. Drug development in the MD Anderson Cancer Center (MDACC) Clinical Translational Research Center (CTRC) - 2011-2015: The challenge of precision medicine in a very broad playing field. Eur J Cancer; 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 68(Suppl 1), 2016.
111. Mahalingam D, Patel M, Sachdev J, Hart LL, Halama N, Ramesh R, Liu X, Salim Y, Dirk J, Yoon MJ, GOzde M, Abid DR, Kerschbaumer R, Tsimberidou AM. Anti-oxidized macrophage migration inhibitory factor (oxMIF) antibody imalumab (BAX69) in advanced solid tumors: Final results of first-in-human phase 1 study. Ann Oncol; ESMO 2016 Congress 27(Suppl 6), 2016.
112. Mahalingam D, Patel MR, Sachdev JC, Hart LL, Halama N, Ramanathan RK, Sarantopoulos J, Liu X, Yazji S, Jaeger D, Adib D, Kerschbaumer R, Tsimberidou AM. First-in-human phase 1 study assessing imalumab (BAX69), a first-in-class anti-oxidized macrophage migration inhibitory. Cancer Research: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research 76(14 Suppl), 2016.
113. Madwani K, Huang HJ, Shelton DN, Fu S, Tsimberidou AM, Piha-Paul SA, Naing A, Hong DS, Karp DD, Andrews DL, Cabrillo G, Kopetz ES, Luthra R, Kee BK, Eng C, Morris VK, Karlin-Neumann GA, Meric-Bernstam F, Janku F. Quantity of KRAS mutations in cell-free DNA is associated with survival of patients with advanced cancers. Cancer Res; AACR 107 Annual Meeting 76(14 Suppl), 2016.
114. Khawaja MR, Khatua S, Karp D, Janku F, Hong D, Munoz J, Tsimberidou A, Zaky W, Sherman SI, Hwu P, Meric-Bernstam F, Subbiah V. A phase I dose escalation trial of vemurafenib in combination with the mTOR inhibitor everolimus for melanoma and non-melanoma cancers with a BRAF aberration. Cancer Res; AACR 107th Annual Meeting 76(14), 2016.
115. Fujii T, Vibat CR, Karp DD, Piha-Paul SA, Subbiah V, Tsimberidou AM, Fu S, Hong DS, Huang HJ, Madwani K, Andrews DL, Hancock S, Naing A, Luthra R, Kee BK, Kopetz S, Erlander MG, Melnikova V, Meric-Bernstam F, Janku F. Circulating tumor DNA assay performance for detection and monitoring of KRAS mutations in urine from patients with advanced cancers. Cancer Res; AACR107th Annual Meeting 76(14), 2016.
116. Mahalingam D, Patel M, Sachdev J, Hart L, Halama N, Ramanathan RK, Sarantopoulos J, Liu X, Yazji S, Jaeger D, Adib D, Kerschbaumer R, Yoon MJ, Manzur GC, Starodub A, Sivarajan K, Wertheim M, Thambi P, Jones M, Goel S, Nemunaitis J, Tsimberidou AM. Safety and efficacy analysis of imalumab, an anti-oxidized (ox) macrophage migration inhibitory factor (MIF) antibody, alone or in combination with 5-fluorouracil/leucovorin (5-FU/LV) or panitumumab, in patients with metastatic colorectal cancer (mCRC). Ann Oncol; ESMO World Congress on GI Cancer (WCGIC) 27(Suppl 2):ii105, 2016.
117. Sen S, Rao A, Janku F, Hong DS, Tsimberidou AM, Piha-Paul SA, Heymach J, Byers LA, Meric-Bernstam F, Subbiah V. Co-occurring genomic alterations and association with progression free survival in BRAFV600 mutated non-melanoma tumors treated with BRAF inhibitor. J Clin Oncol, 2016 ASCO Annual Meeting 34(15 Suppl), 2016.
118. Sen S, Khawaja MR, Khatua S, Karp DD, Janku F, Hong DS, Munoz J, Tsimberidou AM, Zaky WT, Hwu P, Meric-Bernstam F, Subbiah V. Co-targeting BRAF with mTOR inhibition in solid tumors harboring BRAF mutations: A phase I study. J Clin Oncol, 2016 ASCO Annual Meeting 34(15 Suppl), 2016.
119. Tang C, Welsh JW, de Groot P, Massarelli E, Chang JY, Hess KR, Curran MA, Cabanillas ME, Subbiah V, Fu S, Tsimberidou AM, Karp DD, Gomez DR, Komaki R, Sharma P, Naing A, Hong DS. Phase I trial combining ipilimumab + high dose stereotactic radiation: Results and serum immune correlates. J Clin Oncol, 2016 ASCO Annual Meeting 34(15 Suppl), 2016.
120. Westin SN, Stashi E, Pal N, Urbauer DL, Janku F, Piha-Paul SA, Naing A, Tsimberidou AM, Fu S, Hong DS, Subbiah V, Karp DD, Coleman RL, Meric-Bernstam F, Kurzrock R. Phase I trial of paclitaxel, bevacizumab, and temsirolimus in advanced solid malignancies. J Clin Oncol, 2016 ASCO Annual Meeting 34(15 Suppl), 2016.
121. Reilley M, Bailey AM, Subbiah V, Janku F, Naing A, Falchook GS, Karp DD, Piha-Paul Sa, Tsimberidou AM, Fu S, Zinner R, Lim J, Bean SA, Bass A, Montez S, Vence LM, Sharma P, Allison JP, Meric-Bernstam F, Hong DS. Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies. J Clin Oncol, 2016 ASCO Annual Meeting 34(15 Suppl), 2016.
122. Tsimberidou AM, Ou Y, Cutler R, Papadopoulos K, Sharma S, Gore L, Wang Z, Xu Y, Demirhan E, Wang Z, Harvey RD, Pinchansik D, Lee S, Pervan M. A phase 1 study of oprozomib to assess drug-drug interaction with midazolam in patients with advanced malignancies. Clinical Pharmacol Ther: ASCPT 2016 Annual Meeting 99(S1):s100, 2016. e-Pub 2016.
123. Harvey RD, Gore L, Wang D, Mita A, Sharma S, Nemunaitis J, Papadopoulos K, Pinchasik D, Ou Y, Demirhan E, Cutler RE, Tsimberidou AM. A phase 1 study to assess food effect on oprozomib in patients with advanced malignancies. Clin Pharmacol Ther: ASCPT 2016 Annual Meeting 99(S1):s98, 2016. e-Pub 2016.
124. Khawaja MR, Madhusudanannair V, Ng C, Nick A, Janku F, Piha-Paul S, Coleman R, Soliman P, Fu S, Hong D, Karp D, Subbiah V, Tsimberidou A, Meric-Bernstam F, Lu K, Naing A. Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced cancers. Mol Cancer Ther 14(12 Suppl 2), 2015.
125. Subbiah V, Hong DS, Amini B, Piha-Paul S, Fernandez JG, Fu S, Tsimberidou AM, Naing A, Janku F, Karp DD, Overman M, Eng C, Kopetz S, Meric-Bernstam F, Falchook GS. Phase I dose escalation study fo the oral multi-kinase VEGF inhibitor regorafenib and the anti-EGFR monoclonal antibody cetuximab in patients with advanced solid tumors including colorectal cancer. Mol Cancer Ther 14(12 Suppl 2), 2015.
126. Morris V, Janku F, Huang H, Fu S, Overman M, Piha-Paul S, Subbiah V, Kee B, Tsimberidou AM, Fogelman D, Shurieqi I, Manuel S, Scamardo A, Lanman R, Sommer N, Hong D, Kopetz S. Circulating cell-free DNA as a marker for response and resistance to BRAF and EGFR inhibition in BRAF-mutated metastatic colorectal cancer. Mol Cancer Ther 14(12 Suppl 2), 2015.
127. Tang C, Naing A, de Groot P, Chang JY, Massarelli E, Parkhurst K, Erdman D, Barrientes S, Fok J, Subbiah V, Fu S, Tsimberidou A, Karp D, Gomez DR, Heymach J, Hahn SM, Komaki RU, Hong DS, Welsh JW. Phase 1 study of ipilimumab and stereotactic radiation targeting liver or lung lesions in patients with advanced malignancies. International Journal of Radiation Oncology*Biology*Physics 93(3, Suppl 1), 2015.
128. George G, Iwuanyanwu EC, Anderson KO, Piha-Paul SA, Wheler JJ, Zinner R, Naing A, Tsimberidou AM, Janku F, Subbiah, Cleeland CS, Mendoza TR, Hong DS. Sleep quality and its association with fatigue, symptom burden, and mood in patients with advanced cancer in a phase 1 clinic. J Clin Oncol; 2015 ASCO Annual Meeting 33(15s), 2015.
129. Kopetz S, Litzenburger B, Kinyua W, Sajan B, Subbiah S, Zinner R, Wheler JJ, Hong DS, Tsimberidou AM, Overman MJ, Pagliaro LC, Busaidy NL, Westin SN, Glisson BS, Heymach J, Meric-Bernstam F, Shaw KR, Lee JJ, Broaddus R. Prospective evaluation of a 409-gene next generation sequencing platform to facilitate genotype-matched clinical trial enrollment. J Clin Oncol; 2015 ASCO Annual Meeting 33(15s), 2015.
130. Hong DS, Morris VK, El Osta BE, Fu S, Overman MJ, Piha-Paul SA, Subbiah V, Kee Bk, Tsimberidou AM, Zinner R, Fogelman DR, Bellido J, Shureiqi I, Meric-Bernstam F, Kopetz S. Phase Ib study of vemurafenib in combination with irinotecan and cetuximab in patients with BRAF-mutated metastatic colorectal cancer and advanced cancers. J Clin Oncol; 2015 ASCO Annual Meeting 33(15s), 2015.
131. Mahalingam D, Patel MR, Sachdev JC, Hart LL, Halama N, Ramanathan RK, Sarantopoulos J, Liu X, Yazji S, Jaeger D, Adib DR, Kerschbaumer R, Tsimberidou AM. First-in-human, phase I study assessing imalumab (Bax69), a first-in-class anti-oxidized macrophage migration inhibitory factor (oxMIF) antibody in advanced solid tumors. J Clin Oncol; 2015 ASCO Annual Meeting 33(15s), 2015.
132. Kato S, Fontes Jardim DL, Johnson FM, Subbiah V, Piha-Paul SA, Tsimberidou AM, Falchook GS, Karp DD, Wheler JJ, Zinner R, Janku F, Fu S, Dandu L, Browne E, Meric-Bernstam F, Hong Ds. Phase I study of combination of crizotinib (C) and dasatinib (D) in patients (pts) with advanced cancer. J Clin Oncol; 2015 ASCO Annual Meeting 33(15s), 2015.
133. Park H, Garrido-Laguna I, Naing A, Fu S, Falchook GS, Piha-Paul SA, Wheler JJ, Hong DS, Subbiah V, Tsimberidou AM, Kaseb AO, Oki Y, Zinner R, Patel S, Velez Bravo VM, Fanale MA, Meric-Bernstam F, Kurzrock R, Janku F. Phase I study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancies. J Clin Oncol; 2015 ASCO Annual Meeting 33(15s), 2015.
134. Rodrigues HV, Lim J, Stephen B, Janku F, Tsimberidou AM, Piha-Paul SA, Fu S, Naing A, Subbiah V, Falchook GS, Kurzrock R, Wheler JJ. Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy. J Clin Oncol; 2015 ASCO Annual Meeting 33(15s), 2015.
135. Piha-Paul SA, Goldstein JB, Hess KR, Fu S, Hong DS, Janku F, Karp DD, Naing A, Subbiah V, Tsimberidou AM, Wheler JJ, Zinner R, Mills GB, Meric-Bernstam F. Phase II study of the PARP inhibitor talazoparib (BMN-673) in advanced cancer patients with somatic alterations in BRCA1/2, mutations/deletions in PTEN or PTEN loss, a homologous recombination defect, mutations/deletions in other BRCA pathway genes and germline mutation S in BRCA1/2 (not breast or ovarian cancer). J Clin Oncol; 2015 ASCO Annual Meeting 33(15s), 2015.
136. Wagner A, Hess KR, Hong DS, Tang C, Naing A, Fu S, Janku F, Piha-Paul SA, Zinner R, Wheler JJ, Tsimberidou AM, Patel S, Somaiah N, Ravi V, Benjamin RS, Meric-BernstamF, Subbiah V. Validation of the Royal Marsden Hospital (RMH) prognostic score in 100 patients with advanced sarcoma enrolled in early phase clinical trials at a major cancer center. J Clin Oncol; 2015 ASCO Annual Meeting 33(15s), 2015.
137. Wheler JJ, Yelensky R, Stephen B, Hong DS, Zinner R, Subbiah V, Fu S, Karp DD, Falchook GS, Naing A, Tsimberidou AM, Piha-Paul SA, Janku F, Li Y, Lee JJ, Miller VA, Meric-Bernstam F, Kurzrock R. Prospective study comparing outcomes in patients with advanced malignancies on molecular alteration-matched versus non-matched therapy. J Clin Oncol; 2015 ASCO Annual Meeting 33(15s), 2015.
138. Kato S, Janku F, Piha-Paul SA, Naing A, Karp DD, Tsimberidou AM, Subbiah V, Zinner R, Hwu WJ, Javle MM, Parkhurst KL, Ramzanal NM, Kurzrock R, Meric-Bernstam F, Chae YK, Kim K, Falchook GS. Phase I study of combination vemurafenib, carboplatin, and paclitaxel in patients (pts) with BRAF-mutant advanced cancer. J Clin Oncol; 2015 ASCO Annual Meeting 33(15s), 2015.
139. Janku F, Huang HJ, Claes B, Falchook GS, Fu S, Tsimberidou AM, Hong DS, Naing A, Wheler JJ, Piha-Paul SA, Karp DD, Subbiah V, Zinner RG, Ramzanali N, Luthra R, Patel SP, Kopetz ES, Sablon E, Maertens G, Kurzrock R, Meric-Bernstam F. Rapid, automated BRAF mutation testing of cell-free DNA from plasma of patients with advanced cancers using the novel Idylla platform. Cancer Res; Proceedings of the 106th Annual Meeting of the American Association for Cancer Research 75(15 Suppl), 2015.
140. Sakamuri D, Betancourt Cuellar SL, Glitza IC, Fu S, Wheler JJ, Falchook GS, Tsimberidou AM, Hong DS, Subbiah V, Fanale MA, Cabanillas ME, Meric-Bernstam F, Janku F. Phase 1 study: Ipilimumab (anti CTLA-4) in combination with lenalidomide in patients with advanced cancers. Cancer Res; Proceedings of the 106th Annual Meeting of the American Association for Cancer Research 75(15 Suppl), 2015.
141. Subbiah IM, Varadhachary G, Tsimberidou AM, Wheler JJ, Subbiah V, Janku F, Chowdhuri SR, Zinner R, Hong DS. Impaired cell cycle arrest with concurrent epigenetic deregulation identified through next generation sequencing in patients with advanced carcinoma of unknown primary: Implications for personalized medicine. Cancer Res; Proceedings of the 106th Annual Meeting of the American Association for Cancer Research 75(15 Suppl), 2015.
142. Kato S, Naing A, Falchook G, Holley VR, Velez-Bravo VM, Patel S, Zinner RG, Piha-Paul SA, Tsimberidou AM, Hong DS, Kurzrock R, Meric-Bernstam F, Janku F. Overcoming BRAF/MEK resistance using vemurafenib with crizotinib or sorafenib in patients with BRAF-mutant advanced cancers: phase I study. Cancer Res; Proceedings of the 106th Annual Meeting of the American Association for Cancer Research 75(15 Suppl), 2015.
143. Subbiah V, Janku F, Tsimberidou AM, Naing A, Suubiah V, Wheler JJ, Zinner R, Eng C, Overman MJ, Kopetz S, Hong DS. Concurrent aberrations in the Wnt, MAPK and PI3K pathways identified through next generation sequencing of relapsed refractory colorectal adenocarcinoma (CRC): Implications for future therapeutic trials. Cancer Res; Proceedings of the 106th Annual Meeting of the American Association for Cancer Research 75(15 Suppl), 2015.
144. Huang HJ, Shelton DN, Fu S, Piha-Paul SA, Tsimberidou AM, Zinner RG, Wheler JJ, Naing A, Hong DS, Falchook GS, Kopetz S, Luthra R, Kee BK, Karlin-Neumann GA, Meric-Bernstam F, Janku F. Mulitplex KRAS G12/G13 mutation testing of 16ng of unamplified cell-free DNA from plasma of patients with advanced cancers using Droplet Digital PCR. Cancer Res; Proceedings of the 106th Annual Meeting of the AACR 75(15 Suppl), 2015.
145. Tsimberidou AM, Verschraegen C, Heestand G, Kaleta R, Scheuenpflug J, Huck B, Weise A, Kurzrock R. A first in human, dose escalation trial of MSC2363318A - a dual p70S6K/Akt inhibitor, for patients with advanced malignancies. Ann Oncol 26(suppl_2):ii25, 2015.
146. Subbiah IM, Janku F, Tsimberidou AM, Naing A, Subbiah V, Wheler JJ, Zinner RG, Eng C, Overman MJ, Kopetz S, Palmer GA, Hong DS. Next-generation sequencing of advanced, relapsed colorectal adenocarcinoma (CRC) to reveal mutations affecting Wnt, MAPK and PI3K pathway signaling: Emergence of novel combinatorial strategies. J Clin Oncol; 2015 ASCO Gastrointestinal Cancers Symposium 33(3 Suppl), 2015.
147. Goldstein JB, Tang C, Hong DS, Subbiah V, Janku F, Hess KR, Fu S, Karp DD, Naing A, Tsimberidou AM, Wheler JJ, Zinner R, Javle MM, Varadhachary GR, Wolff RA, Fogelman DR, Meric-Bernstam F, Piha-Paul SA. Evolution of phase 1 trials for patients with advanced pancreatic cancer: An update on the experience from MD Anderson Cancer Center. J Clin Oncol; 2015 ASCO Gastrointestinal Cancers Symposium 33(3 Suppl), 2015.
148. Legendre BL, Richardson K, Falchook GS, Naing A, Holley VR, Fu S, Hong DS, Piha-Paul SA, Wheler JJ, Zinner R, Subbiah V, Tsimberidou AM,Luthra R,Meric-Bernstam F, Bedikian AY, Eng C, Melnikova V, Lewis M, Kurzrock R, Janku F. BRAF and KRAS mutation testing in plasma cell-free DNA with ICE COLD-PCR in patients with advanced cancers. J Clin Oncol, 2014 ASCO Annual Meeting 32(15S), 2014.
149. Tsimberidou AM, Ye Y, Wheler JJ, Falchook GS, Hong DS, Naing A, Fu S, Kurzrock R, Piha-Paul SA, Janku F, Zinner R, Moulder SL, Subbiah V, Karp DD, Meric-Bernstam F, Hwu P, Kies MS, Miller VA, Broaddus R, Hess KR. Genomic profiling and precision medicine in 3,745 patients with advanced cancer. J Clin Oncol, 2014 ASCO Annual Meeting 32(15S), 2014.
150. Huang HJ, Claes B, Falchook GS, Naing A, Piha-Paul SA, Tsimberidou AM, Zinner R, Karp DD, Fu S, Subbiah V, Hong DS, Wheler JJ, Luthra R, Kee BK, Overman MJ, Kim K, Maertens GG, Kurzrock R, Meric-Bernstam F, Janku F. BRAF mutation testing in cell-free DNA from plasma of patients with advanced cancers using a novel, rapid, automated molecular diagnostics platform (Idylla). J Clin Oncol, 2014 ASCO Annual Meeting 32(15S), 2014.
151. Subbiah V, Corrales-Medina FF, Herzog CE, Hess KR, Egas Bejar DE, Hong DS, Falchook GS, Anderson PM, Nunez C, Huh WW, Naing A, Tsimberidou AM, Wheler JJ, Piha-Pau SA, Janku F, Kleinerman E, Kurzrock R. Outcomes of pediatric cancer patients enrolled in phase 1 clinical trials designed for adults: Experience from a major cancer center. J Clin Oncol, 2014 ASCO Annual Meeting 32(15S), 2014.
152. Subbiah V, Agarwal R, Janku F, Tsimberidou AM, Patel S, Benjamin RS, Ludwig JA, Anderson PM, Araujo DM, Ravi V, Conley AP, Somaiah N, Wang WL, Naing A, Zinner R, Hong DS, Meric-Bernstam F. Diversity and heterogeneity in molecular analysis of advanced sarcomas: The clinical, regulatory, and financial challenge for drug development and precision medicine. J Clin Oncol, 2014 ASCO Annual Meeting 32(15s), 2014.
153. Subbiah IM, Varadhachary GR, Tsimberidou AM, Wheler JJ, Subbiah V, Falchook GS, Janku F, Zinner R, Roy-Chowdhuri S, Meric-Bernstam F, Hong DS. Next-generation sequencing in carcinoma of unknown primary (CUP) and novel combinatorial strategies in a heterogeneous mutational landscape: Implications for personalized medicine. J Clin Oncol, 2014 ASCO Annual Meeting 32(15S), 2014.
154. Liu X, George GC, Tsimberidou AM, Naing A, Wheler JJ, Kopetz S, Fu S, Piha-Paul SA, Eng C, Falchook GS, Janku F, Garrett CR, Karp DD, Kurzrock R, Zinner R, Singh Raghav KP, Subbiah V, Meric-Bernstam F,Hong DS, Overman MJ. Rechallenge with anti-EGFR–based therapy in metastatic colorectal cancer: Impact of intervening time interval and prior anti-EGFR response. J Clin Oncol, 2014 ASCO Annual Meeting 32(15s), 2014.
155. Livingston JA, Hess KR, Fernandez JG, Naing A, Hong DS, Patel S , Anderson PM, Benjamin RS, Ludwig JA, Herzog CE, Fu S, Wheler JJ, Falchook GS, Tsimberidou AM, Piha-Paul SA, Janku F, Rohren E, Meric-Bernstam F, Kurzrock R, Subbiah V. Eliciting early-response signals from first-in-human clinical trials and validation of prognostic scores in aggressive biology bone cancers: The MD Anderson experience. J Clin Oncol, 2014 ASCO Annual Meeting 32(15S), 2014.
156. Wheler JJ, Janku F, Atkins JT, Moulder SL, Zinner R, Lee JJ, Falchook GS, Tsimberidou AM, Piha-Paul SA, Harp DD, Naing A, Fu S, Hong DS, Subbiah V, Stephens PJ, Yelensky R, Miller VA, Valero V, Kurzrock R, Meric-Bernstam F. PI3K/AKT/mTOR genomic alterations in 94 patients with metastatic breast cancer in the phase I clinic at MD Anderson: Prevalence and association with response. J Clin Oncol, 2014 ASCO Annual Meeting 32(15s), 2014.
157. Hou MM, Bellido J, Naing A, Falchook GS, Hess KR, Zinner R, Wheler JJ, Subbiah V, Hong DS, Piha-Paul SA, Tsimberidou AM, Karp DD, Kurzrock R, Meric-Bernstam F, Fu S. A phase I trial of pazopanib and vorinostat: The role of TP53 mutations. J Clin Oncol, 2014 ASCO Annual Meeting 32(15s), 2014.
158. Bupathi M, Falchook GS, Hong DS, Subbiah IM, Piha-Paul SA, Karp DD, Saigal B, Zinner R, Wheler JJ, Tsimberidou AM, Fu S, Sherman SI, Meric-Bernstam F, Subbiah V. A phase 1 trial of vandetanib (multikinase inhibitor of EGFR, VEGFR, and RET) in combination with everolimus (mTOR inhibitor) in patients with advanced malignancies. J Clin Oncol, 2014 ASCO Annual Meeting 32(15s), 2014.
159. Fu S, Nguyen E, Janku F, Subbiah V, Patel SP, Falchook GS, Zinner R, Tsimberidou AM, Hong DS, Piha-Paul SA, Wheler JJ, Shi N, Bomalaski JS, Hwu P, Meric-Bernstam F. Targeting argininosuccinate synthetase-deficient advanced solid tumors in a phase I trial of ADI-PEG20 plus cisplatin. J Clin Oncol, 2014 ASCO Annual Meeting 32(15s), 2014.
160. Huang M, Parkhurst KL, Jiang Y, Moulder SL, Naing A, Wheler JJ, Hong DS, Piha-Paul SA, Fu S, Tsimberidou AM, Zinner R, Janku F, Kurzrock R, Falchook GS. HER2 extracellular domain (ECD) and HER2 single nucleotide polymorphisms (SNPs) in patients treated with combination trastuzumab, lapatinib, and bevacizumab. J Clin Oncol, 2014 ASCO Annual Meeting 32(15S), 2014.
161. Wheler JJ, Moulder SL, Naing A, Janku F, Piha-Paul SA, Falchook GS, Zinner R, Tsimberidou AM, Fu S, Hong DS, Atkins JT, Cronin M, Yelensky R, Stephens P. A dose-escalation study of anastrozole and everolimus in patients with advanced gynecologic and breast malignancies: tolerance, biological activity, and molecular alterations in the P13K/AKT/mTOR pathway. Cancer Res 73(8 Suppl), 2013.
162. Ganesan P, Piha-Paul S, Naing A, Falchook G, Wheler J, Fu S, Hong DS, Kurzrock R, Jankui F, Laday S, Bedikian AU, Kies M, Wolff R, Tsimberidou AM. Phase I clinical trial of lenalidomide in combinatino with sorafenib in patients with advanced cancer. Cancer Res 73(8, Suppl 1), 2013.
163. Tsimberidou AM, Hong DS, Wheler JJ, Ye Y, Fu S, Piha-Paul SA, Naing A, Falchook GS, Janku F, Aldape K, Wen S, Berry D, Kurzrock R. Personalized medicine for patients with advanced cancer in the phase I program validation analysis. WIN 2013 Meeting Program, 2013.
164. Hou MM, Liu X, Wheler J, Naing A, Hong D, Bodurka D, Schmeler K, Tsimberidou AM, Janku F, Zinner R, Piha-Paul S, Lu K, Wolff R, Kurzrock R, Fu S. Outcome analyses of patients with metastatic cervical cancers in a phase I clinic. J Clin Oncol; Proceedings of the 2013 ASCO Annual Meeting 31(15S), 2013.
165. Tsimberidou AM, Said R, Falchook G, Janku F, Naing A, Zinner R, Blumenschein G, Fu S, Hong D, Piha-Paul S, Wheler J, Ye Y, Hes K, Palmer G, Wolff RA, Kurzrock R. Outcomes of patients with advanced cancer and KRAS mutation in phase I clinical trials. J Clin Oncol; Proceedings of the 2013 ASCO Annual Meeting 31(15S). e-Pub 2013.
166. Liu X, Hong DS, Fu S, Piha-Paul SA, McQuinn L, Falchook GS, Williams J, Karp D, Subbiah V, Tsimberidou AM, Janku F, Zinner R, Wheler JJ, Wolff RA, Kurzrock R, Naing A. Incidence of mucositis in patients treated with mTOR inhibitor-based regimens and correlation to treatment response. J Clin Oncol; 2013 ASCO Annual Proceedings 31(15S), 2013.
167. Wheler JJ, Yelensky, Moulder SL, Tsimberidou AM, Falchook GS, Janku F, Atkins JT, Zinner R, Karp DD, Hong DS, Stephens P, Wolff RA, Kurzrock R. Next generation sequencing (NGS) in patients with advanced metastatic breast cancer: identification of molecular alterations and analysis of associations with treatment on phase I studies at MD Anderson Cancer Center. J Clin Oncol; 2013 ASCO Annual Meeting Proceedings 31(15S):61s, 2013.
168. Subbiah IM, Wheler J, Hess KR, Hong DS, Fu S, Kurzrock R, Wolff RA, Tsimberidou AM. Outcomes of patients ≥65 years with advanced cancer treated on phase clinical trials. J Clin Oncol; 2013 ASCO Annual Meeting Proceedings 31(15S):586s, 2013.
169. Ganesan P, Piha-Paul SA, Naing A, Falchook GS, Wheler JJ, Janku F, Zinner R, Laday S, Kies MS, Tsimberidou AM. Phase I clinical trial of lenalidomide with temsirolimus in patients with advanced cancer. J Clin Oncol; 2013 ASCO Annual Meeting Proceedings 31(15S):166s, 2013.
170. Said R, Ye Y, Hong DS, Janku F, Fu S, Naing A, Wheler JJ, Kurzrock R, Palmer GA, Hess KR, Wolff RA, Thomas C, Tsimberidou AM. Characteristics and survival of patients with advanced cancer and TP53 mutations in phase I clinical trials. J Clin Oncol; 2013 ASCO Annual Meeting Proceedings 31(15S):152s, 2013.
171. Huang HJ, Devogelaere B, Falchook GS, Fu S, Angelo LS, Hong DS, Piha-Paul SA, Naing A, Holley VR, Tsimberidou AM, Stepanek VM, Kim KB, Subbiah V, Wheler JJ, Zinner RG, Wolff RA, Sablon E, Maertens G, Kurzrock R, Janku F. BRAF mutation testing with a novel, rapid, fully-automated molecular diagnostics prototype platform. J Clin Oncol; 2013 ASCO Annual Meeting Proceedings 31(15S):677s, 2013.
172. Prasanth G, Piha-Paul SA, Naing A, Falchook GS, Wheler JJ, Janku F, Zinner R, Laday S, Kies MS, Tsimberidou AM,. Phase I clinical trial of lenalidomide with temsirolimus in patients with advanced cancer. J Clin Oncol; 2013 ASCO Annual Meeting Proceedings 31(15S), 2013.
173. Westin SN, Smart ML, Pal N, Urbauer DL, Janku F, Wheler JJ, Piha-Paul SA, Naing A, Tsimberidou AM, Fu S, Falchook GS, Hong DS, Zinner R, Subbiah V, Culotta KS, Lu KH, Coleman RL, Kurzrock R. Phase I trial of sorafenib, bevacizumab, and temsirolimus in advanced solid tumors. J Clin Oncol; 2013 ASCO Annual Meeting Proceedings 31(15S):168s, 2013.
174. Janku F, Angelo LS, Devogelaere B, Falchook GS, Fu S, Huang HJ, Tsimberidou AM, Hong DS, Stepanek VM, Holley VR, Routbort MJ, Luthra R, Sablon E, Maertens G, Kurzrock R. BRAF mutation testing with a novel rapid fully automated biocartis moecular diagnostics protype platform. Cancer Res 73(8 suppl), 2013.
175. Chae YK, Kim K, Hong DS, Falchook GS, Piha-Paul SA, Wheler JJ, Naing A, Fu S, Tsimberidou AM, Zinner RG, Subbiah V, Stepanek VM, Wolff RA, Kuirzrock R, Janku F. PIK3CA mutation, aspirin use and mortality in patients with metastatic colorectal cancer participating in early-phase clinical trials. Cancer Res 73(8, Suppl 1), 2013.
176. Westin S, Sun C, Pal N, Janku F, Tsimberidou A, Falchook G, Hong D, Lu K, Coleman R, Kurzrock R. KRAS mutation in endometrial and ovarian cancers: Preliminary data on association with phenotype and clinical outcome in primary disease. 2013 SGO Annual Meeting on Women's Cancer, 2013.
177. Subbiah IM, Janku F, Tsimberidou AM, Naing A, Kaseb AO, Hong DS, Subbiah V, Hess KR, Akmal O, Falchook GS, Kurzrock R. Characteristics and outcomes of patients with advanced hepatocellular carcinoma treate on phase I trials. J Clin Oncol 31(No 4 Suppl), 2013.
178. Gonzalez-Angulo AM, Krop I, Piha-Paul S, Li Y, Culotta KS, Moulder-Thompson S, Tsimberidou AM, Velez-Bravo VM, Madden TL, Norberg LM, Doyle A, Winder EP, Mills GB, Meric-Bernstam F, Kurzrock R. Phase 1b dose escalation and biomarker study of MK2206 in combination with standard doses of weekly paclitaxel in patients with locally advanced or metastatic solid tumors with expansion in advanced breast cancer. Cancer Res; Proceedings from the 103 AACR Annual Meeting 72(8 Suppl), 2012.
179. Subbiah IM, subbiah V, Kaseb AO, Janku F, Wheler JJ, Naing A, Fu S, Piha-paul SA, Hong DS, Falchook GS, Tsimberidou AM, Kurzrock R. Characteristics and outcomes of patients with gallbladder cancer and cholangiocarcinoma referred to a phase I clinic. J Clin Oncol, 2012 Gastrointestinal Cancers Symposium 30(Suppl 4), 2012.
180. Amin HM, Falchook GS, Fu S, Hong DS, Tsimberidou AM, Naing, A, Wheler JJ, Piha-Paul SA, Janku J, Klevesath MB, Jego V, Johne A, Kurzrock R. First-in-human phase I dose-escalation study of the oral selective C-Met inhibitor EMD 1204831, in patients with advanced solid tumors. J Clin Oncol, 2012 ASCO Annual Meeting Proceedings 30(15 Suppl), 2012.
181. Madhusudanannair V, Janku F, Falchook GS, hong DS, Wheler JJ, Naing A, Fu S, Piha-Paul S, El-Osta HE, Luthra R, Tsimberidou AM, Kurzrock R. NRAS mutations in patients with advanced cancers treated with targeted therapies in early-phase clinical trials. J Clin Oncol 30(15S), 2012.
182. Amin HM, Falchook GS, Fu S, Hong DS, Tsimberidou AM, Naing A, Wheler JJ, Piha-Paul SA, Janku F, Klevesath MB, Jego V, Johne A, Kurzrock R. First-in-human phase I dose escalation study of the oral selective C-met inhibitor EMD 1204831 inpatients with advanced solid tumors. J Clin Oncol 30(15S), 2012.
183. Rodrigues HV, Parsons HA, Janku F, Naing A, Wheler JJ, Tsimberidou AM, Kurzrock R. A pilot study of temsirolimus and body composition. J Clin Oncol 30(15S), 2012.
184. Subbiah IM, Tsimberidou AM, Naing A, Subbiah V, Kaseb AO, Fu S, Hong DS, Piha-Paul SA, Wheler JJ, Janku F, Hess KR, Falchook GS, Kurzrock R. Early-phase trials compared to first-and second-line FDA-approved treatments in patients with advanced gallbladder cancer and cholangiocarcinoma. J Clin Oncol 30(15S), 2012.
185. Said R, Hong DS, Wheler JJ, Naing A, Falchook GS, Fu S, Janku F, Zinner R, Piha-Paul SA, Warneke CL, Tsimberidou AM, Kurzrock R. p53 mutations in advanced cancers: Clinical characteristics and outcomes in a phase I setting. J Clin Oncol 30(15S), 2012.
186. Janku F, Broaddus R, Bakkar R, Hong DS, Stepanek VMT, Naing, Falchook GS, Fu S, Wheler JJ, Piha-Paul SA, Moulder SL, Luthra R, Tsimberidou AM, Kurzrock R. PTEN assessment and P13K/mTOR inhibitors: Importance of simultaneous assessment of MAPK pathway aberrations. J Clin Oncol 30(15S), 2012.
187. Henary HA, Hong DS, Falchook GS, Tsimberidou AM, George G, Wheler JJ, Fu S, Naing A, Piha-Paul SA, Janku F, Kim KB, Hwu P, Kurzrock R. Targeted agents matched with tumor molecular aberrations: Review of 160 patients with advanced melanoma treated in a phase I clinic. J Clin Oncol 30(15S), 2012.
188. Subbiah IM, Kurzrock R, Naing A, Piha-Paul S, Falchook GS, Hong DS, Wheler JJ, Fu S, Tsimberidou AM. A phase I study of lenalidomide in combination with bevacizumab, sorafenib, temsirolimus, or 5-fluoracil, leucovorin, oxaliplatin (FOLFOX) in patients with advanced cancers. Cancer Res 72(8 Suppl). e-Pub 2012.
189. Subbiah IM, Tsimberidou AM, Naing A, Subbiah V, Kaseb A, Falchook GS, Fu S, Hong, D, Piha-Paul SA, Wheler JJ, Janku F, Kurzrock R. Early-phase trials in patients with advanced gallbladder cancer and cholangiocarcinoma: the MD Anderson Clinical Center for Targeted Therapy experience. Cancer Res 72(8 suppl), 2012.
190. Tsimberidou AM, Hong DS, Wheler J, Ye Y, Fu S, Piha-Paul S, Naing A, Falchook G, Janku F, Luthra R, Wen S, Kurzrock R. Personalized medicine: an update on 1,985 patients with advanced cancer at MD Anderson Cancer Center. Ann Oncol, 4th WIN Symposium 23(Suppl 5):V10, 2012.
191. Naing A, Falchook S, Fu S, Amin HM, Piha-Paul SA, Hong DS, Tsimberidou AM, Wheler JJ, Janku F, Klevesath MB, Jego V, Johne A, Kurzrock R. A phase I dose-escalation study of EMD 1214063, an oral selective c-met inhibitor, in patients with advanced solid tumors. Ann Oncol; 10th Annual Meeting of JSMO 23(Suppl 11):xi21-xi23, 2012.
192. Hong DS, Naing A, Falchook GS, Piha-Paul S, Wheler JJ, Fu S, Tsimberidou AM, Hui D, Scott R, Khan R, Mistry R, Talley J, Bermudez D, Kumar S, Stecher M, Simard J, Kurzrock R. A phase I study of MABp1, a first-in-human use of a true human, monoclonal antibody against IL-1a in patients with advanced cancers. Mol Cancer Ther 10(11, Suppl 1), 2011.
193. Janku F, Naing A, Stepanek VT, Falchook GS, Hong DS, Tsimberidou AM, Fu S, Lee JJ, Luthra R, Wheler JJ, Kurzrock R. PIK3CA mutations H1047R are associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials. Mol Cancer Ther 10(11):S1, 2011.
194. Hong DS, Naing A, Falchook GS, Piha-Paul SA, Wheler JJ, Fu S, Tsimberidou AM , Hui D, Scott R, Khan R, Mistry R, Talley J, Chauhan S, Bermudez D, Stecher M, Simard J, Kurzrock R. A phase I study of MABp1, a first-in-human, first-true human monoclonal antibody against the IL-1 in patients with advanced cancers. Mol Cancer Ther 10(11):S1, 2011.
195. Falchook GS, Fu S, Amin HM, Tsimberidou AM, Hong DS, Naing A, Klevesath MB, Mattiacci MR, Johne A, Kurzrock R. Phase I dose-escalation study of the oral selective c-met inhibitor EMD 1204831 in patients with advanced solid tumors. Eur J Cancer 47(Supplement 1):S158, 2011.
196. Tsimberidou AM, Iskander NG, Hong DS, Wheler JJ, Fu S, Piha-Paul SA, Naing A, Falchook GS, Janku F, Luthra R, Wen S, Kurzrock R. Personalized medicine in a phase I clinical trials program: The M. D. Anderson Cancer Center Initiative. J Clin Oncol 29(18_suppl):165S, 2011.
197. Tsimberidou AM, Wierda W, Wen S, Plunkett W, O'Brien S, Kipps T, Jones J, Kantarjian H, Keating MJ. Final results of a phase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab (OFAR) combination therapy in patients with aggressive, relapsed/refractory chronic lymphocytic leukemia (CLL) and richter syndrome (RS). Ann Oncol; 11th International Conference on Malignant Lymphoma 22(Suppl 4):iv119, 2011.
198. Iskander NG, Tsimberidou AM, Letourneau K, Wen S, Wheler JJ, Hong DS, Naing A, Kurzrock R. Phase I clinical trial outcomes in 93 patients with brain metastases: The M. D. Anderson Cancer Center experience. J Clin Oncol; 2011 ASCO Annual Meeting Proceedings 29(15S), 2011.
199. El-Osta HE, Falchook GS, Tsimberidou AM, Hong DS, Naing A, Kim KB, Wen S, Janku F, Kurzrock R. Clinical characterstics and outcomes of patients with BRAF-mutant advanced cancer in a phase I clinic: The University of Texas M. D. Anderson Cancer Center experience. J Clin Oncol; 2011 ASCO Annual Meeting Proceedings 29(15_suppl):638s, 2011.
200. Sun M, Falchook GS, Wheler JJ, Hong DS, Piha-Paul SA, Tsimberidou AM, Naing A, Fu S, Moulder SL, Wen S, Mueller P, Kurzrock R. Association of VEGF single-nucleotide polymorphisms (SNPs) with response and toxicity in patients treated with bevacizumab. J Clin Oncol; 2011 ASCO Annual Meeting Proceedings 29(15_suppl), 2011.
201. Veasey Rodrigues V, Naing A, Hong DS, Falchook GS, Fu S, Wheler JJ, Tsimberidou AM, Moulder SL, Janku F, Wen S, Fessahaye SN, Golden EC, Westerhold DI, Ewer M, Kurzrock R. The role of the electrocardiogram (ECG) in phase I drug development in patients with cancer: The MD Anderson Cancer Center experience with 8,966 ECGs. J Clin Oncol; 2011 ASCO Annual Meeting Proceedings 29(15S):176s, 2011.
202. Wheler JJ, Janku F, Jackson T, Fu S, Sun M, Yang H, Naing A, Moulder SL, Tsimberidou AM, Hong DS, Falchook GS, Piha-Paul SA, Garcia-Manero G, Kurzrock R. Phase I study of anti-VEGF monoclonal antibody bevacizumab and HDAC inhibitor valproic acid in patients with advanced cancers. J Clin Oncol; 2011 ASCO Annual Meeting Proceedings 29(15S):178s, 2011.
203. Henary HA, Kurzrock R, Falchook GS, Naing A, Moulder SL, Wheler JJ, Tsimberidou AM, Durand JB, Yang P, Johansen J, Newman R, Khan R, Patgel U, Hong DS. Final results of a first-in-human phase I trial of PBI-05204, an inhibitor of AKT, FGF-2, NF-kb and p70S6K in advanced cancer patients. J Clin Oncol; 2011 ASCO Annual Meeting Proceedings 29(15S):199s, 2011.
204. Stephen B, Wheler JJ, Tsimberidou AM, Wen S, Naing A, Hong DS, Falchook GS, Piha-Paul SA, Fu S, Janku F, Moulder SL, Kurzrock R. Survival of 1,181 patients in a phase I clinic: The University of Texas M. D. Anderson Cancer Center experience. J Clin Oncol; 2011 ASCO Annual Meeting Proceedings 29(15S):172s, 2011.
205. Kurzrock R, Patnaik A, Rosenstein L, fu S, Papadopoulos KP, Smith DA, Gonzales T, Tsimberidou AM, Mays TA, Cox DS, Hong DS, DeMarini DJ, Le NT, Morris SR, Tolcher AW. Phase I dose-escalation of the oral MEK1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral AKT inhibitor GSK2141795 (GSK795). J Clin Oncol; 2011 ASCO Annual Meeting Proceedings 29(15_suppl):215s, 2011.
206. Fok J, Kurzrock R, Tsimberidou AM, Wen S, Naing A, Hong DS, Janku F, Falchook GS, Piha-Paul SA, Katz R, Fu S, Moulder SL, Wheler JJ. An umbrella protocol for histology-independent, phase I modular study based on EGFR mutation status: using erlotinib alone or in combination with cetuximab, bortezomib, or dasatinib to overcome resistance. J Clin Oncol; 2011 ASCO Annual Meeting Proceedings 29(15S):174s, 2011.
207. Janku F, Garrido-Laguna I, Wheler JJ, Hong DS, Naing A, Falchook GS, Fu S, Moulder SL, Luthra R, Lee JJ, Tsimberidou AM, Kurzrock R. Screening for PIK3CA mutations, PTEN loss and RAS/RAF mutations in early-phase protocols with PI3K/mTOR pathway inhibitors. J Clin Oncol; 2011 ASCO Annual Meeting Proceedings 29(15S):631s, 2011.
208. Vining D, Tsimberidou AM, Wang J, Garg N. Multimedia structured reporting: a picture is worth a thousand words. American Journal of Roentgenology 196(5):Supplement A10-A13, 2011.
209. Tsimberidou AM, Hong D, Wheler JJ, FU S, Piha-Paul S, Naing A, Falchook G, Luthra R, Iskander NG, Wen S, Kurzrock R. Profile-related evidence to determine individualized cancer therapy (PREDICT): Preliminary results of the personalized phase I clinical trials program at MD Anderson Cancer Center. Cancer Res 71(8 Suppl 1), 2011.
210. Tsimberidou AM, Wierda WG, Wen S, Plunkett P, O'Brien S, Kipps TJ, Jones JA, Kantarjian HM, Keating MJ. Results of a phase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab (OFAR) combination therapy In patients with aggressive, relapsed/refractory chronic lymphocytic leukemia (CLL) and Richter syndrome (RS). Blood; 52nd ASH Annual Meeting Abstracts 116(21), 2010.
211. Janku F, Tsimberidou AM, Garrido-laguna I, Hong DS, Naing A, Falchook GS, Fu S, Luthra R, Wang X, Kurzrock R. Screening for PIK3CA, RAS, and RAF mutations in trials with PI3K/AKT/MTOR signaling pathway inhibitors. EJC Supplements 8(7):83, 2010.
212. Vaklavas C, Tsimberidou AM, Wen S, Fu S, Hong DS, Wheler J, Naing A, Uehara C, Wolff RA, Kurzrock R. Clinical outcomes and prognostic factors of hepatic arterial infusion (HAI) chemotherapy combination regimens in 202 patients with advanced cancer metastatic to the liver: The Phase I Program M. D. Anderson Cancer Center. J Clin Oncol; Proceedings of the 2010 ASCO Annual Meeting 28(15s), 2010.
213. Janku, F, Tsimberidou AM, Garrido-Laguna I, Hong DS, Naing A, Falchook GS, Wheler JJ, Fu S, Piha-Paul SA, Kurzrock R. PIK3CA, KRAS and BRAF mutations in patients with advanced cancers treated with PI3K/AKT/mTor axis inhibitors. J Clin Oncol; Proceedings of the 2010 ASCO Annual Meeting 28(15S):224S, 2010.
214. Cabanillas ME, Kurzrock R, Sherman SI, Tsimberidou AM, Waguespack S, Naing A, Busaidy N, Gagel R, Wright JJ, Hong DS,. Phase I trial of combination sorafenib and tipifarnib: the experience in advanced differentiated thyroid cancer (DTC) and medullary thyroid cancer (MTC). J Clin Oncol; Proceedings of the 2010 ASCO Annual Meeting 28s(15s):442s, 2010.
215. Wheler JJ, Tsimberidou AM, Wen S, Naing A, Hong DS, Falchook GS, Piha-Paul SA, Fu S, Moulder SL, Kurzrock R. Toxicity in 1,181 patients with advanced solid tumors treated in phase I clinical trials of predominantly targeted agents: The M. D. Anderson Cancer Center experience. J Clin Oncol; Proceedings of the 2010 ASCO Annual Meeting 28(15s):230s, 2010.
216. Stephen S, Naing A, Hong DS, Fu S, Wheler JJ, Moulder SL, Falchook GS, Tsimberidou AM, Piha-Paul SA, Kurzrock R. The use of complementary and alternative medicine in patients seen in phase I clinical trials program. J Clin Oncol; Proceedings of the 2010 ASCO Annual Meeting 28(15s):658s, 2010.
217. Tsimberidou AM, Vaklavas C, Wen S, Hong D, Wheler J, Ng CS, Naing A, Uehara C, Wolff R, Kurzrock R. Clinical outcomes and prognostic factors in 83 patients with pancreatic cancer treated in phase I clinical trials at M.D. Anderson Cancer Center. Cancer Res; Proceedings of the AACR 101st Annual Meeting 2010 70(8 Suppl), 2010. e-Pub 2010.
218. Wheler, J, Tsimberidou A, Moulder S, Cristofanilli M, Hong D, Naing A, Pathak R, Liu S, Kurzrock R. Clinical outcomes of patients with breast cancer in a phase I clinic: The M.D. Anderson Cancer Center experience. Clinical Breast Cancer; The 2009 San Antonio Breast Cancer Symposium 10(1), 2010.
219. Tsimberidou AM, Wierda WG, Badoux X, Wen S, Plunkett W, O'Brien Sm, Kipps TJ, Jones JA, Kantarjian H, Keating MJ. Evaluation of oxaliplatin, fludarabine, cytarabine, and rituximab (OFAR) combination therapy in aggressive chronic lymphocytic leukemia (CLL) and Richter Syndrome (RS). J Clin Oncol; Proceedings of the 2010 ASCO Annual Meeting 28(15s):492s, 2010.
220. Tsimberidou AM, Akerley W, Ng C, Hong D, Uehara C, Warren T, Yu, MK, Swabb EA, Kurzrock, R. Azixa a microtubule formation inhibitor in solid tumors: Results of a Phase 1 clinical trial. Cancer Res; Procedings of the 100th AACR Annual Meeting 69(9 Suppl), 2009.
221. Tsimberidou AM, Hong D, Ng C, Wheler J, Naing A, Bedikian A, Eng C, Fortier A, Uehara C, Kurzrock R. A phase I study of hepatic arterial infusion of oxaliplatin in combination with systemic fluorouracil, leucovorin and bevacizumab in patients with advanced solid tumors metastatic to the liver. Cancer Res; Procedings of the 100th AACR Annual Meeting 69(9 Suppl), 2009.
222. Tsimberidou AM, Wierda WG, Plunkett WK, O'Brien S, Lerner S, Smith, SC, Kantarjian HM, Keating, MJ. Phase I/II study of oxaliplatin, fludarabine, cytarabine, and rituximab in patients (OFAR2) with Richter's syndrome (RS), and relapsed or refractory B-cell chronic lymphocytic leukemia (CLL). J Clin Oncol; Proceedings of the 2009 ASCO Annual Meeting 27(15_Suppl):363s, 2009.
223. Wheler J, Tsimberidou A, Moulder S, Cristofanilli M, Hong D, Naing A, Pathak R, Liu S, Kurzrock R. Clinical outcomes of patients with breast cancer in a phase I clinic: The M. D. Anderson Cancer Center experience. J Clin Oncol; Proceedings of the 2009 ASCO Annual Meeting 27(15_Suppl):54s, 2009.
224. Ewald BJ, Sampath D, Zevevic A, Tsimberidou AM, Wierda WG, Plunkett W. Fludarabine and ara-C increase oxaliplatin-induced DNA damage and cytotoxicity in chronic lymphocytic leukemia. Cancer Res; Procedings of the 100th AACR Annual Meeting 69(9 Suppl), 2009.
225. Tsimberidou AM, Wierda W, Plunkett W, O'Brien S, Kipps TJ, Jones J, Smith S, Jalayer A, Kantarjian HM, Keating M. Oxaliplatin, fludarabine, cytarabine, and rituximab induces high response rates in aggressive chronic lymphocytic leukemia (CLL) and Richter's syndrome (RS). Blood (ASH Annual Meeting) 114(22):3443, 2009.
226. Tsimberidou AM, Wen S, O'Brien S , McLaughlin P , Wierda WG , Kantarjian H , Lerner S , Strom S , Freireich EJ, Medeiros L, Keating MJ. Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma: Analysis of 2028 patients. Annals of Oncology 19(Suppl 4), 2008.
227. Wheler JJ, Tsimberidou AM, Hong DS, Jackson TL, Polk DY, Pilat S, Liu S, Feng L, Kurzrock R. Survival of patients in a phase I clinic: The M.D. Anderson Cancer Center experience. J Clin Oncol 26(15_suppl), 2008.
228. Tsimberidou AM, Rudek M , Hong D. Ng C , Blair J , Goldsweig H , Kurzrock R. Phase 1 first-in-human study of s-trans, trans-farnesylthiosalicylic acid (salirasib) in patients with solid tumors. J Clin Oncol; Proceedings of the 2008 ASCO Annual Meeting 26(15_Suppl):593s, 2008.
229. Tsimberidou AM, Estey E, Albitar M, Wen S, Brandt M, Pierce S, Kantarjian H, Kurzrock R,. Prognostic significance of tissue necrosis factor-alpha in newly diagnosed acute myeloid leukemia and high-risk myleodysplastic syndromes. Blood; Proceedings of the 2007 ASH Annual Meeting 110(11):133b, 2007.
230. Tsimberidou AM, Kantarjian H, Faderl S, Pierce S, Freireich E, Estey E,. Untreated patients with acute myeloid leukemia, age 50-59 years and performance status 2 should be as eligible for targeted therapy as older patients. Blood; Proceedings of the 2007 ASH Annual Meeting 110(11):842a, 2007.
231. Tsimberidou AM, Kantarjian H, Faderl S, Pierce S, Freireich E, Estey E.. Exclusion of acute myeloid leukemia (AML) clinical trials of patients unlikely to respond. Blood; Proceedings of the 2007 ASH Annual Meeting 110(11):843a, 2007.
232. Tsimberidou AM, Hantarjian H, O'Brien S, Garcia-Manero G, Koller C, Jones D, Pierce S, Brandt M, Keating M, Estey E.. All-Trans Retinoic Acid (ATRA) and Arsenic Trioxide (As2O3) Combination Therapy Induces High Rates of Durable Molecular Remission in Newly Diagnosed Acute Promyelocytic Leukemia (APL). Blood; Proceedings from the 2007 ASH Annual Meeting 110(11):543a, 2007.
233. Tam C, Keating M, Tsimberidou AM, O'Brien S, Ferrajoli A, Lerner S, Faderl S, Abruzzo L, Schlette E, Kantarjian H, Wierda W. The clinical usefulness of novel prognostic factors in CLL: A study of 477 patients with low-risk (non-11q non-17p) FISH and known IGVH mutation status. Blood; Proceedings of the 2007 ASH Annual Meeting 110(11), 2007.
234. Tsimberidou AM, Tam C, Wierda WG, O'Brien S, Lerner S, Kantarjian HM, Keating MJ. The prognostic significance of 11q deletion detected by fluorescence in situ hybridization (FISH) in untreated chronic lymphocytic leukemia: The MDACC experience. Blood; Proceedings of the 2007 ASH Annual Meeting 110(11):619a, 2007.
235. Tsimberidou AM, Tam C, Wierda W, O'Brien S, Lerner S, Keating M.. Beta-2 microglobulin (β2M) is an independent prognostic factor for clinical outcomes in patients with CLL treated with frontline fludarabine, cyclophosphamide, and rituximab regardless of age, creatinine clearance or performance status. J Clin Oncol; Proceedings of the 2007 ASCO Annual Meeting 25(Suppl 18), 2007.
236. Tsimberidou AM, Kantarjian HM, Wen S, Keating MJ, O'Brien S, Cortes J, Pierce S, Brandt M, Freireich E, Estey E.. Prognostic score including serum β2 microglobulin levels to stratify patients with acute myeloid leukemia: analysis of 1,293 patients. Haematologica; Proceedings of the 12th Congress of The European Hematology Association 92(Suppl 1):22, 2007.
237. Tsimberidou AM, Wierda W, O'Brien S, Wen S, Plunkett W, Kipps T, Lerner S, Kantarjian H, Freireich E, Keating M.. Comparison of oxaliplatin, fludarabine, cytarabine, and rituximab therapy with cyclophosphamide, vincristine, liposomal daunorubicin, dexamethasone, rituximab and GM-CSF alternating with methotrexate, cytarabine, rituximab GM-CSF therapy: Analysis of 53 patients with Richter's syndrome. XII International Workshop on CLL, London, UK ( Supplement 1 to Leukemia and Lymphoma) 48:S170, 2007.
238. Tsimberidou AM, Kantarjian HM, Garcia-Manero G, Koller C, Jones DM, Keating MJ, Estey E.. Clinical outcomes and rates of molecular remission with all-trans retinoic acid and arsenic trioxide combination therapy in newly diagnosed acute promyelocytic leukemia. J Clin Oncol; Proceedings of the 2006 ASCO Annual Meeting 24(18_suppl):337s, 2006.
239. Garcia M, Deavers MT, Knoblock RJ, Chen W, Tsimberidou AM, Manning JM, Medeiros LJ.. Myeloid sarcoma involving the gynecologic tract. A report of 11 cases and review of the literature. Proceedings of the United States and Canadian Academy of Pathology Annual Meeting, Atlanta, Georgia, 2006.
240. Tsimberidou AM, Kantarjian HM, Keating MJ, O'Brien S, Wen S, Cortes J, Giles F, Koller CA, Garcia-Manero G, Pierce S, Brandt M, Freireich EJ, Estey EH.. Prognostic significance of β-2 microglobulin levels in acute myeloid leukemia: analysis of 1293 patients. Blood; Proceedings of the 2006 ASH Annual Meeting 108(11):240a, 2006.
241. Tsimberidou AM, Keating MJ, Kantarjian H, O'Brien S, Cortes J, Koller C, Pierce S, Brandt M, Beran M, Estey E.. Granulocytic sarcoma is associated with event-free survival superior to that of acute myeloid leukemia. Blood; Proceedings of the 2006 ASH Annual Meeting 108(11):568a, 2006.
242. Tsimberidou AM, O'Brien S, McLaughlin P, Wen S, Wierda W, Kantarjian H, Manning H, Lerner S, Hess M, Freireich EJ, Keating MJ.. Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma: analysis of 2083 patients. Blood; Proceedings of the 2006 ASH Annual Meeting 108(11):790a, 2006.
243. Tsimberidou AM, Werida W, O'Brien S, Plunkett W, Kipps T, Brown J, Lerner S, Kantarjian H, Keating MJ.. Combination of oxaliplatin, fludarabine, cytarabine, and rituximab in patients with Richter's syndrome and fludarabine-refractory chronic lymphocytic leukemia. Blood; Proceedings of the 2006 ASH Annual Meeting 108(11):799a, 2006.
244. Tsimberidou AM, McLaughlin P, O'Brien S, Wen S, Wierda W, Manning J, Lerner S, Hess M, Kantarjian H, Freireich E, Keating MJ.. A prognostic score for chronic lymphocytic leukemia and small lymphocytic lymphoma: analysis of 2189 patients. Blood; Proceedings of the 2006 ASH Annual Meeting 108(11):788a, 2006.
245. Tsimberidou AM. Genomic aberrations in chronic lymphocytic leukemia and small lymphocytic lymphoma by absolute analysis of 1694 patients. Blood; Proceedings of the 2006 ASH Annual Meeting 108(11):327b, 2006.
246. Tsimberidou AM. Outcome in patients with Richter's syndrome treated with chemotherapy and/or immunotherapy with or without stem cell transplantation. Blood; Proceedings of the Third Annual Conference on Therapeutic Advances in the Treatment of Hematological Malignancies 106(11), 2005.
247. Tsimberidou AM, O'Brien S, Wierda WG, Garcia-Manero G, Lerner S, Keating MJ. Effects of immunotherapy on survival and progression-free survival in patients with splenic marginal zone lymphoma or marginal zone leukemia/lymphoma. Proceedings of the American Society of Clinical Oncology 23:5805, 2005.
248. Tsimberidou AM, O'Brien S, Wierda WG, Garcia-Manero G, Lerner S, Keating MJ. A comparison of outcomes in patients with splenic marginal zone lymphoma or marginal zone leukemia/lymphoma treated with immunotherapy, chemoimmunotherapy, or chemotherapy. Ann Oncol: Ninth International Conference on Malignant Lymphoma, Lugano 16(Suppl 5):v124, 2005.
249. Tsimberidou AM, Catovsky D, Schlette E, O'Brien S, Wierda W, Garcia-Manero G, Lerner S, Keating MJ.. Rituximab with or without chemotherapy is associated with prolonged survival in patients with splenic marginal zone lymphoma or marginal zone leukemia/lymphoma. XI International Workshop on CLL, New York, NY 46(Suppl 1):91, 2005.
250. Tsimberidou AM, Keating M, McLaughlin P, O'Brien S, Wierda W, Ferrajoli A, Manning J, Kantarjian H.. Comparison of small lymphocytic lymphoma with chronic lymphocytic leukemia. The M. D. Anderson Cancer Center experience. Blood 106(11):270a, 2005.
251. Tsimberidou AM, Catovsky D, Schlette E, O'Brien S, Kantarjian H. Wierda W, Smith S, Wen S, Lerner S, Keating M.. Outcomes in patients with splenic marginal zone lymphoma or marginal zone leukemia/lymphoma treated with immunotherapy, chemoimmunotherapy, or chemotherapy. Blood 106(11):270a, 2005.
252. Tsimberidou AM, O'Brien S, Kantarjian H, Koller C, Hagemeister F, Fayad L, Lerner S, Keating M.. Transformation of chronic lymphocytic leukemia in Hodgkin's disease. The M. D. Anderson Cancer Center experience. Blood 106(11):287a, 2005.
253. Tsimberidou AM, O'Brien S, Khouri I, Giles F, Kantarjian H, Wen S, Smith S, Lerner S, Freireich E, Keating M.. Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy and/or immunotherapy with or without stem cell transplantation. Blood 106(11):593a, 2005.
254. Tsimberidou AM Keating M, Bueso-Ramos C, Kurzrock R.. Epstein-Barr virus in patients with chronic lymphocytic leukemia. Blood 106(11):598a, 2005.
255. Keating MJ, McLaughlin P, Tsimberidou AM, O'Brien S.. Are chronic lymphocytic leukemia and small lymphocytic lymphoma the same disease?. IX International Conference on Malignant Lymhoma, Lugano, Switzerland 16(Suppl 5):v46, 2005.
256. Kurzrock R, Khouri I, Bueso-Ramos C, Giles F, Pilat S, Thomas DA, Cortes J, Tsimberidou AM. Low-dose interleukin-11 has activity in patients with bone marrow failure. J Clin Oncol: Proceedings of the ASCO Annual Meeting 2004 23:172, 2004.
257. Tsimberidou AM, Tirado-Gomez M, Andreeff M, O'Brien S, Kantarjian HM, Keating MJ, Lopez-Berestein G, Estey E.. Single agent liposomal-encapsulated (Lipo) all-trans retinoic acid (ATRA) can cure patients with untreated acute promyelocytic leukemia (APL): an update and comparison with an ATRA+idarubicin induction regimen. J Clin Oncol: Proceedings of the ASCO Annual Meeting 2004 23:559, 2004.
258. Tsimberidou AM, Estey E, Cortes J, Verstovsek S, Faderl S, Thomas D, Wierda W, Garcia Manero G, Kantarjian H, Giles FJ.. Randomized comparison of idarubicin and cytarabine +/- interleukin in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndrome. J Clin Oncol: Proceedings of the ASCO Annual Meeting 2003 21:585, 2003.
259. Kurzrock R, Tsimberidou AM, Giles FJ, Duvic M.. Pilot study of recombinant human soluble tumor necrosis factor receptor (P75) fusion protein etanercept in patients with relapsed cutaneous T-cell lymphomas. J Clin Oncol: Proceedings of the ASCO Annual Meeting 2003 21:590, 2003.
260. Alvarado Y, Kantarjian H, Cortes J, Verstovsek S, Faderl S, Garcia-Manero G, Tsimberidou A, Sznol M, Giles F. Phase I study of VNP4010M, a novel alkylating agent in patients with refractory hematologic malignancies. J Clin Oncol: Proceedings of the ASCO Annual Meeting 2003 21:585, 2003.
261. Tsimberidou AM, Giles FJ, Duvic M, Fayad L, Kurzrock R.. Phase II study of pentostatin in patients with T-cell lymphomas: update of an M. D. Anderson Cancer Center series. Blood 102(11):639a, 2003.
262. Tsimberidou AM, Giles FJ, Duvic M, Fayad L, Kurzrock R.. Activity of interferon-alpha and isotretinoin in patients with advanced, refractory lymphoid malignancies. Blood 102(11):649a, 2003.
263. Tsimberidou AM, Keating MJ, Giles F, Lerner S, Kantarjian H, O'Brien S.. Phase II study of fludarabine and mitoxantrone in patients with chronic lymphocytic leukemia. Blood 102(11):358b, 2003.
264. Giles FJ, List AF, Roboz GJ, Tsimberidou AM, Laurent D, Reitsma D, Kowalski M, Kantarjian H, Feldman EJ.. Phase I/II study of PTK787/ZK222584 (PTK/ZK), a novel, oral VEGF-receptor inhibitor, in patients with myelofibrosis with myeloid metaphasia. Blood 102(11):922a, 2003.
265. Liu Q, Fayad L, Romaguera J, Hagemeister FB, Rodriguez MA, Younes A, Pro B, Verstovsek S, Cabanillas F, Tsimberidou A, Hess M, Ayala A, Clemons M, McLaughlin P.. Stage IV indolent lymphoma: 25 years of treatment progress. Blood 102(11):398a, 2003.
266. Giles F, Kantarjian H, Cortes J, Tsimberidou AM, Faderl S, Verstovsek S, Thomas D, Garcia-Manero G, Wierda W, Ferrajoli A, Kornblau S, Andreeff M, O'Brien S, Beran M, Estey E.. Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with untreated acute myeloid leukemia or high-risk myelodysplastic syndromes. Blood 102(11):253b, 2003.
267. Apostolidou E, Cortes J, Tsimberidou AM, Estey E, Kantarjian H, Giles F. Mylotarg, liposomal daunorubicin, Ara-C and cyclosporine regimen in patients with relapsed/refractory acute myelogenous leukemia. Blood 100(11):268b, 2002.
268. Giles FJ, Tsimberidou AM, Dabaja B, Kantarjian H, Keating M, O'Brien S. Alternating cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone / methotrexate, and ara-C with rituximab and GM-CSF in patients with relapsed / refractory chronic lymphocytic leukemia. Proceedings of the IX International Workshop on CLL, San Diego, California, 2002.
269. Tsimberidou AM, Estey E, Cortes J, Thomas D, Garcia-Manero G, Faderl S, Verstovsek S, O'Brien S, Kantarjian H, Giles F. Adaptive randomization of idarubicin and Ara-C ± interleukin in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndrome. Blood 100(11):264b, 2002.
270. Tsimberidou AM, Estey E, Cortes J, Thomas D, Garcia-Manero G, Faderl S, Verstovsek S, Beran M, Keating M, O'Brien S, Kantarjian H, Giles F. Nonleukemic granulocytic sarcoma in a single institution: frequency, presentation and clinical outcome. Blood 100(11):243b, 2002.
271. Tsimberidou AM, Estey E, Cortes J, Thomas D, Garcia-Manero G, Faderl S, Verstovsek S, O'Brien S, Kantarjian H, Giles F. Feasibility of mylotarg, fludarabine, Ara-c and cyclosporine regimen as post-remission therapy in acute myelogenous leukemia. Blood 100(11):339a, 2002.
272. Tsimberidou AM, Estey E, Cortes J, Thomas D, Garcia-Manero G, Faderl S, Verstovesk S, O'Brien S, Kantarjian H, Giles H. Mylotarg, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33-positive primary resistant or relapsed acute myeloid leukemia. Blood 100(11):339a-340a, 2002.
273. Tsimberidou AM, Estey E, Cortes J, Thomas D, Garcia-Manero G, Faderl S, Verstovsek S, O'Brien S, Kantarjian H, Giles F.. Mylotarg, fludarabine, cytarabine and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndrome. Blood 100(11):339a, 2002.
274. Tsimberidou AM, McLaughlin P, Feng L, Ayala A, Younes A, Rodriguez MA, Romaguera J, Hagemeister FB, Smith TL, Cabanillas F. Duration of decreased absolute number of circulating CD4 cells and CD4/CD8 ratio in patients with indolent lymphoma treated with fludarabine. Blood 100(11):775a, 2002.
275. Tsimberidou AM, Stavroyanni N, Viniou N, Tiniakou M, Papaioannou M, Marinakis T, Papadopoulos A, Papadaki HA, Megalakaki C, Sakellari I, Skandali A, Panagiotidis P, Matsouka P, Rombos Y, Yataganas X. Comparison of allogeneic stem cell transplantation, high-dose cytarabine, and autologous peripheral blood stem cell transplantation as post-remission treatment in patients with de novo acute myelogenous leukemia. Blood 100(11):861a, 2002.
276. Tsimberidou AM, Waddelow T, Xiao QD, Albitar M, Giles FJ. Increase in plasma TNF-α levels during enbrel treatment of patients with refractory multiple myeloma. J Clin Oncol: Proceedings of ASCO Annual Meeting 2002:276a, 2002.
277. Tsimberidou AM, Tsionos K, Lee MS, Ford R, Lichtiger B, Luthra R, McLaughlin P, Medeiros LJ, Cabanillas F, Sarris AH. Quantitation of circulating cells bearing the t(14;18) in normal donors and patients with lymphoma. J Clin Oncol: Proceedings of the ASCO Annual Meeting 2000:15a, 2000.

Book Chapters

1. Tsimberidou AM, Fountzilas E, Kurzrock R. Precision medicine in oncology drug development. In: Holland-Frei Cancer Medicine. 10th ed. Wiley Blackwell: Hoboken, New Jersey, 613-630, 2023.
2. Tsimberidou AM, Bast R, Khuri FR, Byrd JC. Principles of Medical Oncology. In: Holland-Frei Cancer Medicine. 10th ed. Wiley Blackwell: Hoboken, New Jersey, 553-566, 2023.
3. Said R, Tsimberidou AM. Targeted therapies in cancer. In: MD Anderson Manual of Medical Oncology. 4th ed. McGraw-Hill Education: New York, United States, Chapter 57, 2022.
4. Tsimberidou AM, Muller P, Schilsky R. Clinical trials in the year 2025. In: Oncology Clinical Trials: Design, Conduct and Analysis. 2nd ed. Demos Medical Publishing: New York, 2018.
5. Said R, Nickolich M, Lenihan DJ, Tsimberidou AM. Cardiotoxicity of anticancer therapies. In: Cardio-Oncology: The Clinical Overlap of Cancer and Heart Disease. Springer: Switzerland, 2017.
6. Tsimberidou AM. Targeted therapies in cancer. In: MD Anderson Manual of Medical Oncology. 3rd ed. McGraw-Hill Education: New York, United States, 1003-1019, 2016.
7. Said R, Tsimberidou AM. Future perspectives. In: Targeted Therapy in Translational Cancer Research. Wiley Blackwell: New Jersey, United States, 363-70, 2015.
8. Tsimberidou AM, Keating, MJ. Chronic lymphocytic leukemia (CLL) /small lymphocytic lymphoma (SLL). In: 60 Years of Survival Outcomes at UTMDACC. Springer: New York, NY, 211-223, 2013.
9. Tsimberidou AM, Keating MJ. Targeted therapy in chronic lymphocytic leukemia. In: Targeted Cancer Therapy. Humana Press: New York, 61-86, 2008.
10. Tsimberidou AM, Keating MJ. Hyperuricemic syndromes in cancer patients. In: Hyperuricemic Syndromes: Pathophysiology and Therapy. S. Karger, AG Basel, 47-60, 2005.
11. Tsimberidou AM, Jiang YF, Ford R, Cabanillas F, Sarris AH. Real-time polymerase chain reaction of genomic DNA for quantitation of t(14;18). In: Detection of minimal residual disease in hematologic malignancies by Zipf and Johnston. Humana Press: New York, 223-236, 2002.

Books (edited and written)

1. Bast RC, Byrd JC, Croce C, Hawk E, Khuri FR, Pollock R, Tsimberidou AM, Willett C, Willman C (Editors). Holland-Frei Cancer Medicine. 10th ed. Wiley Blackwell: Hoboken, New Jersey, 2023.
2. Tsimberidou AM, Kurzrock R, Anderson KC. Targeted Therapy in Translational Cancer Research. In: Translational oncology. 1st. Wiley-Blackwell: New Jersey, United States, 2016.